7.1 PREHĽAD PUBLIKAČNEJ ČINNOSTI

7.2 PREHĽAD OHLASOV, CITÁCIÍ

doc. MUDr. Ferdinand Sasváry, PhD.

Kateg.		Počet*/	Počet **/
V1	**Vedecký výstup publikačnej činnosti ako celok**		
AAA	Vedecké monografie vydané v zahraničných vydavateľstvách	4	
AAB	Vedecké monografie vydané v domácich vydavateľstvách	1	
V2	**Vedecký výstup publikačnej činnosti ako časť editovanej knihy alebo zborníka**		
AED	Vedecké práce v domácich recenzovaných vedeckých zborníkoch	3	
AFD	Publikované príspevky na domácich vedeckých konferenciách	6	
AFG	Abstrakty príspevkov zo zahraničných konferencií	4	
AFH	Abstrakty príspevkov z domácich konferencií	5	
AFK	Postery zo zahraničných konferncií	3	
AFL	Postery z dom.konferencií	1	
V3	**Vedecký výstup publikačnej činnosti z časopisu**		
ADF	Vedecké práce v domácich nekarentovaných časopisoch	3	
ADM	Vedecké práce v zahraničných časopisoch registrovaných v databázach Scopus, WoS, ERIH PLUS	7	
ADN	Vedecké práce v domácich časopisoch registrovaných vo WoS alebo Scopus	9	
O2	**Odborný výstup publikačnej činnosti ako časť knižnej publikácie alebo zborníka**		
BEF	Odborné práce v nerecenzovaných domácich zborníkoch	3	
BFB	Abstrakty odborných prác z domácich podujatí	3	
O3	**Odborný výstup publikačnej činnosti z časopisu**		
BDE	Odborné práce v nekarentovaných zahraničných časopisoch	1	
BDF	Odborné práce v nekarentovaných domácich časopisoch	2	
P1	**Pedagogický výstup publikačnej činnosti ako celok**		
ACB	Vysokoškolské učebnice vydané v domácich vydavateľstvách	2	
BCI	Skriptá a učebné texty	2	

P2	**Pedagogický výstup publikačnej činnosti ako časť učebnice alebo skripta**		
ADC	Vedecké práce v zahraničných karentovaných časopisoch	4	
I1	**Iný výstup publikačnej činnosti ako celok**		
GHG	Práce zverejnené spôsobom umožňujúcim hromadný prístup	1	
	Práce zverejnené spôsobom umožňujúcim hromadný prístup		
DAI	Kvalifikačné práce (dizertačné, habilitačné, atestačné...)	2	
	Spolu	**66**	

Štatistika ohlasov

Spolu: 764

Kateg.		Počet*/	Počet **/
1	**Citácie v publikáciách registrované v citačných indexoch**		50
[1]	Citácie v zahraničných publikáciách registrované v citačných indexoch Web of Science, v databáze SCOPUS, v databáze EBSCO	665	
[2]	Citácie v domácich publikáciách registrované v citačných indexoch Web of Science, v databáze SCOPUS, v databáze EBSCO	2	
[3]	Citácie v zahraničných publikáciách neregistrované v citačných indexoch	22	
[4]	Citácie v domácich publikáciách neregistrované v citačných indexoch	22	
[5]	Recenziev zahraničných publikáciách	2	
[6]	Recenzie v domácich publikáciách	1	
	Spolu:	**714**	**50**

Pozn.: Poradie publikácií bolo upravené v zmysle vyhlášky MŠVVaŠ SR č. 397/2020

***/ podľa vyhlášky MŠVVaŠ SR č. 456/2012**
****/ podľa vyhlášky MŠVVaŠ SR č. 397/2020**

V1 – vedecký výstup publikačnej činnosti ako celok

AAA Vedecké monografie vydané v zahraničných vydavateľstvách (4)

AAA 01

SUPINOVA, M. - KRALINSKY, K. -**SASVARY, F**. - JANKECHOVA, M. Health status analysis of Roma population in Slovakia In: SUVADA, J. - CZARNECKI, P. - MRAZOVA, M.*Interdisciplinary Updates on Health in Europe*.Warsaw Management University Publishing House Prof. Leszka J. Kryžanowskiego. Warsaw 2016. ISBN 978-83-7520-214-4, s.375-394.(AH 1; 8 %,)

AAA 02

SASVÁRY, F. – ŠUPÍNOVÁ, M. Význam interdisciplinárneho prístupu v prevencii chorôb. Expharma, Budapest, 2016. ISBN 978-80-972557-1-8 185s. (AH 5; 53 %)

AAA 03

KRÁLINSKÝ, K. – **SASVÁRY, F.** – ŠUPÍNOVÁ, M. Význam interdisciplinárneho prístupu v prevencii chorôb III. Expharma, Budapešť, 2019. ISBN 978-615-00-7222-7 132s. (AH 2; 30%)

AAA 04

ŠUPÍNOVÁ, M. – FRČOVÁ, B. – **SASVÁRY, F.** Nursing in practice. Expharma, Budapešť, 2017. ISBN 978-693-12-9678-5 444s. (AH 1; 6%)

AAB Vedecké monografie vydané v domácich vydavateľstvách (1)

AAB 01

HULÍN, I. - ŠIMKO, F. - ZLATOŠ, L.- SAPÁKOVÁ, H. - MAASOVÁ, D. – MURIN, J. - HATALA, R. - SOCHOROVÁ, R. - MLADOSIEVIČOVÁ, B. - BERNADIČ, M. - BAKOŠOVÁ, M. - HOLZEROVÁ, J. - KRÁĽ, A. - ĎURIŠ, I. - TURČÁNI, M. -

JAKUBOVSKÝ, J. - FERENČÍK, M. – **SASVÁRY, F.** Patofyziológia - 2. vyd. - Bratislava, SAP, 1996. - 702 s. - ISBN 80-85665-62-X (AH 2,5; 7.5 %)

Ohlasy (13)

1. [5] TROJAN, S., Patofyziologie. Bratislava : Slovac Academic Press, 1996. In:*Čs. Fysiologie*, ISSN 1210-6313. 1997, 46, s. 121.
2. [4] BLAHOŠ, J. In:*Lekárske listy*, ISSN 1335-4477. 1996, 35, s. 6.
3. [4] ROVENSKÝ, J. Reumatológia v teórii a praxi. Martin, Osveta, 1998, s. 1024. ISBN 978-80-969225-5-0.

4. [4] KALISTOVÁ, K. Problematika klasifikácie duševných porúch v detskom veku. In:*Psychiatria,* ISSN 1335-423X. 1996, 3, s. 92-100.

5. [4] ŠVEC, P. - AMBRÓŠOVÁ, Ž. - BRAŠŠANOVÁ, J. - BLAŠKOVÁ, E. - ŤAŽKÁ, D. - VAJA, V. - KYSELOVIČ, J. - SEGINKO, J. Účinok fytosterolov na vybrané parametre aterosklerózy na Pražských hereditárne hypercholesterolemických potkanoch (PHHC). In:*Farm. Obzor*, ISSN 0014-8172. 2001, 70, s. 29-35.

6. [3] VESELÝ, J. Guanyliny - nová nadějná cesta ve výzkumu postprandiální natriurézy. In:*Čs. Fysiol.*, ISSN 1210-6313. 2001, 50, 2, s. 64-70.

7. [3] LOVÁSOVÁ, K. - KLUCHOVÁ, D. - SCHMIDTOVÁ, K. - MIKLOŠOVÁ, M. - RYBÁROVÁ, S. Účinok NADPH-diaforázy na štruktútu sciatického nervu potkanov s diabetom vyvolaným streptozotocínom. In:*Folia Veterinaria,* ISSN 0015-5748. 2000, 44, 2, s. 80-84.

8. [3] VIOLA, A. - STVRTINA, S. - BAUER, V. - ZAVIAČIČ, M. Morfologické a klinické následky fokálnych ischemicných lézií. In:*Čs. patologie*, ISSN 1210-7875. 2000, 36, 4, s. 140-145.

9. [4] ŠEFRÁNEK, V. Ochorenia končatinových artérií a ich chirurgická liečba,Bratislava : SAP, 2001, 240 s.ISBN 80-88908-82-5. 2001,

10. [3] EHRMANN, J. Etiopatogeneze průjmu a základní principy diagnostiky a léčby. In:*Vnitř. Lék.*, ISSN 0042-773X. 2002, 48, 6, s. 563-566.

11. [3] ŠČIGEL, V. V. Repetitorium klinické farmakologie I : antikoagulační a antiagregační léčba. In:*LKS.,* ISSN 1210-3381. 2003, 13, 1, s. 10-15.

12. [3] DANIEL, M. - SOCHOR, M. - IGLIC, A. - KRAJL-IGLIC, V. Hypothesis od regulation of hip joint cartilage activity by mechanical loading. In:*Med. Hypotheses*, ISSN 0306-9877. 2003, 60, 6, s. 936-937.

13. [4] ADAMEOVÁ, A. - KUŽELOVÁ, M. - KLIMAS, J. - KŘENEK, P. - KYSELOVIČ, J. Potencovanie kvality výskumno-vývojovej práce mladých vedeckých a pedagogických pracovníkov na Farmaceutickej fakulte UK. In:*Európsky sociálny fond : č. projektu 13120200090 , Bratislava : Univerzita Komenského*, ISBN 978-80-2232-463-2. 2008, s. 5.

V2 Vedecký výstup publikačnej činnosti ako časť editovanej knihy alebo zborník

AED Vedecké práce v domácich recenzovaných vedeckých zborníkoch, monografiách (3)

AED 01

SASVÁRY, F. Primárna a sekundárna prevencia venózneho tromboembolizmu v gravidite. In: Zborník. Škola hematológie 2. ročník. Offprint, Bratislava, 2017, ISBN 978-80-89037-56-8. s.25

AED 02

HOMONAI, V. – SASVÁRY, F. – VIRSTA, O. Analýza príčin sideropenickej anémie. In: Zborník. Škola hematológie 2. ročník. Offprint, Bratislava, 2017, ISBN 978-80-89037-56-8. s.38

AED 03

SASVÁRY, F. – VIRSTA, O. – HOMONAI, V. Trombotické koomplikácie myeloproliferiácií. In: Zborník. Škola hematológie 3. ročník. Layout architects, Bratislava, 2018, ISBN 978-80-971468-3-2. s.5

AFD Publikované príspevky na domácich vedeckých konferenciách (6)

AFD 01

SASVÁRY, F. - RUSNÁK, R. - zost. TISOŇOVÁ, V. Perioperačná prevencia venózneho tromboembolizmu. In: *Zborník - Ružomberok : Verbum.*ISBN 978-8084-811-8. 2011, s. 100-102.

AFD 02

SASVÁRY, F. Vlastné skúsenosti s liečbou venózneho tromboembolizmu. In: *Zborník. Škola hematologie. 1.ročník 5.-7. februára 2016. Offprint, Bratislava.* ISBN 978-80-8084. 2016, 811-8, s.11-14.

AFD 03

SASVÁRY, F. Vrodený trombofílny stav a gravidita. - kazuistika. In: *Užívateľské stretnutie Instrumentation Laboratory. Jasná, 2010.* [CD-ROM] ISBN sine numero, s. nestránkované.

AFD 04

SASVÁRY, F. Antitrombotická prevencia u pacientov s fibriláciou predsiení. In: *Užívateľské stretnutie Instrumentation Laboratory, Podbanské, 2011*. [CD-ROM] ISBN sine numero, s. nestránkované.

AFD 05

SASVÁRY, F. Monitorovanie efektivity antitrombotickej liečby u hemodialyzovaných pacientov. In: *Užívateľské stretnutie Instrumentation Laboratory, Jasná, 2012*. [CD-ROM] ISBN sine numero, s. nestránkované.

AFD 06

SASVÁRY, F. - BIELIK, P. - SASVÁRY, F.JR. Perioperačná prevencia venózneho tromboembolizmu. In:*Užívateľské stretnutie Instrumentation Laboratory, Nový Smokovec, 2013*. In: [CD-ROM] ISBN sine numero, s. nestránkované.

AFG Abstrakty príspekov zo zahraničných vedeckých konferencií (4)

AFG 01

SASVÁRY, F. - RUSNÁK, R. - SPROH, M. - SASVÁRY. F. JR. - BIELIK, P. -MARŠÍK, L. Antithrombotic prevention in neurosurgery. In: *Haematologica[(IF 5.867)]*. ISSN 0390-6078. 2013, roč. 98, Suppl. 1, s. 753-754.

AFG 02

SASVÁRY, F. Management of venous thromboembolism at General hospitaly Sahy [3rd International Conference on Translational Medicine, Las Vegas, USA, 3. - 5. 11. 2014]. In: *Transl. Med*. ISSN 2161-1025. 2014, roč. 4, č. 2, s. 33.

AFG 03

SASVÁRY, F. - RUSNÁK, R. - SPROH, M. - SASVÁRY, F. JR. - BIELIK, P. - MARŠÍK, L. Antithrombotic prevention in neurosurgery. In: *Abstracts and educational book.* - 2013. - Abstract No B1973.

AFG 04

SASVARY, F. - SASVARY, F.JR. Is Warfarin safe and effective enough in the 21st century? In: *The 3rd World Congresson controversies in hematology 11 – 13 September 2014, Istanbul, Turkey.* Dostupné na internete: http://www.comtecmed.com55)/cohem/2014/Uploads/Editor/PDF/Poster%20List/20.pdf

AFH Abstrakty príspekov z domácich vedeckých konferencií (5)

AFH 01

MURÍN, J. - KVASZOVÁ, E. - KASPER, J. - BULAS, J. - MALÍK, J. - SABOLOVÁ, K. - SASVÁRY, F. - HULIN, I. - KILLINGER, Z. Využitie dynamických zmien myoglobinémie v priebehu akútneho infarktu myokardu pre hodnotenie jeho priebehu. In: *Neinvazívna kardiológia[Abstraktá]*.ISSN 1210-0048. roč. 3, č. 4 suppl. s. B21.

AFH 02

KASPER, J. JR. - MALÍK, J. - SASVÁRY, F. -KRIVOSUDSKÝ, A. - ŠIMO, J. - MURÍN, J. Vzťah medzi trvaním stimulovaného QRS komplexu a funkciou ľavej komory. In: *Neinvazívna kardiológia[Abstraktá]*. ISSN 1210-0048. 1994, roč. 3, č. 4 suppl., s. B14.

AFH 03

SASVÁRY, F. Účinnosť a bezpečnosť nových orálnych antikoagulancií (NOAK). In: *Zborník abstraktov*. - *Ružomberok : NeuroPrevent,* 2014. - s. 47.

AFH 04

SASVÁRY, F. - RUSNÁK, R. - SASVÁRY, F. JR. - BIELIK, P. - MARŠÍK, L. Prevencia venózneho tromboembolizmu u pacientov s ischemickou cievnou mozgovou príhodou a ich rehabilitácia. In: *Zborník abstraktov NeuroRehab 2013, NeuroPrevent 2013, Ružomberok.* ISBN 978-80-85659-75-7. s.80-81.

AFH 05

SASVÁRY, F. - RUSNÁK, R. - SASVÁRY, F. JR. - BIELIK, P. - MARŠÍK, L. Venous thromboembolism prevention and rehabilitation in patients suffering for ischemic stroke. In: *Zborník abstraktov NeuroRehab 2013, NeuroPrevent 2013, Ružomberok.* ISBN 978-80-85659-75-7. s.81-82.

AFK Postery zo zahraničných konferncií (3)

AFK 01

SASVÁRY, F. - ŠOMLÓ, P. - DUBA, G. - ALI, M. – EKSHMIDT, G.A computer-tomográfiás vizsgálat helye a myelóma csontbetegségenek diagnosztikájában és lefolyásának értékelésében. Maďarsko, 7. - 8. 2. 2014[Részletes program és poszter összefoglalók]. - Miskolc : 2014. - s. 12.

AFK 02

SASVÁRY, F. - SASVÁRY, F. JR. Is Warfarin safe and effective enough in the 21st century? The 3rd World Congresson controversies in hematology 11 – 13 September 2014, Istanbul, Turkey. Poster No20

AFK 03

SASVÁRY, F. - SASVÁRY, F. JR. - BIELIK, P. - MARŠÍK, L.(Vrodená trombofília a gravidita - opis prípadu). Veleszületett thrombophilia és graviditas - esettanulmány. Magyar Hematológiai és Transzfuziológiai Társaság XXIV. Kongresszusa. 2013. Debrecen, Maďarsko In: *Hematológia - Transzfuziológia.*ISSN 0324-7309. 2013, 46, 1.suppl, s.107.

AFL Postery z domácicho konferncií (1)

AFL 01

SASVÁRY, F. Liečba starších pacientov s DLBCL - kauzistika. In: *Zborník[Poster].*, 2010.

V3 – vedecký výstup publikačnej činnosti z časopisu

ADF Vedecké práce v ostatmých domácih časopisoch (3)

ADF 01

MALÍK, J. - MURIN, J. - KASPER, J.JR. - MIKLA, F. - SASVÁRY, F. Hodnotenie úspešnosti trombolytickej liečby akútneho infarktu myokardu stanovením dynamiky myoglobinémie. In: *Kardiológia.* ISSN 1210-0048. 1997, roč. 6, č. 1, s. 19-22.

ADF 02

SASVÁRY, F. Variabilita srdcového rytmu - marker aktivity vegetatívneho nervového systému. In: *Neinv. Kardiol.*ISSN 1210-0048. 1995, roč. 4, č. 3, s. 179-186.

Ohlasy (2)

1. [1] BERKOVÁ, M. - OPAVSKÝ, J. - BERKA, Z. - ŠKRAŇKA, V. - SALINGER, J. Left ventricular diastolic filling in young persons with type 1 diabetes mellitus. In:*Biomedical papers of the Medical Faculty of the University Palacky Olomouc*. ISSN 1213-8118. 2003, 147, 1, s. 57-61.
2. [4] OLEXA, P. - GONSORČÍK, J. - KUČINSKÝ, R. - BRAČOKOVÁ, I. - KASSAYOVÁ, K. - RANJIČ, A. Dysfunkcia autonómneho nervového systému - patofyziologické aspekty a jej význam v klinickej kardiológii. In:*Kardiológia*. ISSN 1210-0048. 2000, 9, 4, s. 222-230.

ADF 03

MURIN, J. - KVASZOVÁ, E. - KILLINGER, Z. - KASPER, J. JR. - BULAS, J. - MALIK, J. - SABOLOVÁ, K. - SASVÁRY, F. - HULÍN, I. Využitie dynamických zmien myoglobinémie v priebehu akútneho infarktu myokardu pre hodnotenie jeho priebehu. In: *Neinvazívna kardiológia.* ISSN 1210-0048. 1995, roč. 4, č. 1, s. 6-11.

ADM Vedecké práce v zahraničných časopisoch registrovaných v databázach Scopus, WoS, ERIH PLUS (7)

ADM 01

KHALIED, I. - CAUDA, R. - BENCA, J. - TAKAC, B. - BURIANCOVA, K. - PUTEKOVA, S. - MARTINKOVA, J. - KOMLOSI, M. - ONDOVA, P. - JACKULIKOVA, M. - SVOBODOVA, H. - KAFKOVA, J. - NEVOLNA, Z. - BIBZA, M. - KOLIBAB, M. - MIKOLASOVA, G. - ZOLLEROVA, K. - MURGOVA, A. - TKACOVA, L. - JANKECHOVA, M. - POPELOVA, M. - SASVARY, F. - KRCMERY, V. Screen or not to screen? 7 questions in prevention if infection from refugees and migrants. V. CSW 2016, 7(3): 16-18. IF=1.363

ADM 02

SASVARY, F. - SUPINOVA, M. Accidental Cymoxanil (TANOS) pesticide poisonong (Case report). CSW 2016, 7(3): 27-31. IF=1.363

ADM 03

BYDZOVSKY, J. - CHRASC, S. - PECIAR, A. - BENCA, J. - POPELOVA, M. - SASVARY, F. - MATEL, A. - CERNICKY, M. - KALATOVA, D. - NEVOLNA, Z. - KAFKOVA, J. - ZOLLEROVA, C. - KOLIBAB, M. - PUTEKOVA, S. - MARTINKOVA, J. - MIKOLASOVA, G. - KOMLOSI, M. Experience with migrants on Balkan Route from the Field Hospital on the Slovenian-Croatian Border. CSW 2016, 7(3): 32-34. IF=1.363

Ohlasy (1)

[1]NAJA, F., SHATILA, H., EL KOUSSA, M., MEHO, L., GHANDOUR, L., SALEH, S. (2019). Burden of non-communicable diseases among Syrian refugees: a scoping review. *BMC Public Health*, *19*(1), 1-13.

ADM 04

DUDOVA, Z. - TRILISINKAYA, Y. - JACKULIAKOVA, T. - JANKECHOVA, M. - SASVARY, F. - MATEL, A. - TAKAC, B. - KRIZANOVA, A. - OTRUBOVA, J. - KOMLOSI, M. - BENCA, J. - KRCMERY, V. - KMIT, I. - KURANOVA, Z. - MAMOVA, A. - ZIDISINOVA, M. - PETRIK, A. Six month follow up in communicable versus non-communicable diseases in an Iraqi refugee camp. CSW2016, 7(3): 38-41. IF=1.363

Ohlasy (7)

1. [1] SUBRAMANIAN, S., BUSCH, E., RAJOO, M., JANKECHOVA, M. (2017). Infectious Diseases Among Imprisoned-Risk Factors and Outcomes. *Clinical social work and health intervention*, *8*(1), 7-10.

2. [1] COSTELLO, M., SHAHUM, A. A daily Low-threshold Integration Center for the Homeless. Model of Social and Healthcare for Excluded Populations. *CLINICAL SOCIAL WORK*, 19.

3. [1] SUVADA, J., CAUDA, R. The Most Common Diseases among Syrian and Palestinian Refugees to Lebanon: Acute and Chronic Stress Related Diseases are Prevalent. *CLINICAL SOCIAL WORK*, 47.

4. [1] TOMANEK, P., KIMULI, D., MULAMA, K., RONGAI, K. E. (2017). St. Louise Hospital for Marginalized Homeless Population: TB and Other Infectious Diseases are Rare. *CLINICAL SOCIAL WORK*, 46.

5. [1] MIKOLASOVA, G., ALI, P. H., SYRIA, U. A., ZOLLER, C., UNHCR, A., GREECE, E. L. (2017). Spectrum of Communicable Diseases at the Mea Culpa Shelter for the Homeless in Bratislava–15 year follow up. *CLINICAL SOCIAL WORK*, 39.

6. [1] OLAH, M., LEZCANO, G., MULLERA, K. Antimicrobial Susceptibility of Respiratory Isolates from Homeless Population in an Urban Environment. *CLINICAL SOCIAL WORK*, 11.

7. [1] RAFAJDUS, M., MACHAJOVA, M. (2021). Steps to Development and Increase of Physical Movement and Health Literacy. *Clinical Social Work and Health Intervention, 12*(5), 66-71.

ADM 05

ALI, P.H., SASVÁRY, F., KRČMÉRY, V., JANKECHOVÁ, M., PUTEKOVÁ, S., KABÁTOVÁ, J., TKÁČOVÁ, L., MURGOVÁ, A., BYDZOVSKÝ, J., TOPOLSKÁ, A., BUČKO, L., PÁLENÍKOVÁ, M., , LÍŠKOVÁ, A., TOMIC, L., ČERVENÁ, L., KHALIL, I., HEIDEROVA, H. HERDICS, GY. (2017). Migrants are colonized by resistant bacteria during their prolonged stays in refugee camps. *Clinical Social Work and Health Intervention, 8*(1), 15-18.

Ohlasy (3)

1. [1] PAPADIMOS, T., PAPPADA, S., LYAKER, M., PAPADIMOS, J., CASABIANCA, A. (2020). Health Security and the Refugee Crisis in Greece: The Refugee Perspective. In *Contemporary Developments and Perspectives in International Health Security-Volume 1*. Intechopen.

2. [1] RAFAJDUS, M., MACHAJOVÁ, M. (2021). Steps to Development and Increase of Physical Movement and Health Literacy. *Clinical Social Work and Health Intervention, 12*(5): 66-71.

3. [1] SIMONEK T., CAMP U., SHAHUM A., BENCA G. (2018) Refugees after Long Distance Migrating and Camping: Secondary Wound Infection Etiology and Management. *Clinical Social Work and Health Intervention, 9* (4): 68-71.

ADM 06

PALOCKOVA, M., CHOVANCOVA, S. SUGAROVA, D., ZDILOVA, E., SASVARY, F., SASVARY, M., BARKASI, D., GULASOVA, M., KMIT, I., OLAH, M., HOCHMAN, R., HALUSKOVA, E., PARTELOVA, M., TRICHARD, E. (2021)Covid-19 has only Temporarily Interrupted Social and Health Services in rural Albania in 2020. *Clinical Social Work and Health Intervention ; 12(1):*17-19.ID: covidwho-1200458

ADM 07

SIMONEK, T., JACKULIKOVA, M., TOPOLSKA, A., JANCOVIC, M., JANCOVICOVA, L., SLUSNA, L., HARDY, M., VALACH, M., SRAMKOVA, M., POPOVICOVA, M., BARKASI, D., PROCHAZKOVA, K.,LIBOVA, L., MRAZOVA, M., VLCEK, R., GULASOVA, M., OTRUBOVA, J., RADKOVA, L., MURGOVA, A., VANSAC, P., HOCHMAN, R., KONOSOVA, H., KATUNSKA, M., BAKOS, M., BIELOVA, M., SASVARY, F., GREY, E. (2019) Spectrum of Communicable Diseases in Lesbos Island UNHCR Refugee Camp *Clinical Social Work and Health Intervention 10(4*): 57 – 59;

ADN Vedecké práce v domácich časopisoch registrovaných v databázach Scopus, WoS, ERIH PLUS (9)

ADN 01

BIELIK, P. - SASVÁRY, F. - MARŠÍK, L. - KUBOVČÍK, B. Riešenie syndrómu pelvickej kongescie - multidisciplinárny prístup. In: *Lekársky obzor*. ISSN 0457-4214. 2014, roč. 63, č. 6, s. 243-245.

ADN 02

SASVÁRY, F. - BIELIK, P. - SASVÁRY, F. JR. Manažment gravidity u trombofilných žien. In: *Lekársky obzor.*ISSN 0457-4214. 2015, roč. 64, č. 4, s. 151-153.

ADN 03

BIELIK, P. - SASVÁRY, F. - MARŠÍK, L. - KUBOVČÍK, B. Syndróm pelvickej koncesie (MiniAtlas gynekológie). In: *Lekársky obzor.*ISSN 0457-4214. 2014, 63, s. 247-248.

ADN 04

SASVÁRY, F. - SASVÁRY, F. JR. Riziká TECH u onkochirurgického pacienta - nutnosť prevencie. In: *Miniinv. Chirurg. Endoskopia.* ISSN 1336-6572. 2014,18, s. 31-35.

ADN 05

SASVÁRY, F. - MURIN, J. - ĎURIŠ, I. - PONŤUCH, P. - SEDLÁK, T. - LABAŠ, P. Intrakavitárny trombus - neobvyklá komplikácia pri uceróznej kolitíde. In: *Bratisl.lek. Listy.*ISSN 0006-9248. 1996, roč. 97, č. 11, s. 669-672.

Ohlasy (5)

1. [1] URGESI, R. - ZAMPALETTA, C. - MASINI, A. - FAGGIANI, R. Spontaneous right ventricular thrombus in a patient with active ulcerative colitis and protein C deficiency: A review with a case report. In:*Eur. Rev. Med. Pharmacol Sci*. ISSN 1128-3602. 2010, 14, 5, s. 455-463.
2. [1] RAHMAN, M. - THEKKUDAN, J. - IONESCU, A. - ASHARF, S. Spontaneous right atrial thrombus in a patient with Crohn's disease: An unusual right atrial mass. In:*Interactive Cardiovasc Thorasic Surg*. ISSN 1569-9293. 2006, 5, 5, s. 664-665.

3. [1] KATSANOS, K.H. - TSIANOS, E.V. The heart in inflammatory bowel disease. In: *Ann Gastroenterol*. ISSN 1108-7471. 2002, 15, 2, s. 124-133.

4. [3] HUANG, B. - KWAN, L. Y. - SHIH, D. Q. Extraintestinal manifestations of ulcerative colitis. In:*Ed.: O´Connor, M.: Ulcerative colitis - epidemiology, pathogenesis and complications [online]*. ISBN 978-953-307-880-9. 2011, s. 131-172. Dostupné na internete.

5. [1] SAVAS, N. Inflamatuvar Bağırsak Hastalıklarının Kardiyopulmoner Komplikasyonları. In: *Güncel Gastroenteroloji*, 2013, 17, s.339-343.

ADN 06

BERNADIČ, M. - MAASOVÁ, D. - SASVÁRY, F. - HOLZEROVÁ, J. - HULÍN, I. Môže byť permanentná sínusová arytmia u bdelých psov potlačená anestéziou? [Can permanent sinus arrhythmia in conscious dogs be suppressed with anesthesia?]. In: *Bratislavské lekárske listy*.ISSN 0006-9248.1996, roč. 97, č. 5, s. 273-278.

Ohlasy (2)

1. [2] NAVARČÍKOVÁ, Š. Akcesórne dráhy a supraventrikulárna tachykardia. In:*Bratislavské lekárske listy*. ISSN 0006-9248. 1999, 100, 5, s. 263-266.
2. [4] JAVORKA, K. Využitie hodnotenia variability frekvencie srdca v anesteziológii. In:*Javorka, K.: Variabilita frekvencie srdca: mechanizmy, hodnotenie, klinické využitie, Martin: Osveta.* ISBN 978-80-8063-269-4. 2008, s. 160-167.

ADN 07

LABAŠ, P. - VRTÍK, L. - ŠVEC, R. - SASVÁRY, F. Komplexná prevencia pooperačnej trombózy. In: *Bratislavské lekárske listy.* ISSN 0006-9248. 1996, roč. 97, č. 2, s. 90-95.

Ohlasy (6)

1. [4] PECHÁŇ, J. Rádionuklidová diagnostika hlbokej venóznej trombózy. In:*Slovenský lekár*. ISSN 1335-0234. 1996, 6(20), 9, s. 7-11.
2. [2] ŠKULTÉTY, J. - OHRÁDKA, B. - MATIS, P. - HRBATÝ, B. - ZÁHOREC, B. Reoperácie pre adhezívny ileus. In:*Bratislavské lekárske listy*. ISSN 0006-9248. 1996, 97, 12, s. 749-750.
3. [3] ŠTVRTINOVÁ, V. Je nutné presne klasifikovať CHVI? In:*Praktická Flebologie*. ISSN 1210-3411. 1997, 6, 1, s. 16-17.
4. [4] MARESCH, P. Tromboembolická choroba v ortopédii a iných operačných odboroch. Martin, Osveta. ISBN 80-8063-002-X. s. 84.
5. [4] LUKÁČ, Ľ. - HUORKA, M. - VYSKOČIL, M. - HLAVATÝ, T. - DANIŠ, D. Reštrikčná kardiomyopatia ako príčina Gordonovej choroby a jej zlepšenie liečbou heparínom. In:*Interná medicína s prílohou Všeobecné lekárstvo*. ISSN 1335-8359. 2001, 1, 2, s. 98-99.

6. [4] REMKOVÁ, A. Prevencia venózneho tromboembolizmu v internej medicíne. In:*Interná medicína s prílohou Všeobecné lekárstvo*. ISSN 1335-8359. 2002, 2, 10, s. 593-597.

ADN 08

SASVÁRY, F. Complications of central venous catheterization in hemodialysis patients. In: *Bratislavské lekárske listy*. ISSN 0006-9248. 2005, roč. 106, č. 1, s. 26-29.

Ohlasy (12)

1. [1] TRASKA, T. - SCHAEFFER, M. - BERG, W. - VIEBAHN, R. - CLAEYSl, L. Zespól ciasnoty przedzialów powieziowych szyi w nastepstwie cewnikowania zyly centralnej. In: *Polski przeglad chirurgiczny.* ISSN 0032-373X. 2007, 79, 2, s. 223-226.
2. [1] RAHMAN, M. - THEKKUDAN, J. - IONESCU, A. - ASHRAF, S. Spontaneous right atrial thrombus in a patient with Crohn´s disease: an unusual right atrial mass. In:*Interactive cardiovascular and thoracic surgery*. ISSN 1569-9293. 2006, 5, 5, s. 664-665.

3. [1] TRASKA, T. - SCHAEFFER, M. - BERG, W. - VIEBAHN, R. - CLAEYSl, L. Cervical compartment syndrome - complication of central venous cathetrization. In:*Polski przeglad chirurgiczny.* ISSN 0032-373X. 2007, 79, 2, s. 126-128.
4. [3] SHAHMORADI, M. K. - ZADEH, M. K. - TAMANNAIE, Z. - VAZIRI, M. Survival and catheter related complications among Iranian end stage renal disease patients: Hasheminejad Kidney Center, 2012 to 2011. In:*Journal of minimally invasive surgery sciences*. ISSN 2251-7022. 2012, 1, 3, s. 103-107.
5. [3] WANG, H. - XU, M. - JIA, L. L. The analysis of complications with deep vein inserted catheter in blood purification in children. In:*Journal of Clinical Medicine in Practice*. ISSN 1672-2353. 2011, 8, s. 86-88.
6. [3] LIU, CH. Foreseeable nursing for the complications of internal jugular vein cathetering after surgery of Bystric cancer. In: *Journal of Clinical Medicine in Practice.* ISSN 2251-7022. 2014, 11, s.66-69.
7. [3] FAN, G. Application and nursing care of four ways of deep venipuncture catheterization for patients accepting hemodialysis. In: *Chinese Nursing Research.* ISSN 2095-7718. 2011, 25, s. 2502-2505.
8. [3] ZHONG, H. - HUANG, S. - LIAO, A. Application of Central Venous Catheterization for Emergency Hemodialysis. In:*Applied Journal of General Practice.* ISSN 1674-4152. 2007, 5. s. 964-965.
9. [3] XU, M. - FAN, G. Hemodialysis atheter insertion through external iliac vein. In: *Journal of Nursing Science*. ISSN 2381-1056. 2010, 25. s.10-11.
10. [3] CARRILLO, C.M.O. Complicationes de la colocación de via venosa central para hemodiálisis con y sin guía ecográfica. (práca k špecializačnej skúške z radiologie). Faculdad de medicina humana Lima, Peru, 2014, s.75.
11. [3] AJUZIEOGU, V. O. Anaesthesia for removal of missing guidewire. A case report. In:*Internet journal of anesthesiology [online].(*Dostupné na internete). ISSN 1092-406X. 2011, 28, 2.
12. [3] GAUTAM, S. N. - BHATTA, S. K. - SHRESTHA, B. C. - SHARMA, N. R. - NAYAK, S. - RAWAL, S. B. - SHRESTHA, S. Placement of double lumen central venous catheter for hemodialysis patients: an experience [online]. In: *Dostupné na internete.* 2014, s. 54-59.

ADN 09

MURÍN, J. - KASPER, J. - KOZLÍKOVÁ, K. - MALÍK, J. - SASVÁRY, F. - SABOLOVÁ, K. - BULAS, J. Remodelácia po akútnom infarkte myokardu [Prednesené na Spolku slovenských lekárov, Bratislava, 31.1.1994]. In: *Bratislavské lekárske listy*. ISSN 0006-9248. 1994, roč. 95, č. 5, s. 234.

O2 Odborný výstup publikačnej činnosti ako časť knižnej publikácie alebo zborníka
BEF Odborné práce v domácich zborníkoch (3)

BEF 01

BIELIK, P - SPODNIAKOVÁ, J. - ŠUPÍNOVÁ, M. - zost. NEMCOVÁ, L. - zost. ZÓLYOMIOVÁ, P. - zost. BIELIK, P. - zost. SPODNIAKOVÁ, J. - zost. ŠUPÍNOVÁ, M. - zost. MARŠÍK, L. - zost. SASVÁRY, F. - zost. TAUFER, I. - zost. KRIŽO, P. - rec. VIŠŇOVSKÝ, Ľ. - rec. EMMEROVÁ, I. Sexuálne prenosné infekcie, prevencia. In: *Teória rodinnej výchovy. I. : Vysokoškolské učebné texty. - Banská Bystrica : Pedagogická fakuta Univerzity Mateja Bela.*ISBN 978-80-557-0713-6. 2014, s. 85-90.

BEF 02

BIELIK, P. - SASVÁRY, F. Metódy plánovaného rodičovstva. In: *Teória rodinnej výchovy 1. diel[Vysokoškolské učebné texty]. - Banská Bystrica : Univerzita Mateja Bela.*ISBN 978-80-557-0713-6. 2014, s. 64-67.

BEF 03

SASVÁRY, F. - TAUFER, I. Nežiadúce účinky hormonálnej antikoncepcie. In:*Teória rodinnej výchovy 1. diel[Vysokoškolské učebné texty]. - Banská Bystrica : Univerzita Mateja Bela.* ISBN 978-80-557-0713-6. 2014, s. 68-74.

BFB Abstrakty odborných prác z domácich podujatí (3)

BFB 01

SABOLOVÁ, K. - SASVÁRY, F. - MURIN, J. - BULAS, J. -KASPER, J. -KASPEROVÁ, V. -ŠKULTÉTYOVÁ, D. Estimation and computation of left ventricular ejection fraction. In: *Noninvas Cardiol.* 1995, roč. 4, č. 4, s. 25A.

BFB 02

ŠKULTÉTYOVÁ, D. - KASPEROVÁ, V. - SABOLOVÁ, K. - BULAS, J. - SASVÁRY, F. Vplyv rizikových faktorov na zotavovacie obdobie po akútnom infarkte myokardu.In: *100. internistický deň, Nitra, 1995. - 1995.*

BFB 03

SASVÁRY, F. Diagnostika a sledovanie trombofilného (i.e. trombofilného stavu) v tehotenstve. In: *Zborník abstraktov.- Bratislava* : [S.1.: s.n.], 2011. - s. 14.

Ohlasy (5)

1. [4] MARŠÍK, L. - ĎURECHOVÁ, A. - OROSZOVÁ, V. Hormonálna liečba neplodnosti. In *Gynekológia pre prax*. ISSN 1336-3425. 2013, 11, 3, s. 132-139.
2. [4] MARŠÍK, L. - ĎURECHOVÁ, A - KONÝČKOVÁ, I. - BOROVSKÝ, M. - PETRENKO, M. - OROSZOVÁ, V. Budúcnosť asistovanej reprodukcie - návrat k prírode? In: *Gynekológia pre prax*. ISSN 1336-3425. 2013, 11, 4, s. 203-206.
3. [4] BIELIK, P. - PANČÍKOVÁ, J. - FULAJTÁROVÁ, J. - KRÁLINSKÝ, K. Špecifiká gravidity a pôrodu dievčat do 15 rokov. In:*Eds.: Marková, D., Rovňanová, L.: Sexuality V.: zborník vedeckých príspevkov, 1. vyd. Banská Bystrica : Univerzita Mateja Bela.*ISBN 978-80-55703-79-4. 2012, s. 135-140.

4. [4] MARŠÍK, L. - BIELIK, P. Asistovaná reprodukcia. Definícia, základné pojmy. In:*Základy asistovanej reprodukcie. Učebnica reprodukčnej medicíny, Banská Bystrica : PRO,*2015, s. 11-17.

5. [4] MARŠÍK, L. - ĎURECHOVÁ, A. Hormonálna liečba v asistovanej reprodukcii. In:*Základy asistovanej reprodukcie. Učebnica reprodukčnej medicíny, Banská Bystrica* : PRO, 2015, s. 18-34.

O3 – odborný výstup publikačnej činnosti z časopisu

BDE Ostatné práce v ostatných zahraničných časopisoch (1)

BDE 01

SASVÁRY, F. - SASVÁRY, F. JR. - BIELIK, P. - MARŠÍK, L. Veleszulettet trombophilia és graviditas. Esettanulmány. P 35. In: *Hemat. Transfuz.* ISSN 1335-2075. 2013, roč. 46, č. 1 suppl., s. 107.

BDF Ostatné práce v ostatných zahraničných časopisoch (2)

BDF 01

BIELIK, P. - SASVÁRY, F. - RUSNÁK, R. - MARŠÍK, L. - VODECKÝ, M. Polyp endometria v postmenopauze - vždy rizikový nález? In: *Slovenský lekár.* ISSN 1335-0234. 2013, roč. 23/37, č. 9-10, s. 163-165.

BDF 02

MALÍK, J. - KUČERA, P. - MURIN, J. - KASPER, J. - BULAS, J. - SABOLOVÁ, K. - SASVÁRY, F. Vznik spinálneho epidurálneho hematómu po trombolytickej liečbe pre akútny

infarkt myokardu. In: *Neinvazívna kardiológia*. ISSN 1210-0048. 1994, roč. 3, č. 4, s. 225-229.

P1 Pedagogický výstup publikačnej činnosti ako celok
ACB Vysokoškolské učebnice vydané v domácich vydavateľstvách (2)

ACB 01
HULÍN, I. - BAKOŠOVÁ, M. - BERNADIČ, M. - HOLZEROVÁ, J. - JAKUBOVSKÝ, J. - KRÁĽ, A. - MAASOVÁ, D. - MLADOSIEVIČOVÁ, B. - MURÍN, J. - SAPÁKOVÁ, E. - SASVÁRY, F.- SOCHOROVÁ, R. - ŠIMKO, F. - ŠTVRTINOVÁ, V. - ZLATOŠ, L. Pathophysiology: principles of diseases. Bratislava : [s.n.], 1995, 320 s. (AH 1; 7.5 %)

Ohlasy (9)

1. [1] KILLEBREW, D.A. - TROELSTRUP, D. - VALCOUR, V. - WILLIAMS, A. - AGUON, J. - SAPALO, D. - SHIKUMA, C. - RATTO-KIM, S. - SHIRAMIZU, B. Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia. In:*Celllular and molecular biology(Noisy-le-Grand).* ISSN 0145-5680. 2005, roč. 51, suppl. S, s. OL745-OL754.

2. [1] BARRET, C. - ALLEY, J. - PULIDO, J.C. - SPURLING, H. - LI, P: - PARSONS, T. - MALLENDER, W.D. - BEMBENEK, M.E. Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. In:*Assay and drug development technologies*. ISSN 1540-658X. 2006, roč. 4, č. 6, s. 661-669.

3. [1] LUNDBERG, U. - SALAZAR, V. - TOVAR, M. - RODRIGUEZ, J. Isolation and partial characterization of proteins with vasodegenerative and proinflammatory properties from the egg-nests of Hylesia metabus (Lepidoptera: Saturniidae) In:*Journal of medical entomology.* ISSN 0022-2585. 2007, roč. 44, č. 4, s. 440-449.

4. [1] LIN, C.X. - RHALEB, N.E. - YANG, X.P.- LAIO, T.D. - D'AMBROSIO, M.A. - CARRETERO, O.A. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. In:*American journal of physiology.Heart and circulatory physiology*. ISSN 0363-6135. 2008, roč. 295, č. 3, s. H1253-H1261.

5. [1] NICKELEIT, V. - ANDREONI, K. Inflammatory cells in renal allografts. In:*Frotiers in bioscience.* ISSN 1093-9946, 2008, roč. 13, s. 6202-6213.

6. [1] JOHNSON, L.B. - ADAWI, D. - SANDBERG, S: - OTTOCHIAN, B. - ALBERTSEN, C. - MANJER, J. - ZOUCAS, E. - BOHE, M. - JEPPSSON, B. Peripheral leucocyte count variations in rectal cancer treatment. In:*European journal of surgical oncology.* ISSN 0748-7983. 2009, roč. 35, č. 6, s. 611-616.

7. [1] LYU, S.Y. - PARK, W.B. Effect of Korean mistletoe lectin on gene expression profile in human T lymphocytes: a microarray study. In:*Biomolecules & therapeutics.* 2010, roč. 18, č. 4, s. 411-419.

8. [1] XIA, Z. - TRIFFITT, J.T. A review on macrophage responses to biomaterials. In:*Biomedical materials*. ISSN 1748-6041. 2006, roč. 1, č. 1, s. R1-R6.

9. [1] WANG, YU - HO CHI TANG. Flavors in noncarbonated beverages. Book series ACS symposium series, 2010, 1036, 2010, s. 45-59.

ACB 02

HULÍN, I. - ZLATOŠ, L. - BERNADIČ, M. - MAASOVÁ, D. - KRÁĽ, A. - MLADOSIEVIČOVÁ, B. - SAPÁKOVÁ, E. - BAKOŠOVÁ, M. - HOLZEROVÁ, J. - SOCHOROVÁ, R. - SASVÁRY, F. - FERENČIk, M. - JAKUBOVSKÝ, J. Patofyziológia 2. 2. preprac. a rozš. vyd. Bratislava. Slovac Academic Press, 1994. s. 313-716. [403]s. ISBN 80-85665-35-2. (AH1) 5 %

Ohlasy (12)

1. [4] KALISTOVÁ, K. Problematika klasifikácie duševných porúch v detskom veku. In:*Psychiatria.* ISSN 1335-423X. 1996, 3, 3, s. 92-100.
2. [4] ŠVEC, P. - AMBROŠOVÁ, Ž. - BRAŠŠANOVÁ, J. - BLAŠKOVÁ, E. - ŤAŽKÁ, D. - VAJA, V. - KYSELOVIČ, J. - SEGINKO, J. Účinok fytosterolov na vybrané parametre aterosklerózy na pražských hereditárne hypercholesterolemických potkanoch (PHHC). In:*Farmaceutický obzor*. ISSN 0014-8172. 2001, 70, 2, s. 29-35.
3. [1] VESELÝ, J. Guanyliny-nová nadějná cesta ve výzkumu postprandiální natriurézy. In:*Československá fyziologie*. ISSN 1210-6313. 2001, 50, 2, s. 64-70.
4. [6] BLAHOŠ, J. Patofyziológia. In:*Zdravotnícke noviny - Lekárske listy*. ISSN 1335-4477. 1996, 35, s. 6.
5. [5] TROJAN, S. Patofyziologie. Bratislava: Slovac Academic Press, 1996. In:*Československá fyziologie*. ISSN 1210-6313. 1997, 46, 3, s. 121.

6. [3] LOVÁSOVÁ, K. - KLUCHOVÁ, D. - SCHMIDTOVÁ, K. - MIKLOŠOVÁ, M. - RYBÁROVÁ, S. Účinok NADPH-diaforázy na štruktúru sciatického nervu potkanov s diabetom vyvolaným streptozotocínom. In:*Folia Veterinaria*. ISSN 0015-5748. 2000, 44, 2, s. 80-84.

7. [3] VIOLA, A. - STVRTINA, S. - BAUER, V. - ZAVIAČIČ, M. Morfologické a klinické následky fokálnych ischemicných lézií. In: *Čs. patologie*, ISSN 1210-7875. 2000, 36, 4, s. 140-145.

8. [4] ŠEFRÁNEK, V. Ochorenia končatinových artérií a ich chirurgická liečba. Bratislava : SAP, 2001, 240 s.ISBN 80-88908-82-5. 2001,

9. [3] EHRMANN, J. Etiopatogeneze průjmu a základní principy diagnostiky a léčby. In: *Vnitř. Lék.*, ISSN 0042-773X. 2002, 48, 6, s. 563-566.

10. [3] ŠČIGEL, V. V. Repetitorium klinické farmakologie I : antikoagulační a antiagregační léčba. In: *LKS.*, ISSN 1210-3381. 2003, 13, 1, s. 10-15.

11. [3] DANIEL, M. - SOCHOR, M. - IGLIC, A. - KRAJL-IGLIC, V. Hypothesis od regulation of hip joint cartilage activity by mechanical loading. In: *Med. Hypotheses*, ISSN 0306-9877. 2003, 60, 6, s. 936-937.

12. [4] ADAMEOVÁ, A. - KUŽELOVÁ, M. - KLIMAS, J. - KŘENEK, P. - KYSELOVIČ, J. Potencovanie kvality výskumno-vývojovej práce mladých vedeckých a pedagogických pracovníkov na Farmaceutickej fakulte UK. In: *Európsky sociálny fond : č. projektu 13120200090 , Bratislava : Univerzita Komenského,* ISBN 978-80-2232-463-2. 2008, s. 5.

BCI Skriptá a učebné texty (2)

BCI 01

HULÍN, I. - ZLATOŠ, L. - BERNADIČ, M. - MAASOVÁ, D. - KRÁĽ, A. - MLADOSIEVIČOVÁ, B. - SAPÁKOVÁ, E. - BAKOŠOVÁ, M. - HOLZEROVÁ, J. - SOCHOROVÁ, R. - SASVÁRY, F. - FERENČIK, M. - JAKUBOVSKÝ, J. Patofyziológia 2. 2. preprac. a rozš. vyd. Bratislava, Slovac Academic Press. ISBN 80-85665-35-2. 1994, s. 313-716. 403s. (AH1; 5%)

BCI 02

NEMCOVÁ, L. - ZÓLYOMIOVÁ, P. - BIELIK, P. - SPODNIAKOVÁ, Z. - ŠUPÍNOVÁ, M. - MARŠÍK, L. - SASVÁRY, F. - TAUFER, I. - KRIŽO, P. Teória rodinnej výchovy. Vysokoškolské učebné texty. 1.diel. 1. vydanie. Banská Bystrica, Pedagogická fakulta UMB. ISBN 978-80-557-0713-6. 2014, 95s.(AH 2; 11 %)

P2 – pedagogický výstup publikačnej činnosti ako časť učebnice alebo skripta

ADC Vedecké práce v zahraničných karentovaných časopisoch (4)

ADC 01

LEE, A. Y. Y., KAMPHUISEN, P.W., MEYER, G., BAUERSACHS, R., JANAS, M.S., JARNER M.F., KHORANA, A.A.,Tinzaparin vs Warfarin forTreatment of AcuteVenous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial JAMA. 2015;314(7):677–686. doi:10.1001/jama.2015.9243

On behalf of CATCH Investigators:

BELLA., S. R., CERANA, S., ZARBÁ J. J., ANDEL, J., BARRIOS, C. H., BORBA, R. A., CESARIO, F., DE AZEVEDO, S., FERREIRA F. A. F., FRANKE, F. A., PADILHA, S., PAIVA, Q. R., PIMENTA, A., RERIN, J., RIGO, R., ROCHA VAN EYLL, S. B., SANTOS, B. G., VACARO, G., ANASTASOV, V., DRAGNEVA, T., GEORGIEV, G.EORGI, CHAMPION, P., KURUVILLA, P., GONZALEZ, C., DITL, P., FÖRSTER, J, BUNCEK, L. VYDRA, J., ABO, E. H. R., SABRI, S., ALLAHLOUBI, N., ELZAWAWY, A., EZZAT, S. S., SABRY, E. K. M., BAUERSACHS, R., BACCHUS, L., BEYER-WESTENDORF, J., KAMPHAUSEN, U., NIEDERWIESER, D., OSTERMANN, H., SOSADA, M., ANAGNOSTOPOULOS, N., FOUNTZILAS, G., IOANNOU, C., LIAPIS, C., BARRIOS, S. F. J., ATILLI, S., BALSUBRAMANIAN, S., BONDARDE, S., DESAI, S., DESHMUKH, C., SINGH, D. P., GHARAMI, F., GOYAL, L., GUPTA S., GUPTE, S., MUKHERJEE, K. K., KRISHNAN, S., KUMAR, K., MEHTA, A., MISHRA, K., NAIK, R., PAWAR, S., RAJNISH, V. N., WARRIER, N., BRENNER, B. GAVISH, I., LUGASSY, G., KOLIN, M., BREDA, E., MAZZUCCONI, M. G., VISANI, G., AWIDI, A., NOVIKOVS, N., MISCUKS, J., ABIGERGES, D., KHOUEIRY, P., MAKAREM, J., ALVAREZ, O. O., ANAYA, S. E., CALDERILLO, R. G., DE LA CONCHA, U. H. J., PANTIGOSO W. S. R., PHILCO, M., ROMERO, P. A., VARGAS, Q. E. A., GAWRYCHOWSKI, K., WITKIEWICZ, W., MACIAS, E., TEIXEIRA, E., CIULEANU, T. E., LIGIA, C. C., LUNGULESCU, D., MANOLESCU I. G., RODICA, A., VOLOVAT, C., BUROV, Y., KATELNITSKY, I., SVISTOV, D., AHMAD, K., ALGAHTANI, F., AL-ZAHRANI, H., QARI, M., JOVANOVIC, D., PERIN, B., STOJANOVIC, V., TOMASIC, L., CHOVANEC, J., HERMAN O., KISSOVA, V., SASVARY, F., ŠPÁNIK, S., SZENTIVANYI, M., BARÓN,

F., GALLARDO, E., JIMÉNEZ, D., REMEDIOS, O., SANCHEZ, A., ENGELBRECHT, J., JONAS, N., MCADAM, G., PATEL, M., RAPOPORT, B., ROBERTSON, B., DOYEUN, O., HAWK, K.; HOON-KYO, K., HYO J., K., HYO S., K., JIN S. A., JOOSEOP, C., JOUNG S. J., KEON, U. P., SANG-WON, S., SE H. K., SUNG-SOO, Y., YANG-KI, K., CHANG-FANG, C., CHENG-SHYONG, C., JIN-HWANG, L., SHANG-WEN, C., CHITTIMA, S., EKKAPONG, T., NONGLAK, K., PANTEP, A., PRAMOOK, M., THANAKRIT, S., PATRAPIM, S., SUMITRA, T., UDOMLUCK, C., KOBZA, I., NYKONENKO, O., PRASOL, V., VLADYCHUK, I.

Ohlasy (598)

1. [1]KEARON, C., AKL, E. A., ORNELAS, J., BLAIVAS, A., JIMENEZ, D., BOUNAMEAUX, H., MOORES, L. (2016). Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest*, *149*(2), 315-352.

2. [1]KONSTANTINIDES, S. V., MEYER, G., BECATTINI, C., BUENO, H., GEERSING, G. J., HARJOLA, V. P., ZAMORANO, J. L. (2020). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *European heart journal*, *41*(4), 543-603.

3. [1]RASKOB, G. E., VAN ES, N., VERHAMME, P., CARRIER, M., DI NISIO, M., GARCIA, D., BÜLLER, H. R. (2018). Edoxaban for the treatment of cancer-associated venous thromboembolism. *New England Journal of Medicine*, *378*(7), 615-624.

4. [1] YOUNG, A. M., MARSHALL, A., THIRLWALL, J., CHAPMAN, O., LOKARE, A., HILL, C., LEVINE, M. (2018). Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol*.

5. [1]AKL, E. A., VASIREDDI, S. R., GUNUKULA, S., BARBA, M., SPERATI, F., TERRENATO, I., SCHUENEMANN, H. (2011). Anticoagulation for the initial

treatment of venous thromboembolism in patients with cancer. *Cochrane Database of Systematic Reviews*, (6).

6. [1]DI NISIO, M., VAN ES, N., BÜLLER, H. R. (2016). Deep vein thrombosis and pulmonary embolism. *The Lancet*, *388*(10063), 3060-3073.

7. [1]AGNELLI, G., BECATTINI, C., MEYER, G., MUÑOZ, A., HUISMAN, M. V., CONNORS, J. M., VERSO, M. (2020). Apixaban for the treatment of venous thromboembolism associated with cancer. *New England Journal of Medicine*.

8. [1]FARGE, D., BOUNAMEAUX, H., BRENNER, B., CAJFINGER, F., DEBOURDEAU, P., KHORANA, A. A., KAKKAR, A. (2016). International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *The Lancet Oncology*, *17*(10), e452-e466.

9. [1]AY, C., PABINGER, I., COHEN, A. T. (2017). Cancer-associated venous thromboembolism: burden, mechanisms, and management. *Thrombosis and haemostasis*, *117*(02), 219-230.

10. [1]BURNETT, A. E., MAHAN, C. E., VAZQUEZ, S. R., OERTEL, L. B., GARCIA, D. A., ANSELL, J. (2016). Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *Journal of thrombosis and thrombolysis*, *41*(1), 206-232.

11. [1]KHORANA, A. A., NOBLE, S., LEE, A. Y. Y., SOFF, G., MEYER, G., O'CONNELL, C., CARRIER, M. (2018). Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. *J Thromb Haemost*, *16*(9), 1891-1894.

12. [1]KONSTANTINIDES, S. V., BARCO, S., LANKEIT, M., MEYER, G. (2016). Management of pulmonary embolism: an update. *Journal of the American College of Cardiology*, *67*(8), 976-990.

13. [1]MCBANE, R. D., WYSOKINSKI, W. E., LE-RADEMACHER, J. G., ZEMLA, T., ASHRANI, A., TAFUR, A., LOPRINZI, C. L. (2020). Apixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE trial. *Journal of thrombosis and haemostasis*, *18*(2), 411-421.

14. [1]KHORANA, A. A., CARRIER, M., GARCIA, D. A., LEE, A. Y. (2016). Guidance for the prevention and treatment of cancer-associated venous thromboembolism. *Journal of thrombosis and thrombolysis*, *41*(1), 81-91.

15. [1] LI, A., GARCIA, D. A., LYMAN, G. H., CARRIER, M. (2019). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. *Thrombosis research*, *173*, 158-163.

16. [1]STREIFF, M. B., HOLMSTROM, B., ANGELINI, D., ASHRANI, A., BOCKENSTEDT, P. L., CHESNEY, C., ENGH, A. M. (2018). NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. *Journal of the National Comprehensive Cancer Network*, *16*(11), 1289-1303.

17. [1]LYMAN, G. H., CARRIER, M., AY, C., DI NISIO, M., HICKS, L. K., KHORANA, A. A., ALONSO-COELLO, P. (2021). American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood advances*, *5*(4), 927-974.

18. [1]RASKOB, G. E., VAN ES, N., SEGERS, A., ANGCHAISUKSIRI, P., OH, D., BODA, Z., BÜLLER, H. R. (2016). Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. *The Lancet Haematology*, *3*(8), e379-e387.

19. [1]AKL, E. A., KAHALE, L. A., HAKOUM, M. B., MATAR, C. F., SPERATI, F., BARBA, M., SCHÜNEMANN, H. (2017). Parenteral anticoagulation in ambulatory patients with cancer. *Cochrane Database of Systematic Reviews*, (9).

20. [1]AKL, E. A., VAN DOORMAAL, F. F., BARBA, M., KAMATH, G., KIM, S. Y., KUIPERS, S., SCHÜNEMANN, H. (2007). Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. *Cochrane Database of Systematic Reviews*, (3).

21. [1]AGNELLI, G., BECATTINI, C., BAUERSACHS, R., BRENNER, B., CAMPANINI, M., COHEN, A., CARAVAGGIO STUDY INVESTIGATORS. (2018). Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. *Thrombosis and haemostasis*, *118*(09), 1668-1678.

22. [1]KAHALE, L. A., HAKOUM, M. B., TSOLAKIAN, I. G., ALTURKI, F., MATAR, C. F., TERRENATO, I., AKL, E. A. (2018). Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. *Cochrane Database of Systematic Reviews*, (6).

23. [1]CAMPIA, U., MOSLEHI, J. J., AMIRI-KORDESTANI, L., BARAC, A., BECKMAN, J. A., CHISM, D. D., AMERICAN HEART ASSOCIATION COUNCIL ON PERIPHERAL VASCULAR DISEASE; COUNCIL ON ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY; AND COUNCIL ON CARDIOVASCULAR AND STROKE NURSING. (2019). Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. *Circulation*, *139*(13), e579-e602.

24. [1]CHEN, A., STECKER, E., A. WARDEN, B. (2020). Direct oral anticoagulant use: a practical guide to common clinical challenges. *Journal of the American Heart Association*, *9*(13), e017559.

25. [1]VAN ES, N., DI NISIO, M., BLEKER, S. M., SEGERS, A., MERCURI, M. F., SCHWOCHO, L., RASKOB, G. E. (2015). Edoxaban for treatment of venous thromboembolism in patients with cancer. *Thrombosis and haemostasis*, *114*(12), 1268-1276.

26. [1] AKL, E. A., KAHALE, L. A., SPERATI, F., NEUMANN, I., LABEDI, N., TERRENATO, I., SCHUENEMANN, H. (2014). Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database of Systematic Reviews*, (6).

27. [1]MOSARLA, R. C., VADUGANATHAN, M., QAMAR, A., MOSLEHI, J., PIAZZA, G., GIUGLIANO, R. P. (2019). Anticoagulation strategies in patients with cancer: JACC review topic of the week. *Journal of the American College of Cardiology*, *73*(11), 1336-1349.

28. [1]JARA-PALOMARES, L., SOLIER-LOPEZ, A., ELIAS-HERNANDEZ, T., ASENSIO-CRUZ, M., BLASCO-ESQUIVIAS, I., MARIN-BARRERA, L., OTERO, R. (2017). Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. *Thrombosis research*, *157*, 90-96.

29. [1]AKL, E. A., KAMATH, G., YOSUICO, V. E., KIM, S. Y., BARBA, M., SPERATI, F., SCHÜNEMANN, H. (2007). Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. *Cochrane database of systematic reviews*, (3).

30. [1]STREIFF, M. B., MILENTIJEVIC, D., MCCRAE, K., YANNICELLI, D., FORTIER, J., NELSON, W. W., KHORANA, A. A. (2018). Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. *American journal of hematology*, *93*(5), 664-671.

31. [1]FERNANDES, C. J., MORINAGA, L. T., ALVES, J. L., CASTRO, M. A., CALDERARO, D., JARDIM, C. V., SOUZA, R. (2019). Cancer-associated thrombosis: the when, how and why. *European Respiratory Review*, *28*(151).

32. [1]HEIL, J., MIESBACH, W., VOGL, T., BECHSTEIN, W. O., REINISCH, A. (2017). Deep vein thrombosis of the upper extremity: a systematic review. *Deutsches Ärzteblatt International*, *114*(14), 244.

33. [1]KUMBHANI, D. J., CANNON, C. P., BEAVERS, C. J., BHATT, D. L., CUKER, A., GLUCKMAN, T. J., THOURANI, V. H. (2021). 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, *77*(5), 629-658.

34. [1]MULDER, F. I., BOSCH, F., YOUNG, A. M., MARSHALL, A., MCBANE, R. D., ZEMLA, T. J., VAN ES, N. (2020). Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. *Blood*, *136*(12), 1433-1441.

35. [1]AY, C., BEYER-WESTENDORF, J., PABINGER, I. (2019). Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. *Annals of Oncology*, *30*(6), 897-907.

36. [1]GALANAUD, J. P., MONREAL, M., KAHN, S. R. (2018). Epidemiology of the post-thrombotic syndrome. *Thrombosis research*, *164*, 100-109.

37. [1]DUFFETT, L., CARRIER, M. (2017). Inferior vena cava filters. *Journal of Thrombosis and Haemostasis*, *15*(1), 3-12.

38. [1]MAHÉ, I., CHIDIAC, J., BERTOLETTI, L., FONT, C., TRUJILLO-SANTOS, J., PERIS, M., REIS, A. (2017). The clinical course of venous thromboembolism may differ according to cancer site. *The American journal of medicine*, *130*(3), 337-347.

39. [1]MAHÉ, I., CHIDIAC, J., HELFER, H., NOBLE, S. (2016). Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. *Journal of Thrombosis and Haemostasis*, *14*(11), 2107-2113.

40. [1]STEVENS, S. M., WOLLER, S. C., KREUZIGER, L. B., BOUNAMEAUX, H., DOERSCHUG, K., GEERSING, G. J., MOORES, L. K. (2021). Antithrombotic

therapy for VTE disease: second update of the CHEST guideline and expert panel report. *Chest*, *160*(6), e545-e608.

41. [1] MANTIA, C., UHLMANN, E. J., PULIGANDLA, M., WEBER, G. M., NEUBERG, D., ZWICKER, J. I. (2017). Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. *Blood, The Journal of the American Society of Hematology*, *129*(25), 3379-3385.

42. [1]MCBANE II, R., LOPRINZI, C. L., ASHRANI, A., BOTERO, J. P., FERRE, R. A. L., HENKIN, S., WYSOKINSKI, W. E. (2017). Apixaban and dalteparin in active malignancy associated venous thromboembolism. *Thrombosis and Haemostasis*, *117*(10), 1952-1961.

43. [1]CARRIER, M., BLAIS, N., CROWTHER, M., KAVAN, P., LE GAL, G., MOODLEY, O., LEE, A. Y. Y. (2018). Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. *Current Oncology*, *25*(5), 329-337.

44. [1]SHETH, R. A., NIEKAMP, A., QUENCER, K. B., SHAMOUN, F., KNUTTINEN, M. G., NAIDU, S., OKLU, R. (2017). Thrombosis in cancer patients: etiology, incidence, and management. *Cardiovascular diagnosis and therapy*, *7*(Suppl 3), S178.

45. [1]KAHALE, L. A., TSOLAKIAN, I. G., HAKOUM, M. B., MATAR, C. F., BARBA, M., YOSUICO, V. E., AKL, E. A. (2018). Anticoagulation for people with cancer and central venous catheters. *Cochrane Database of Systematic Reviews*, (6).

46. [1]KHORANA, A. A., KAMPHUISEN, P. W., MEYER, G., BAUERSACHS, R., JANAS, M. S., JARNER, M. F., LEE, A. Y. (2017). Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. *Journal of Clinical Oncology*, *35*(10), 1078-1085.

47. [1]JONMARKER, S., HOLLENBERG, J., DAHLBERG, M., STACKELBERG, O., LITORELL, J., EVERHOV, Å. H., CRONHJORT, M. (2020). Dosing of

thromboprophylaxis and mortality in critically ill COVID-19 patients. *Critical Care*, *24*(1), 1-10.

48. [1]DAVIES, G. A., LAZO-LANGNER, A., GANDARA, E., RODGER, M., TAGALAKIS, V., LOUZADA, M., KOVACS, M. J. (2018). A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). *Thrombosis research*, *162*, 88-92.

49. [1]STUBBS, M. J., MOUYIS, M., THOMAS, M. (2018). Deep vein thrombosis. *bmj*, *360*.

50. [1]AKL, E. A., KAMATH, G., KIM, S. Y., YOSUICO, V. E., BARBA, M., TERRENATO, I., SCHÜNEMANN, H. (2007). Oral anticoagulation for prolonging survival in patients with cancer. *Cochrane Database of Systematic Reviews*, (2).

51. [1]VAN DER WALL, S. J., KLOK, F. A., DEN EXTER, P. L., BARRIOS, D., MORILLO, R., CANNEGIETER, S. C., HUISMAN, M. V. (2017). Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. *Journal of Thrombosis and Haemostasis*, *15*(1), 74-79.

52. [1]KEKRE, N., CONNORS, J. M. (2019). Venous thromboembolism incidence in hematologic malignancies. *Blood Reviews*, *33*, 24-32.

53. [1]FUENTES, H. E., TAFUR, A. J., CAPRINI, J. A. (2016). Cancer-associated thrombosis. *Disease-a-Month*, *5*(62), 121-158.

54. [1]WANG, T. F., LI, A., GARCIA, D. (2018). Managing thrombosis in cancer patients. *Research and Practice in Thrombosis and Haemostasis*, *2*(3), 429-438.

55. [1]WANG, K. L., CHU, P. H., LEE, C. H., PAI, P. Y., LIN, P. Y., SHYU, K. G., YEH, S. J. (2016). Management of venous thromboembolisms: part I. The consensus for deep vein thrombosis. *Acta Cardiologica Sinica*, *32*(1), 1.

56. [1] MARSHALL, A., LEVINE, M., HILL, C., HALE, D., THIRLWALL, J., WILKIE, V., YOUNG, A. M. (2020). Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). *Journal of Thrombosis and Haemostasis*, *18*(4), 905-915.

57. [1]ROSSEL, A., ROBERT-EBADI, H., COMBESCURE, C., GROSGURIN, O., STIRNEMANN, J., ADDEO, A., MARTI, C. (2019). Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. *PloS one*, *14*(3), e0213940.

58. [1]CHOPARD, R., ALBERTSEN, I. E., PIAZZA, G. (2020). Diagnosis and treatment of lower extremity venous thromboembolism: a review. *Jama*, *324*(17), 1765-1776.

59. [1]PIRAN, S., SCHULMAN, S. (2016). Management of venous thromboembolism: an update. *Thrombosis journal*, *14*(1), 107-115.

60. [1]HAKOUM, M. B., KAHALE, L. A., TSOLAKIAN, I. G., MATAR, C. F., YOSUICO, V. E., TERRENATO, I., AKL, E. A. (2018). Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. *Cochrane Database of Systematic Reviews*, (1).

61. [1]ROSS, J. A., MILLER, M. M., HERNANDEZ, C. M. R. (2017). Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. *Thrombosis Research*, *150*, 86-89.

62. [1]STREIFF, M. B. (2016). Thrombosis in the setting of cancer. *Hematology 2014, the American Society of Hematology Education Program Book*, *2016*(1), 196-205.

63. [1]FINAZZI, G., DE STEFANO, V., BARBUI, T. (2018). Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. *Blood Cancer Journal*, *8*(7), 1-6.

64. [1]LEEBEEK, F. W. (2016). Update of thrombosis in multiple myeloma. *Thrombosis Research*, *140*, S76-S80.

65. [1]DENTALI, F., PEGORARO, S., BARCO, S., DI MINNO, M. N. D., MASTROIACOVO, D., POMERO, F., DI NISIO, M. (2017). Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. *Journal of thrombosis and haemostasis*, *15*(9), 1757-1763.

66. [1]SCHULMAN, S. (2017). How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. *Blood, The Journal of the American Society of Hematology*, *129*(25), 3285-3293.

67. [1]AL-SAMKARI, H., CONNORS, J. M. (2019). Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. *Hematology 2014, the American Society of Hematology Education Program Book*, *2019*(1), 71-79.

68. [1]WYSOKINSKI, W. E., HOUGHTON, D. E., CASANEGRA, A. I., VLAZNY, D. T., BOTT-KITSLAAR, D. M., FROEHLING, D. A., MCBANE, R. D. (2019). Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. *American Journal of Hematology*, *94*(11), 1185-1192.

69. [1]KLOK, F. A., HUISMAN, M. V. (2017). Management of incidental pulmonary embolism. *European Respiratory Journal*, *49*(6).

70. [1]RIESS, H., PRANDONI, P., HARDER, S., KREHER, S., BAUERSACHS, R. (2018). Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug–drug interactions. *Critical Reviews in Oncology/Hematology*, *132*, 169-179.

71. [1]DE STEFANO, V., FINAZZI, G., BARBUI, T. (2018). Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. *Blood Cancer Journal*, *8*(7), 1-7.

72. [1]VAN ES, N., LOUZADA, M., CARRIER, M., TAGALAKIS, V., GROSS, P. L., SHIVAKUMAR, S., WELLS, P. S. (2018). Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. *Thrombosis research*, *163*, 41-46.

73. [1]GUALANDRO, D. M., YU, P. C., CARAMELLI, B., MARQUES, A. C., CALDERARO, D., FORNARI, L. S., MATHIAS, W. (2017). 3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. *Arquivos Brasileiros de Cardiologia*, *109*, 1-104.

74. [1]SIMMONS, B., WYSOKINSKI, W., SAADIQ, R. A., BOTT-KITSLAAR, D., HENKIN, S., CASANEGRA, A., MCBANE, R. (2018). Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. *European journal of haematology*, *101*(2), 136-142.

75. [1]AY, C., KAMPHUISEN, P. W., AGNELLI, G. (2017). Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. *ESMO open*, *2*(2), e000188.

76. [1]BRUNSON, A., HO, G., WHITE, R., WUN, T. (2017). Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study. *Thrombosis Research*, *153*, 57-64.

77. [1]KAHALE, L. A., MATAR, C. F., TSOLAKIAN, I., HAKOUM, M. B., BARBA, M., YOSUICO, V. E., AKL, E. A. (2021). Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database of Systematic Reviews*, (10).

78. [1]BAUERSACHS, R., LEE, A. Y., KAMPHUISEN, P. W., MEYER, G., JANAS, M. S., JARNER, M. F., CATCH INVESTIGATORS. (2018). Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism—analysis of the CATCH study. *Thrombosis and Haemostasis*, *118*(05), 914-921.

79. [1]ANGELINI, D., KHORANA, A. A. (2017, July). Risk assessment scores for cancer-associated venous thromboembolic disease. In *Seminars in thrombosis and hemostasis* (Vol. 43, No. 05, pp. 469-478). Thieme Medical Publishers.

80. [1] AL-SAMKARI, H., CONNORS, J. M. (2018). The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. *Cancers*, *10*(8), 271.

81. [1]CZUPRYNSKA, J., PATEL, J. P., ARYA, R. (2017). Current challenges and future prospects in oral anticoagulant therapy. *British Journal of Haematology*, *178*(6), 838-851.

82. [1]CAJFINGER, F., DEBOURDEAU, P., LAMBLIN, A., BENATAR, V., FALVO, N., BENHAMOU, Y., FARGE-BANCEL, D. (2016). Low-molecular-weight heparins for cancer-associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. *Thrombosis Research*, *144*, 85-92.

83. [1]LEE, A. Y. (2017). When can we stop anticoagulation in patients with cancer-associated thrombosis?. *Hematology 2014, the American Society of Hematology Education Program Book*, *2017*(1), 128-135.

84. [1]JARA-PALOMARES, L., SOLIER-LOPEZ, A., ELIAS-HERNANDEZ, T., ASENSIO-CRUZ, M. I., BLASCO-ESQUIVIAS, I., SANCHEZ-LOPEZ, V., OTERO-CANDELERA, R. (2018). D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. *British journal of cancer*, *119*(8), 915-921.

85. [1]SCHMAIER, A. A., AMBESH, P., CAMPIA, U. (2018). Venous thromboembolism and cancer. *Current Cardiology Reports*, *20*(10), 1-10.

86. [1]ANNIBALI, O., NAPOLITANO, M., AVVISATI, G., SIRAGUSA, S. (2018). Incidence of venous thromboembolism and use of anticoagulation in hematological

malignancies: Critical review of the literature. *Critical Reviews in Oncology/Hematology*, *124*, 41-50.

87. [1]VEDOVATI, M. C., GIUSTOZZI, M., BONITTA, G., AGNELLI, G., BECATTINI, C. (2018). Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. *Thrombosis Research*, *170*, 175-180.

88. [1]GIRARD, P., PENALOZA, A., PARENT, F., GABLE, B., SANCHEZ, O., DURIEUX, P., ROY, P. M. (2017). Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention. *Journal of Thrombosis and Haemostasis*, *15*(4), 662-669.

89. [1]SOBIERAJ, D. M., BAKER, W. L., SMITH, E., SASIELA, K., TREXLER, S. E., KIM, O., COLEMAN, C. I. (2018). Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. *Clinical and Applied Thrombosis/Hemostasis*, *24*(9_suppl), 182S-187S.

90. [1]SHET, A. S., WUN, T. (2018). How I diagnose and treat venous thromboembolism in sickle cell disease. *Blood, The Journal of the American Society of Hematology*, *132*(17), 1761-1769.

91. [1]MOIK, F., PABINGER, I., AY, C. (2019). How I treat cancer-associated thrombosis. *ESMO open*, *4*, e000610.

92. [1]GOERTZ, L., SCHNEIDER, S. W., DESCH, A., MAYER, F. T., KOETT, J., NOWAK, K., BAUER, A. T. (2016). Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. *Oncotarget*, *7*(42), 68527.

93. [1]SAMUELSON BANNOW, B. T., WALTER, R. B., GERNSHEIMER, T. B., GARCIA, D. A. (2017). Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. *Journal of thrombosis and thrombolysis*, *44*(4), 442-447.

94. [1]WOODRUFF, S., FEUGERE, G., ABREU, P., HEISSLER, J., RUIZ, M. T., JEN, F. (2016). A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. *Journal of Thrombosis and Thrombolysis*, *42*(4), 494-504.

95. [1]MALAVASI, V. L., FANTECCHI, E., GIANOLIO, L., PESCE, F., LONGO, G., MARIETTA, M., BORIANI, G. (2019). Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. *European journal of internal medicine*, *59*, 27-33.

96. [1]IORGA, R. A., BRATU, O. G., MARCU, R. D., CONSTANTIN, T., MISCHIANU, D. L. D., SOCEA, B., DIACONU, C. C. (2019). Venous thromboembolism in cancer patients: Still looking for answers. *Experimental and therapeutic medicine*, *18*(6), 5026-5032.

97. [1]KIRKILESIS, G. I., KAKKOS, S. K., TSOLAKIS, I. A. (2019). Editor's choice–a systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. *European Journal of Vascular and Endovascular Surgery*, *57*(5), 685-701.

98. [1]FUENTES, H. E., MCBANE II, R. D., WYSOKINSKI, W. E., TAFUR, A. J., LOPRINZI, C. L., MURAD, M. H., RIAZ, I. B. (2019, December). Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: a systematic review and network meta-analysis. In *Mayo Clinic Proceedings* (Vol. 94, No. 12, pp. 2444-2454). Elsevier.

99. [1]MATAR, C. F., KAHALE, L. A., HAKOUM, M. B., TSOLAKIAN, I. G., ETXEANDIA-IKOBALTZETA, I., YOSUICO, V. E., AKL, E. A. (2018). Anticoagulation for perioperative thromboprophylaxis in people with cancer. *Cochrane Database of Systematic Reviews*, (7).

100. [1]SONG, A. B., ROSOVSKY, R. P., CONNORS, J. M., AL-SAMKARI, H. (2019). Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. *Vascular health and risk management*, *15*, 175.

101. [1]AMBRUS, D. B., REISMAN, J. I., ROSE, A. J. (2016). The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. *Thrombosis research*, *144*, 21-26.

102. [1]KAMPHUISEN, P. W., LEE, A. Y. Y., MEYER, G., BAUERSACHS, R., JANAS, M. S., JARNER, M. F., RAU, K. M. (2018). Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. *Journal of Thrombosis and Haemostasis*, *16*(6), 1069-1077.

103. [1]LEE, A. Y. (2018). Overview of VTE treatment in cancer according to clinical guidelines. *Thrombosis research*, *164*, S162-S167.

104. [1]CARRIER, M., PRANDONI, P. (2017). Controversies in the management of cancer-associated thrombosis. *Expert Review of Hematology*, *10*(1), 15-22.

105. [1]DOUKETIS, J. D. (2016). The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. *Internal and emergency medicine*, *11*(8), 1031-1035.

106. [1]MENAPACE, L. A., MCCRAE, K. R., KHORANA, A. A. (2016). Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. *Thrombosis Research*, *140*, S93-S98.

107. [1]LACROIX, R., VALLIER, L., BONIFAY, A., SIMONCINI, S., MEGE, D., AUBERT, M., DIGNAT-GEORGE, F. (2019). Microvesicles and cancer associated thrombosis. In *Seminars in Thrombosis and Hemostasis* (Vol. 45, No. 06, pp. 593-603). Thieme Medical Publishers.

108. [1]MAI, V., TANGUAY, V. F., GUAY, C. A., BERTOLETTI, L., MAGNAN, S., TURGEON, A. F., PROVENCHER, S. (2020). DOAC compared to LMWH in the

treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. *Journal of Thrombosis and Thrombolysis*, *50*(3), 661-667.

109. [1]TOMKOWSKI, W., KUCA, P., URBANEK, T., CHMIELEWSKI, D., KRASIŃSKI, Z., PRUSZCZYK, P., ZUBILEWICZ, T. (2017). Venous thromboembolism—recommendations on the prevention, diagnostic approach and management. The 2017 Polish Consensus Statement. *Acta Angiologica*, *23*(2), 35-71.

110. [1]MUÑOZ MARTÍN, A. J., GALLARDO DÍAZ, E., GARCÍA ESCOBAR, I., MACÍAS MONTERO, R., MARTÍNEZ-MARÍN, V., PACHÓN OLMOS, V. SALGADO FERNÁNDEZ, M. (2020). SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). *Clinical and Translational Oncology*, *22*(2), 171-186.

111. [1]ABDULLA, A., DAVIS, W. M., RATNAWEERA, N., SZEFER, E., SCOTT, B. B., LEE, A. Y. (2020). A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. *Thrombosis and haemostasis*, *120*(04), 702-713.

112. [1]BACH, M., BAUERSACHS, R. (2016). Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE. *Thrombosis and Haemostasis*, *116*(S 02), S24-S32.

113. [1]FRERE, C., BENZIDIA, I., MARJANOVIC, Z., FARGE, D. (2019). Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges. *Cancers*, *11*(1), 71.

114. [1]PIRAN, S., SCHULMAN, S. (2018). Management of recurrent venous thromboembolism in patients with cancer: a review. *Thrombosis Research*, *164*, S172-S177.

115. [1]COHEN, A. T., MARAVEYAS, A., BEYER-WESTENDORF, J., LEE, A. Y., MANTOVANI, L. G., BACH, M. (2018). COSIMO–patients with active cancer

changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. *Thrombosis journal*, *16*(1), 1-9.

116. [1]LEVY-MENDELOVICH, S., BARG, A. A., KENET, G. (2018). Thrombosis in pediatric patients with leukemia. *Thrombosis research*, *164*, S94-S97.

117. [1]KRAAIJPOEL, N., TRITSCHLER, T., GUILLO, E., GIRARD, P., LE GAL, G. (2019). Definitions, adjudication, and reporting of pulmonary embolism–related death in clinical studies: a systematic review. *Journal of thrombosis and haemostasis*, *17*(10), 1590-1607.

118. [1]RIESS, H., AY, C., BAUERSACHS, R., BECATTINI, C., BEYER-WESTENDORF, J., CAJFINGER, F., YOUNG, A. M. (2018). Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting. *The oncologist*, *23*(7), 822-839.

119. [1]ANTIC, D., JELICIC, J., VUKOVIC, V., NIKOLOVSKI, S., MIHALJEVIC, B. (2018). Venous thromboembolic events in lymphoma patients: actual relationships between epidemiology, mechanisms, clinical profile and treatment. *Blood Reviews*, *32*(2), 144-158.

120. [1]NOBLE, S., SUI, J. (2016). The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?. *Thrombosis Research*, *140*, S154-S159.

121. [1]PATEL, H. K., KHORANA, A. A. (2019). Anticoagulation in cancer patients: a summary of pitfalls to avoid. *Current Oncology Reports*, *21*(2), 1-8.

122. [1]GRANDONI, F., ALBERIO, L. (2019). Direct oral anticoagulant drugs: On the treatment of cancer-related venous thromboembolism and their potential anti-neoplastic effect. *Cancers*, *11*(1), 46.

123. [1]CHAUDHURY, A., BALAKRISHNAN, A., THAI, C., HOLMSTROM, B., NANJAPPA, S., MA, Z., JAGLAL, M. V. (2018). The efficacy and safety of

rivaroxaban and dalteparin in the treatment of cancer associated venous thrombosis. *Indian Journal of Hematology and Blood Transfusion*, *34*(3), 530-534.

124. [1]ARONIS, K. N., HYLEK, E. M. (2018). Evidence gaps in the era of non–vitamin K Oral anticoagulants. *Journal of the American Heart Association*, *7*(3), e007338.

125. [1]TAFUR, A. J., CAPRINI, J. A., COTE, L., TRUJILLO-SANTOS, J., DEL TORO, J., GARCIA-BRAGADO, F., RIETE INVESTIGATORS. (2017). Predictors of active cancer thromboembolic outcomes. *Thrombosis and Haemostasis*, *117*(06), 1192-1198.

126. [1]ROTH, P., PACE, A., LE RHUN, E., WELLER, M., AY, C., MOYAL, E. C. J., PREUSSER, M. (2021). Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. *Annals of Oncology*, *32*(2), 171-182.

127. [1]KRESOJA, K. P., EBNER, M., ROGGE, N. I., SENTLER, C., KELLER, K., HOBOHM, L., LANKEIT, M. (2019). Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. *International journal of cardiology*, *290*, 144-149.

128. [1]DIMAKAKOS, E. P., VATHIOTIS, I., SYRIGOS, K. (2018). The role of tinzaparin in oncology. *Clinical and Applied Thrombosis/Hemostasis*, *24*(5), 697-707.

129. [1]EDWARDS, E., WAYANT, C., BESAS, J., CHRONISTER, J., VASSAR, M. (2018). How fragile are clinical trial outcomes that support the CHEST clinical practice guidelines for VTE?. *Chest*, *154*(3), 512-520.

130. [1]SIGNORELLI, J. R., GANDHI, A. S. (2019). Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: a pilot study. *Journal of Oncology Pharmacy Practice*, *25*(2), 362-368.

131. [1]LI, A., DAVIS, C., WU, Q., LI, S., KESTEN, M. F., HOLMBERG, L. A., GARCIA, D. A. (2017). Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. *Blood Advances*, *1*(12), 707-714.

132. [1]RHEA, I. B., LYON, A. R., FRADLEY, M. G. (2019). Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies. *Current Oncology Reports*, *21*(5), 1-11.

133. [1]PACHÓN, V., TRUJILLO-SANTOS, J., DOMÈNECH, P., GALLARDO, E., FONT, C., GONZÁLEZ-PORRAS, J. R., LECUMBERRI, R. (2018). Cancer-associated thrombosis: beyond clinical practice guidelines—a multidisciplinary (SEMI–SEOM–SETH) expert consensus. *TH Open*, *2*(04), e373-e386.

134. [1]CHAI-ADISAKSOPHA, C., IORIO, A., CROWTHER, M. A., DE MIGUEL, J., SALGADO, E., ZDRAVESKA, M., KIGITOVICA, D. (2018). Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism. *The American journal of medicine*, *131*(4), 430-437.

135. [1]VOIGTLAENDER, M., LANGER, F. (2018). Management of cancer-associated venous thromboembolism–a case-based practical approach. *Vasa*, *47*(2), 77-89.

136. [1]SOFF, G. A., MONES, J., WILKINS, C. Y., DEVLIN, S., HAEGLER-LAUBE, E., WILLS, J., MANTHA, S. (2019). Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. *Research and practice in thrombosis and haemostasis*, *3*(3), 349-356.

137. [1]ROMUALDI, E., AGENO, W. (2016). Management of recurrent venous thromboembolism in cancer patients. *Thrombosis research*, *140*, S128-S131.

138. [1]SHATZEL, J. J., DAUGHETY, M. M., OLSON, S. R., BEER, T. M., DELOUGHERY, T. G. (2017). Management of anticoagulation in patients with

prostate cancer receiving enzalutamide. *Journal of oncology practice*, *13*(11), 720-727.

139. [1]WOODRUFF, S., LEE, A. Y., CARRIER, M., FEUGÈRE, G., ABREU, P., HEISSLER, J. (2019). Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high-and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. *Journal of Thrombosis and Thrombolysis*, *47*(4), 495-504.

140. [1]D'ALESSIO, A., MARCHETTI, M., TARTARI, C. J., RUSSO, L., CECCHINI, S., LAMBREGTS, K. W., FALANGA, A. (2017). Long term low molecular weight heparin anticoagulant therapy modulates thrombin generation and D-dimer in patients with cancer and venous thromboembolism. *Cancer investigation*, *35*(7), 490-499.

141. [1]MULDER, F. I., BOSCH, F. T., VAN ES, N. (2020). Primary thromboprophylaxis in ambulatory cancer patients: Where do we stand?. *Cancers*, *12*(2), 367.

142. [1]POUDEL, S. K., PARK, D. Y., JIA, X., WILKS, M., PINKAVA, V., O'BRIEN, M., ANGELINI, D. E. (2020). Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. *Journal of Thrombosis and Haemostasis*, *18*(3), 651-659.

143. [1]SERHAL, M., BARNES, G. D. (2019). Venous thromboembolism: A clinician update. *Vascular Medicine*, *24*(2), 122-131.

144. [1]PRITCHARD, E. R., MURILLO JR, J. R., PUTNEY, D., & HOBAUGH, E. C. (2019). Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. *Journal of Oncology Pharmacy Practice*, *25*(1), 52-59.

145. [1]ROJAS-HERNANDEZ, C. M., OO, T. H., GARCÍA-PERDOMO, H. A. (2017). Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. *Journal of thrombosis and thrombolysis*, *43*(2), 233-240.

146. [1]SCHMIDT, R. A., AL ZAKI, A., DESILET, N., SZEFER, E., RATNAWEERA, N., PETERSON, E., LEE, A. Y. (2020). Patient characteristics and long–term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. *Thrombosis research*, *188*, 106-114.

147. [1]SMRKE, A., GROSS, P. L. (2017). Cancer-associated venous thromboembolism: a practical review beyond low-molecular-weight heparins. *Frontiers in medicine*, *4*, 142.

148. [1]IMBERTI, D., CIMMINIELLO, C., DI NISIO, M., MARIETTA, M., POLO FRIZ, H., AGENO, W. (2018). Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. *Expert Opinion on Pharmacotherapy*, *19*(11), 1177-1185.

149. [1]WANG, Y., LV, H., LI, D., CHEN, C., GU, G., SUN, Y., XIA, Y. (2019). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *Frontiers in Pharmacology*, *10*, 773.

150. [1]GERVASO, L., DAVE, H., KHORANA, A. A. (2021). Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. *JACC: CardioOncology*, *3*(2), 173-190.

151. [1]RASCHI, E., BIANCHIN, M., DE PONTI, R., DE PONTI, F., AGENO, W. (2017). Emerging therapeutic uses of direct-acting oral anticoagulants: an evidence-based perspective. *Pharmacological Research*, *120*, 206-218.

152. [1]PHELPS, M. K., WICZER, T. E., ERDELJAC, H. P., VAN DEUSEN, K. R., PORTER, K., PHILIPS, G., WANG, T. F. (2019). A single center retrospective

cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer–A real world experience. *Journal of Oncology Pharmacy Practice*, *25*(4), 793-800.

153. [1]LOPEZ-NUNEZ, J. J., TRUJILLO-SANTOS, J., MONREAL, M. (2018). Management of venous thromboembolism in patients with cancer. *Journal of Thrombosis and Haemostasis*, *16*(12), 2391-2396.

154. [1]VOIGTLAENDER, M., LANGER, F. (2017). Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. *Hämostaseologie*, *37*(04), 241-255.

155. [1]PEÑALOZA-MARTÍNEZ, E., DEMELO-RODRÍGUEZ, P., PROIETTI, M., SORIA FERNANDEZ-LLAMAZARES, G., LLAMAZARES-MENDO, C., ALVAREZ-SALA WALTHER, L., DEL TORO-CERVERA, J. (2018). Update on extended treatment for venous thromboembolism. *Annals of Medicine*, *50*(8), 666-674.

156. [1]PRISCO, D., TUFANO, A., CENCI, C., PIGNATELLI, P., SANTILLI, F., DI MINNO, G., PERTICONE, F. (2019). Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. *Internal and Emergency Medicine*, *14*(1), 21-38.

157. [1]VEDOVATI, M. C., GIUSTOZZI, M., BECATTINI, C. (2019). Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. *Thrombosis Research*, *177*, 33-41.

158. [1]HELFER, H., SIGURET, V., MAHÉ, I. (2020). Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications. *American Journal of Cardiovascular Drugs*, *20*(3), 223-228.

159. [1]VALLAT, B., WEBB, B., WESTBROOK, J., SALI, A., BERMAN, H. M. (2019). Archiving and disseminating integrative structure models. *Journal of biomolecular NMR*, *73*(6), 385-398.

160. [1]LI, A., MANOHAR, P. M., GARCIA, D. A., LYMAN, G. H., STEUTEN, L. M. (2019). Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. *Thrombosis research*, *180*, 37-42.

161. [1]BOON, G. J. A. M., VAN DAM, L. F., KLOK, F. A., HUISMAN, M. V. (2018). Management and treatment of deep vein thrombosis in special populations. *Expert review of hematology*, *11*(9), 685-695.

162. [1]BRENNER, B., HULL, R., ARYA, R., BEYER-WESTENDORF, J., DOUKETIS, J., ELALAMY, I., ZHAI, Z. (2019). Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. *Thrombosis journal*, *17*(1), 1-12.

163. [1]YHIM, H. Y., CHOI, W. I., KIM, S. H., NAM, S. H., KIM, K. H., MUN, Y. C., BANG, S. M. (2019). Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. *The Korean journal of internal medicine*, *34*(5), 1125.

164. [1]KRAAIJPOEL, N., VAN ES, N., BLEKER, S. M., BREKELMANS, M. P., EERENBERG, E. S., MIDDELDORP, S., BÜLLER, H. R. (2018). Clinical impact and course of anticoagulant-related major bleeding in cancer patients. *Thrombosis and haemostasis*, *118*(01), 174-181.

165. [1]BRUNETTI, N. D., TRICARICO, L., CORREALE, M., DE GENNARO, L., SANTORO, F., IEVA, R., DI BIASE, M. (2020). Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials. *Journal of Thrombosis and Thrombolysis*, *50*(2), 305-310.

166. [1]BRUNSON, A., KEEGAN, T., MAHAJAN, A., WHITE, R., WUN, T. (2019). High incidence of venous thromboembolism recurrence in patients with sickle cell disease. *American journal of hematology*, *94*(8), 862-870.

167. [1]FRANCO-MORENO, A., CABEZÓN-GUTIÉRREZ, L., PALKA-KOTLOWSA, M., VILLAMAYOR-DELGADO, M., GARCÍA-NAVARRO, M. (2019). Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update. *Journal of Thrombosis and Thrombolysis*, *47*(3), 409-419.

168. [1]LEADER, A., TEN CATE, H., SPECTRE, G., BECKERS, E. A. M., FALANGA, A. (2018). Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps. *Critical Reviews in Oncology/Hematology*, *132*, 76-88.

169. [1]FARGE, D., FRERE, C. (2019). Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. *F1000Research*, *8*.

170. [1]MOY, R. H., YOUNES, A. (2018). Immune checkpoint inhibition in Hodgkin lymphoma. *HemaSphere*, *2*(1).

171. [1]LIU, M. Y., BALLARD, D. W., HUANG, J., RAUCHWERGER, A. S., REED, M. E., BOUVET, S. C., VINSON, D. R. (2018). Acute pulmonary embolism in emergency department patients despite therapeutic anticoagulation. *Western Journal of Emergency Medicine*, *19*(3), 510.

172. [1]O'CONNELL, C., ESCALANTE, C. P., GOLDHABER, S. Z., MCBANE, R., CONNORS, J. M., RASKOB, G. E. (2021). Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. *The Oncologist*, *26*(1), e8-e16.

173. [1]KOHN, C. G., LYMAN, G. H., BEYER-WESTENDORF, J., SPYROPOULOS, A. C., BUNZ, T. J., BAKER, W. L., COLEMAN, C. I. (2018). Effectiveness and safety of rivaroxaban in patients with cancer-associated venous thrombosis. *Journal of the National Comprehensive Cancer Network*, *16*(5), 491-497.

174. [1]KHORANA, A. A., WEITZ, J. I. (2018). Treatment challenges in venous thromboembolism: an appraisal of rivaroxaban studies. *Thrombosis and Haemostasis*, *118*(S 01), S23-S33.

175. [1]RENNER, E., BARNES, G. D. (2020). Antithrombotic management of venous thromboembolism: JACC focus seminar. *Journal of the American College of Cardiology*, *76*(18), 2142-2154.

176. [1]WOJTUKIEWICZ, M. Z., SKALIJ, P., TOKAJUK, P., POLITYNSKA, B., WOJTUKIEWICZ, A. M., TUCKER, S. C., HONN, K. V. (2020). Direct oral anticoagulants in cancer patients. Time for a change in paradigm. *Cancers*, *12*(5), 1144.

177. [1]AMATO, B., COMPAGNA, R., ROCCA, A., BIANCO, T., MILONE, M., SIVERO, L., SERRA, R. (2016). Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. *Drug Design, Development and Therapy*, *10*, 2041.

178. [1]COHEN, A., KESHISHIAN, A., LEE, T., WYGANT, G., ROSENBLATT, L., HLAVACEK, P., LUO, X. (2021). Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis. *Thrombosis and haemostasis*, *121*(03), 383-395.

179. [1]HOROWITZ, N. A., BRENNER, B. (2020). Thrombosis in hematological malignancies: mechanisms and implications. *Thrombosis Research*, *191*, S58-S62.

180. [1]RECIO-BOILES, A., VEERAVELLI, S., VONDRAK, J., BABIKER, H. M., SCOTT, A. J., SHROFF, R. T., MCBRIDE, A. (2019). Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. *World Journal of Gastrointestinal Oncology*, *11*(10), 866.

181. [1]TAO, D. L., OLSON, S. R., DELOUGHERY, T. G., SHATZEL, J. J. (2020). The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis. *European journal of haematology*, *105*(3), 360.

182. [1]HAMZA, M. S., MOUSA, S. A. (2020). Cancer-associated thrombosis: risk factors, molecular mechanisms, future management. *Clinical and Applied Thrombosis/Hemostasis*, *26*, 1076029620954282.

183. [1]VOIGTLAENDER, M., LANGER, F. (2019). Low-molecular-weight heparin in cancer patients: overview and indications. *Hämostaseologie*, *39*(01), 067-075.

184. [1]BAUERSACHS, R. M. (2016). LMWH in cancer patients with renal impairment–better than warfarin?. *Thrombosis Research*, *140*, S160-S164.

185. [1]KHORANA, A. A., MCCRAE, K., MILENTIJEVIC, D., MCCORMICK, N., LALIBERTÉ, F., CRIVERA, C., STREIFF, M. B. (2019). The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. *American journal of hematology*, *94*(2), E58.

186. [1]GUALANDRO, D. M., YU, P. C., CARAMELLI, B., MARQUES, A. C., CALDERARO, D., FORNARI, L. S., MATHIAS, W. (2017). 3ª Diretriz de avaliação cardiovascular perioperatória da Sociedade Brasileira de Cardiologia. *Arquivos Brasileiros de Cardiologia*, *109*, 1-104.

187. [1]BORJAS-HOWARD, J. F., DE LEEUW, K., RUTGERS, A., MEIJER, K., TICHELAAR, V. Y. I. G. (2019, March). Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. In *Seminars in thrombosis and hemostasis* (Vol. 45, No. 02, pp. 141-149). Thieme Medical Publishers.

188. [1]PARK, J., KIM, J., LEE, S. H., LEE, J. H., MIN, J. J., KWON, J. H., GWON, H. C. (2020). Postoperative statin treatment may be associated with improved

mortality in patients with myocardial injury after noncardiac surgery. *Scientific reports*, *10*(1), 1-9.

189. [1]MARTINEZ, B. K., SHETH, J., PATEL, N., BAKER, W. L., COLEMAN, C. I. (2018). Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *38*(6), 610-618.

190. [1]KIM, J. H., SEO, S., KIM, K. P., CHANG, H. M., RYOO, B. Y., YOO, C., PARK, S. R. (2020). Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. *in vivo*, *34*(2), 829-837.

191. [1]CHIN-YEE, N., TANUSEPUTRO, P., CARRIER, M., NOBLE, S. (2019). Thromboembolic disease in palliative and end-of-life care: A narrative review. *Thrombosis research*, *175*, 84-89.

192. [1]XIONG, W. (2021). Current status of treatment of cancer-associated venous thromboembolism. *Thrombosis Journal*, *19*(1), 1-12.

193. [1]ELEWA, H., ELREFAI, R., BARNES, G. D. (2016). Cancer-associated venous thromboembolism. *Current treatment options in cardiovascular medicine*, *18*(4), 1-9.

194. [1]SHAH, S., KARATHANASI, A., REVYTHIS, A., IOANNIDOU, E., BOUSSIOS, S. (2021). Cancer-Associated thrombosis: A new light on an old story. *Diseases*, *9*(2), 34.

195. [1]MAHAJAN, A., WUN, T. (2019). Biomarkers of cancer-associated thromboembolism. In *Thrombosis and Hemostasis in Cancer* (pp. 69-85). Springer, Cham.

196. [1]LIM, G., HO, C., URGOTI, G. R., LEUGNER, D., EASAW, J. (2018). Risk of venous thromboembolism in glioblastoma patients. *Cureus*, *10*(5).

197. [1]LE RHUN, E., PERRY, J. R. (2016). Vascular complications in glioma patients. *Handbook of clinical neurology*, *134*, 251-266.

198. [1]FALANGA, A., MARCHETTI, M., SCHIEPPATI, F. (2021). Prevention and management of thrombosis in BCR/ABL-negative myeloproliferative neoplasms. *Hämostaseologie*, *41*(01), 048-057.

199. [1]KOZAK, P. M., XU, M., FARBER-EGER, E., GAILANI, D., WELLS, Q. S., BECKMAN, J. A. (2019). Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. *Journal of the American Heart Association*, *8*(22), e013395.

200. [1]SIDAHMED, S., ABDALLA, A., KHEIRI, B., BALA, A., SALIH, M., BACHUWA, G., LYMAN, G. H. (2020). Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. *Critical Reviews in Oncology/Hematology*, *152*, 103005.

201. [1]MARTÍNEZ-ZAPATA, M. J., MATHIOUDAKIS, A. G., MOUSA, S. A., BAUERSACHS, R. (2018). Tinzaparin for long-term treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. *Clinical and Applied Thrombosis/Hemostasis*, *24*(2), 226-234.

202. [1]PARK, J., HYEON, C. W., LEE, S. H., KIM, J., KWON, J. H., YANG, K., GWON, H. C. (2020). Mildly elevated cardiac troponin below the 99th-Percentile upper reference limit after noncardiac surgery. *Korean Circulation Journal*, *50*(10), 925-937.

203. [1]LABRADOR, J., GONZÁLEZ-RIVERO, J., MONROY, R., LOZANO, F. S., LÓPEZ-CORRAL, L., CABALLERO, M. D., GONZÁLEZ-PORRAS, J. R. (2016). Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center. *Thrombosis Research*, *142*, 52-56.

204. [1]MAHÉ, I., ELALAMY, I., GEROTZIAFAS, G. T., GIRARD, P. (2019). Treatment of cancer-associated thrombosis: beyond HOKUSAI. *TH Open*, *3*(03), e309-e315.

205. [1]VAN ES, N., BLEKER, S. M., WILTS, I. T., PORRECA, E., DI NISIO, M. (2016). Prevention and treatment of venous thromboembolism in patients with cancer: focus on drug therapy. *Drugs*, *76*(3), 331-341.

206. [1]BEYER-WESTENDORF, J., KLAMROTH, R., KREHER, S., LANGER, F., MATZDORFF, A., RIESS, H. (2019). Non-vitamin K antagonist oral anticoagulants (NOAC) as an alternative treatment option in tumor-related venous thromboembolism. *Deutsches Ärzteblatt International*, *116*(3), 31.

207. [1]CZAP, A. L., BECKER, A., WEN, P. Y. (2019, June). Thrombotic complications in gliomas. In *Seminars in Thrombosis and Hemostasis* (Vol. 45, No. 04, pp. 326-333). Thieme Medical Publishers.

208. [1]KIM, S. A., YHIM, H. Y., BANG, S. M. (2019). Current management of cancer-associated venous thromboembolism: focus on direct oral anticoagulants. *Journal of Korean Medical Science*, *34*(6).

209. [1]CESARMAN-MAUS, G., J RUIZ-ARGUELLES, G. (2017). News in the indications of direct oral anticoagulants according to the American College of Chest Physicians 2016 guidelines. *Current Drug Metabolism*, *18*(7), 651-656.

210. [1]TUKAYE, D. N., BRINK, H., BALIGA, R. (2016). Venous thromboembolism in cancer patients: risk assessment, prevention and management. *Future Cardiology*, *12*(2), 221-235.

211. [1]ROJAS-HERNANDEZ, C. M. (2018). The role of direct oral anticoagulants in cancer-related venous thromboembolism: a perspective beyond the guidelines. *Supportive Care in Cancer*, *26*(3), 711-720.

212. [1]SCHAEFER, J. K., LI, M., WU, Z., BASU, T., DORSCH, M. P., BARNES, G. D., SOOD, S. L. (2021). Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. *Journal of Thrombosis and Haemostasis*, *19*(1), 212-220.

213. [1]MARAVEYAS, A., MUAZZAM, I., NOBLE, S., BOZAS, G. (2017). Advances in managing and preventing thromboembolic disease in cancer patients. *Current opinion in supportive and palliative care*, *11*(4), 347-354.

214. [1]RUIZ-ARTACHO, P., TRUJILLO-SANTOS, J., LÓPEZ-JIMÉNEZ, L., FONT, C., DEL CARMEN DÍAZ-PEDROCHE, M., MUÑOZ-TORRERO, J. F. S., RIETE INVESTIGATORS. (2018). Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism. *TH Open*, *2*(02), e210-e217.

215. [1]PRANDONI, P. (2015). The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. *Expert Opinion on Pharmacotherapy*, *16*(16), 2391-2394.

216. [1]BAUERSACHS, R. (2016). Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. *Thrombosis Research*, *144*, 12-20.

217. [1]CONNELL, N. T., ABEL, G. A., CONNORS, J. M. (2017). Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. *Thrombosis Research*, *150*, 53-58.

218. [1]ROBERTI, R., IANNONE, L. F., PALLERIA, C., CURCIO, A., ROSSI, M., SCIACQUA, A., CITRARO, R. (2021). Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. *Frontiers in pharmacology*, *12*, 684638.

219. [1]ROJAS-HERNANDEZ, C. M., ZAPATA-COPETE, J. A., GARCÍA-PERDOMO, H. A. (2018). Role of vena cava filters for the management of cancer-

related venous thromboembolism: systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, *130*, 44-50.

220. [1]CARRIER, M., SOFF, G., GAL, G. L. (2019). Treatment of venous thromboembolism in cancer. Historical perspective and evolving role of the direct oral anticoagulants. In *Thrombosis and Hemostasis in Cancer* (pp. 103-115). Springer, Cham.

221. [1]KWON, J. H., PARK, J., LEE, S. H., LEE, J. H., MIN, J. J., KIM, J., GWON, H. C. (2021). Pre-operative anaemia and myocardial injury after noncardiac surgery: A retrospective study. *European Journal of Anaesthesiology| EJA*, *38*(6), 582-590.

222. [1]LEADER, A., HOFSTETTER, L., SPECTRE, G. (2021). Challenges and advances in managing thrombocytopenic cancer patients. *Journal of Clinical Medicine*, *10*(6), 1169.

223. [1]FALANGA, A., LE GAL, G., CARRIER, M., ABDEL-RAZEQ, H., AY, C., MARTIN, A. J. M., BRENNER, B. (2021). Management of cancer-associated thrombosis: unmet needs and future perspectives. *TH Open*, *5*(03), e376-e386.

224. [1]AY, C., MACKMAN, N. (2017). Tissue factor: catch me if you can!. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, *35*(10), 1128-1130.

225. [1]PARK, J., OH, A. R., LEE, S. H., LEE, J. H., MIN, J. J., KWON, J. H., LEE, S. M. (2021). Associations between preoperative glucose and hemoglobin A1c level and myocardial injury after noncardiac surgery. *Journal of the American Heart Association*, *10*(7), e019216.

226. [1]SCOTTÉ, F., LEROY, P., CHASTENET, M., AUMONT, L., BENATAR, V., ELALAMY, I. (2019). Treatment and prevention of cancer-associated thrombosis in frail patients: Tailored management. *Cancers*, *11*(1), 48.

227. [1]NAPOLITANO, M., MANSUETO, M. F., RASO, S., SIRAGUSA, S. (2020). Quality of life in patients with cancer under prolonged anticoagulation for high-risk deep vein thrombosis: a long-term follow-up. *Clinical and Applied Thrombosis/Hemostasis*, *26*, 1076029620918290.

228. [1]EASAW, J. C., MCCALL, S., AZIM, A. (2019). ClotAssist: A program to treat cancer-associated thrombosis in an outpatient pharmacy setting. *Journal of Oncology Pharmacy Practice*, *25*(4), 818-823.

229. [1]STREIFF, M., MILENTIJEVIC, D., MCCRAE, K. R., LALIBERTÉ, F., LEJEUNE, D., LEFEBVRE, P., KHORANA, A. A. (2019). Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. *Journal of Medical Economics*, *22*(11), 1134-1140.

230. [1]VOUKALIS, C., LIP, G. Y., SHANTSILA, E. (2016). Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. *Expert Opinion on Pharmacotherapy*, *17*(15), 2033-2047.

231. [1]JEAN, G. W., KELLY, K., MATHEW, J., LARUMBE, E., HUGHES, R. (2017). Venous thromboembolism treatment outcomes in cancer patients and effect of third-party payers on anticoagulant choice. *Supportive Care in Cancer*, *25*(1), 59-66.

232. [1]RABINOVICH, E., BARTHOLOMEW, J. R., WILKS, M. L., TRIPP, B. L., MCCRAE, K. R., KHORANA, A. A. (2016). Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. *Thrombosis Research*, *147*, 102-103.

233. [1]SURYANARAYAN, D., LEE, A. Y., WU, C. (2019, September). Direct oral anticoagulants in cancer patients. In *Seminars in Thrombosis and Hemostasis* (Vol. 45, No. 06, pp. 638-647). Thieme Medical Publishers.

234. [1]VERSO, M., FRANCO, L., GIUSTOZZI, M., BECATTINI, C., AGNELLI, G. (2018). Treatment of venous thromboembolism in patients with cancer: What news from clinical trials?. *Thrombosis research*, *164*, S168-S171.

235. [1]KHAN, M., COX, T. M., NASSIF, M., ALZUBAIDI, M. A., GARG, N., QIAO, W., ROJAS-HERNANDEZ, C. M. (2018). Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. *Journal of Thrombosis and Thrombolysis*, *45*(3), 377-385.

236. [1]POSCH, F., AY, C. (2017). Symptoms, signs, suspicion and setting: a PESI score for cancer-associated pulmonary embolism?. *European Respiratory Journal*, *49*(1).

237. [1]GOCKEL, L. M., PONERT, J. M., SCHWARZ, S., SCHLESINGER, M., BENDAS, G. (2018). The low molecular weight heparin tinzaparin attenuates platelet activation in terms of metastatic niche formation by coagulation-dependent and independent pathways. *Molecules*, *23*(11), 2753.

238. [1]BAUERSACHS, R., KHORANA, A. A., LEE, A. Y., SOFF, G. (2020). Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. *Research and Practice in Thrombosis and Haemostasis*, *4*(4), 532-549.

239. [1]UEYAMA, H., MIYASHITA, H., TAKAGI, H., CRUZ, C., BURGER, A., BRIASOULIS, A., KUNO, T. (2021). Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. *Journal of Thrombosis and Thrombolysis*, *51*(1), 102-111.

240. [1]WANG, K. L., KAO, Y. T., CHANG, W. T., CHANG, H. Y., HUANG, W. C., HSU, P. C., CHU, P. H. (2020). Management of venous thromboembolisms: part II. The consensus for pulmonary embolism and updates. *Acta Cardiologica Sinica*, *36*(6), 562.

241. [1]PATEL, S. H., GEORGE, T. L., WANG, T. F., VOGT, S. M., FOLEFAC, E., XU, M., YIN, M. (2021). Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. *Cancer*, *127*(6), 938-945.

242. [1]LEADER, A., TEN CATE, V., TEN CATE-HOEK, A. J., BECKERS, E. A., SPECTRE, G., GIACCHERINI, C., TEN CATE, H. (2020). Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. *European journal of internal medicine*, *77*, 86-96.

243. [1]CARRIER, M., BLAIS, N., CROWTHER, M., KAVAN, P., LE GAL, G., MOODLEY, O., LEE, A. Y. (2021). Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. *Current Oncology*, *28*(6), 5434-5451.

244. [1]DRANITSARIS, G., SHANE, L. G., WOODRUFF, S. (2019). Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: a systematic literature review of efficacy and cost-effectiveness. *Journal of Oncology Pharmacy Practice*, *25*(1), 68-75.

245. [1]BOEY, J. P., GALLUS, A. (2016). Drug treatment of venous thromboembolism in the elderly. *Drugs & aging*, *33*(7), 475-490.

246. [1]DRANITSARIS, G., SHANE, L. G., CROWTHER, M., FEUGERE, G., WOODRUFF, S. (2017). Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. *Clinicoeconomics and Outcomes Research: CEOR*, *9*, 65.

247. [1]PANAHI, L., UDEANI, G., HORSEMAN, M., WESTON, J., SAMUEL, N., JOSEPH, M., BAZAN, D. (2021). Review of medical therapies for the management of pulmonary embolism. *Medicina*, *57*(2), 110.

248. [1]TOMKOWSKI, W., KUCA, P., URBANEK, T., CHMIELEWSKI, D., KRASIŃSKI, Z., PRUSZCZYK, P., ZUBILEWICZ, T. (2017). Żylna choroba zakrzepowo-zatorowa—wytyczne profilaktyki, diagnostyki i terapii Konsensus Polski 2017. *Acta Angiologica*, *23*(2), 73-113.

249. [1]TARANTINI, L., GULIZIA, M. M., DI LENARDA, A., MAUREA, N., ABRIGNANI, M. G., BISCEGLIA, I., INNO13, A. (2017). Documento di consenso ANMCO/AICO/AIOM: Snodi clinico-gestionali in ambito cardioncologico. *G Ital Cardiol*, *18*(1), 14-66.

250. [1] BHATIA, K., UBEROI, G., BAJAJ, N. S., JAIN, V., ARORA, S., TAFUR, A., QAMAR, A. (2020). Meta-analysis comparing direct oral anticoagulants to low molecular weight heparin for treatment of venous thromboembolism in patients with cancer. *American Journal of Cardiology*, *133*, 175-178.

251. [1]DESAI, R., KOIPALLIL, G. K., THOMAS, N., MHASKAR, R., VISWESHWAR, N., LABER, D., JAGLAL, M. (2020). Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. *Scientific Reports*, *10*(1), 1-11.

252. [1]OH, A. R., PARK, J., LEE, S. H., KIM, J., LEE, J. H., MIN, J. J., GWON, H. C. (2021). Elevated high-sensitivity C-reactive protein concentrations may be associated with increased postdischarge mortality in patients with myocardial injury after noncardiac surgery: A retrospective observational study. *European Journal of Anaesthesiology| EJA*, *38*, S33-S40.

253. [1]PAPAKOTOULAS, P., TSOUKALAS, N., CHRISTOPOULOU, A., ARDAVANIS, A., KOUMAKIS, G., PAPANDREOU, C., BOUKOVINAS, I. (2020). Management of cancer-associated thrombosis (CAT): symptomatic or incidental. *Anticancer Research*, *40*(1), 305-313.

254. [1]PAPAKONSTANTINOU, P. E., TSIOUFIS, C., KONSTANTINIDIS, D., ILIAKIS, P., LEONTSINIS, I., TOUSOULIS, D. (2020). Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non-Vitamin K Antagonists Oral Anticoagulants. *Current pharmaceutical design*, *26*(23), 2692-2702.

255. [1]TAFUR, A. J., FUENTES, H., CAPRINI, J. A., RIVAS, A., URESANDI, F., DUCE, R., MONREAL, M. (2018). Predictors of early mortality in cancer-associated thrombosis: analysis of the RIETE database. *TH Open*, *2*(02), e158-e166.

256. [1]LEADER, A., GUREVICH-SHAPIRO, A., SPECTRE, G. (2020). Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia. *Thrombosis Research*, *191*, S68-S73.

257. [1]MUMOLI, N., BARCO, S., CEI, M., GIORGI-PIERFRANCESCHI, M., CAMPANINI, M., FONTANELLA, A., DENTALI, F. (2017). Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians. *Internal and Emergency Medicine*, *12*(4), 437-443.

258. [1]PARK, J., KWON, J. H., LEE, S. H., LEE, J. H., MIN, J. J., KIM, J., GWON, H. C. (2021). Intraoperative blood loss may be associated with myocardial injury after non-cardiac surgery. *PloS one*, *16*(2), e0241114.

259. [1]DRANITSARIS, G., SHANE, L. G., GALANAUD, J. P., STEMER, G., DEBOURDEAU, P., WOODRUFF, S. (2017). Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria. *Supportive Care in Cancer*, *25*(7), 2093-2102.

260. [1]MOYER, G. C., BANNOW, B. S., THORNBURG, C., ROSOVSKY, R., WANG, T. F., WOLLER, S., KREUZIGER, L. B. (2018). Venous thromboembolism: a survey of oral anticoagulant preferences in the treatment of challenging patient populations. *Clinical and Applied Thrombosis/Hemostasis*, *24*(9_suppl), 209S-216S.

261. [1]KHORANA, A. A., MCCRAE, K. R., MILENTIJEVIC, D., FORTIER, J., NELSON, W. W., LALIBERTÉ, F., SCHEIN, J. (2019). Duration of anticoagulant therapy and VTE recurrence in patients with cancer. *Supportive Care in Cancer*, *27*(10), 3833-3840.

262. [1]KREUZIGER, L. B., STREIFF, M. (2016). Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. *Hematology 2014, the American Society of Hematology Education Program Book, 2016*(1), 206-207.

263. [1]HANNEVIK, T. L., BREKKE, J., ENDEN, T., FRØEN, H., GARRESORI, H., JACOBSEN, E. M., DAHM, A. E. A. (2020). Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. *Thrombosis Research*, *196*, 238-244.

264. [1]FRERE, C., CRICHI, B., LEJEUNE, M., SPANO, J. P., JANUS, N. (2020). Are patients with active cancer and those with history of cancer carrying the same risks of recurrent VTE and bleeding while on anticoagulants?. *Cancers*, *12*(4), 917.

265. [1]RAFII, H., FRERE, C., BENZIDIA, I., CRICHI, B., ANDRE, T., ASSENAT, E., FARGE, D. (2020). Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). *JMV-Journal de Médecine Vasculaire*, *45*(1), 28-40.

266. [1]ROJAS-HERNANDEZ, C. M., TANG, V. K., SANCHEZ-PETITTO, G., QIAO, W., RICHARDSON, M., ESCALANTE, C. (2020). Development of a clinical prediction tool for cancer-associated venous thromboembolism (cat): the MD Anderson cancer center cat model. *Supportive Care in Cancer*, *28*(8), 3755-3761.

267. [1]GOUIN, B., ROBERT-EBADI, H., RIGHINI, M., BLONDON, M. (2017). Pharmacological management of pulmonary embolism. *Expert opinion on pharmacotherapy*, *18*(1), 79-93.

268. [1]GRESSEL, G. M., MARCUS, J. Z., MULLEN, M. M., SINNO, A. K. (2021). Direct oral anticoagulant use in gynecologic oncology: a Society of Gynecologic Oncology clinical practice statement. *Gynecologic oncology*, *160*(1), 312-321.

269. [1]MULDER, F. I., KRAAIJPOEL, N., DI NISIO, M., MEYER, G., MAHÉ, I., MUÑOZ, A., VAN ES, N. (2019). The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism. *Thrombosis Research, 181,* 59-63.

270. [1]PARK, J., YANG, K., LEE, S. H., LEE, J. H., MIN, J. J., KWON, J. H., LEE, S. M. (2020). Comparison of acute and chronic myocardial injury in noncardiac surgical patients. *PloS one*, *15*(7), e0234776.

271. [1]AL-SAMKARI, H., SONG, A. B., CONNORS, J. M. (2020). Cancer-associated thrombosis: Where do we stand?. *Advances in Cell and Gene Therapy*, *3*(1), e73.

272. [1]YEUNG, J., DIX, C. H., RITCHIE, A. G., KOW, M., CHEN, V. M. (2020). Tinzaparin for venous thromboembolism in patients with renal impairment–a single-centre, prospective pilot study. *Internal Medicine Journal*.

273. [1]KIMPTON, M., CARRIER, M. (2019). Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. *Expert Opinion on Drug Safety*, *18*(4), 313-320.

274. [1]FIORELLI, E. M., ROSSI, R. E. (2018). Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin. *Internal and Emergency Medicine*, *13*(7), 1089-1091.

275. [1]RAMACCIOTTI, E., AGATI, L. B., CAFFARO, R. A., VOLPIANI, G. G., LOPES, R. D., COMEROTA, A. J., FAREED, J. (2019). Direct oral anticoagulants and cancer-associated thrombosis management. Where do we stand in 2019?. *Clinical and Applied Thrombosis/Hemostasis*, *25*, 1076029619856433.

276. [1]NOBLE, S. (2018). Are new anticoagulants a safe and reasonable alternative to low molecular heparins?. *Thrombosis Research, 164,* S157-S161.

277. [1]NOBLE, S. (2016). Thromboembolic disease and breathlessness. *Current Opinion in Supportive and Palliative Care*, *10*(3), 249-255.

278. [1]VAN DER WALL, S. J., KLOK, F. A., DEN EXTER, P. L., BARRIOS, D., MORILLO, R., CANNEGIETER, S. C., HUISMAN, M. V. (2018). Higher adherence to treatment with low-molecular-weight-heparin nadroparin than enoxaparin because of side effects in cancer-associated venous thromboembolism. *HemaSphere*, *2*(1).

279. [1]DONADINI, M. P., SQUIZZATO, A., AGENO, W. (2016). Treating patients with cancer and acute venous thromboembolism. *Expert Opinion on Pharmacotherapy*, *17*(4), 535-543.

280. [1]CHIASAKUL, T., REDD, R., PATELL, R., KHAN, A. M., MCCARTHY, E. P., NEUBERG, D., ZWICKER, J. I. (2021). Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. *Journal of Thrombosis and Haemostasis*, *19*(11), 2825-2834.

281. [1]MAJMUDAR, K., GOLEMI, I., TAFUR, A. J., TORO, J. D., VISONÀ, A., FALGÁ, C., RIETE INVESTIGATORS. (2020). Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. *Vascular Medicine*, *25*(3), 210-217.

282. [1]MUNOT, P. N., NORONHA, V., PATIL, V., JOSHI, A., MENON, N., PRABHASH, K. (2020). Cancer thrombosis: Narrative review. *Cancer Research, Statistics, and Treatment*, *3*(3), 501.

283. [1]WOOD, P., BOYER, G., MEHANNA, E., CAGNEY, D., LAMBA, N., CATALANO, P., AIZER, A. (2021). Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. *Journal of Neurology, Neurosurgery & Psychiatry*, *92*(6), 655-661.

284. [1]OH, S. B., SEOL, Y. M., KIM, H. J., CHOI, Y. J. (2019). Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: a single-center study. *Medicine*, *98*(30).

285. [1]RIESS, H., VERHAMME, P., WEITZ, J. I., YOUNG, A., BAUERSACHS, R., BEYER-WESTENDORF, J., MARAVEYAS, A. (2021). Treatment of cancer-

associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. *Critical Reviews in Oncology/Hematology*, *157*, 103125.

286. [1]BARG, A. A., KENET, G. (2020). Cancer-associated thrombosis in pediatric patients. *Thrombosis Research*, *191*, S22-S25.

287. [1]DEN EXTER, P. L., HOOIJER, J., VAN DER HULLE, T., VAN OOSTEN, J. P., DEKKERS, O. M., KLOK, F. A., HUISMAN, M. V. (2017). Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. *Thrombosis and Haemostasis*, *117*(11), 2163-2167.

288. [1]SOBIESZCZYK, P. (2018). Factors to consider regarding the need for inferior vena cava filters. *Progress in Cardiovascular Diseases*, *60*(6), 622-628.

289. [1]PERNOD, G., JOLY, M., SONNET, B. (2020). Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). *JMV-Journal de Médecine Vasculaire*, *45*(6), 6S17-6S23.

290. [1]ELALAMY, I., HANON, O., DERAY, G., LAUNAY-VACHER, V. (2018). Anticoagulants in frail patients. Seven situations at risk. *JMV-Journal de Médecine Vasculaire*, *43*(5), 302-309.

291. [1]MORENO, A. I. F., GUTIÉRREZ, L. C., NAVARRO, M. J. G. (2019). Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer. *Medicina Clínica (English Edition)*, *153*(3), 122-125.

292. [1]ENGLISCH, C., MOIK, F., AY, C. (2021). Risk assessment for recurrent venous thromboembolism in patients with cancer. *Thrombosis Update*, *5*, 100080.

293. [1]HOWARD, L. S. (2018). Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?. *Expert Review of Respiratory Medicine*, *12*(5), 387-402.

294. [1]BECATTINI, C., FRANCO, L., AGNELLI, G. (2017, February). Acute pulmonary embolism after discharge: duration of therapy and follow-up testing. In *Seminars in Respiratory and Critical Care Medicine* (Vol. 38, No. 01, pp. 094-106). Thieme Medical Publishers.

295. [1]SANFILIPPO, K. M., WANG, T. F. (2019). Prevention and treatment of cancer-associated venous thromboembolism: a review. *Current Treatment Options in Cardiovascular Medicine*, *21*(11), 1-11.

296. [1]CASANEGRA, A. I., LANDRUM, L. M., TAFUR, A. J. (2016). Retrievable inferior vena cava filters in patients with cancer: complications and retrieval success rate. *International journal of vascular medicine*, *2016*.

297. [1]SCHELLONG, S., KRETZSCHMAR, A., HEINKEN, A., MAY, M., KOLBE, K., SCHREIBER, S., RIESS, H. (2020). Anticoagulation treatment of cancer patients with deep or superficial leg vein thrombosis–a retrospective observational study of German statutory health insurance claims data (the CERTIFICAT initiative). *Vasa*, *49*(5), 403-409.

298. [1]LOPES, D. G., TAMAYO, A., SCHIPP, B., SIEPMANN, T. (2020). Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil. *Thrombosis Research*, *196*, 4-10.

299. [1]FULLER, K., MALECKI, S., ANSELMO, L., BORREGO, M. E., JAKEMAN, B., BURNETT, A. (2018). Once-daily versus Twice-daily enoxaparin for the treatment of acute venous thromboembolism in cancer patients. *Annals of Pharmacotherapy*, *52*(3), 257-262.

300. [1]NAPOLITANO, M., SIRAGUSA, S. (2017). Prolonged anticoagulant treatment in patients with cancer: Where do we stand?. *Thrombosis Research*, *158*, 152-153.

301. [1]SINGH, A. K., NORONHA, V., GUPTA, A., SINGH, D., SINGH, P., SINGH, A., SINGH, A. (2020). Rivaroxaban: drug review. *Cancer Research, Statistics, and Treatment*, *3*(2), 264.

302. [1]FRERE, C. (2021). Burden of venous thromboembolism in patients with pancreatic cancer. *World Journal of Gastroenterology*, *27*(19), 2325.

303. [1]SPEHLMANN, M. E., FREY, N., MÜLLER, O. J. (2020). Prevention and treatment of venous thromboembolism in cancer patients. *Herz*, *45*(7), 652-658.

304. [1]NENE, R. V., COYNE, C. J. (2017). Management of cancer-associated venous thromboembolism in the emergency department. *Annals of Emergency Medicine*, *69*(6), 768-776.

305. [1]SCHAEFER, J. K., LI, M., WU, Z., BASU, T., BARNES, G. D., CARRIER, M., SOOD, S. L. (2021). Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. *Journal of Thrombosis and Thrombolysis*, *52*(1), 214-223.

306. [1]ISCH, J., NGUYEN, D., ALI, A. N. (2016). Drugs that affect blood coagulation, fibrinolysis and hemostasis. *Side Effects of Drugs Annual*, *38*, 365-377.

307. [1]MCKILLOP, S., WU, C., BRUCE, A., BRANDWEIN, J. (2016). Optimal management of venous thromboembolism in adolescent and young adult oncology patients. *Clinical Oncology in Adolescents and Young Adults*, *6*(1), 39-49.

308. [1]DRANITSARIS, G., SHANE, L., BURGERS, L., WOODRUFF, S. (2016). Economic analysis comparing dalteparin to vitamin K antagonists to prevent recurrent venous thromboembolism in patients with cancer having renal impairment. *Clinical and Applied Thrombosis/Hemostasis*, *22*(7), 617-626.

309. [1]OVERVAD, T. F., LARSEN, T. B., SØGAARD, M., ALBERTSEN, I. E., ORDING, A. G., NOBLE, S., NIELSEN, P. B. (2020). Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of

clinical outcomes and patient perspectives. *Expert Review of Cardiovascular Therapy*, *18*(11), 791-800.

310. [1]HELWICK, C. Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management. *The ASCO Post. Режим доступа: http://www. ascopost. com/issues/march-25-2016/anticoagulation-in-patients-withcancer-understanding-the-complexities-of-prophylaxis-and-management*.

311. [1]DOUROS, A., FILLITER, C., AZOULAY, L., TAGALAKIS, V. (2021). Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. *Thrombosis Research*, *202*, 128-133.

312. [1]DAHM, A. E. A. (2021). Cancer and thrombosis: new treatments, new challenges. *Medical Sciences*, *9*(2), 41.

313. [1]YAN, M., KIESER, R., WU, C. C., QIAO, W., ROJAS-HERNANDEZ, C. M. (2021). Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. *Blood Advances*, *5*(4), 1050-1058.

314. [1]FRERE, C., FONT, C., ESPOSITO, F., CRICHI, B., GIRARD, P., JANUS, N. (2021). Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. *Supportive Care in Cancer*, 1-13.

315. [1]PARK, J., KWON, J. H., LEE, S. H., LEE, J. H., MIN, J. J., KIM, J., GWON, H. C. (2021). Prognosis of myocardial injury after non-cardiac surgery in adults aged younger than 45 years. *Circulation Journal*, *85*(11), 2081-2088.

316. [1]ATTIA, D., KHORANA, A. A. (2020). Evolving treatment options for cancer-related venous thromboembolism. *Cardio Oncology*, *2*(3), 441-442.

317. [1]VAN ES, J., CHEUNG, Y. W., VAN ES, N., KLOK, F. A., DRONKERS, C. E. A., TEN WOLDE, M., MIDDELDORP, S. (2020). Short-term prognosis of

breakthrough venous thromboembolism in anticoagulated patients. *Thrombosis Research*, *187*, 125-130.

318. [1]LAPORTE, S., CHAPELLE, C., TRONE, J. C., BERTOLETTI, L., GIRARD, P., MEYER, G., GROUP, M. E. (2020). Early detection of the existence or absence of the treatment effect: A cumulative meta-analysis. *Journal of Clinical Epidemiology*, *124*, 24-33.

319. [1]DI NISIO, M., RUTJES, A. W. (2016). Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer. *BMJ evidence-based medicine*, *21*(2), 66-66.

320. [1]TSAI, C. J., LEE, C. Y. (2019). Comparative outcomes of catheter-directed thrombolysis plus rivaroxaban vs rivaroxaban alone in patients with acute iliofemoral deep vein thrombosis. *Journal of the Chinese Medical Association*, *82*(12), 902-908.

321. [1]VOIGTLAENDER, M., BECKMANN, L., SCHULENKORF, A., SIEVERS, B., ROLLING, C., BOKEMEYER, C., LANGER, F. (2020). Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. *Journal of Thrombosis and Haemostasis*, *18*(12), 3267-3279.

322. [1]MCCRAE, K. R. (2018). Novel mechanism of cancer thrombosis induced by microvesicles. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *38*(4), 692-694.

323. [1]LAVALLE, C., V MARIANI, M., FEDELE, F. (2020). Factor Xa inhibitors in the prevention of cancer-related venous thromboembolism: lessons learned by clinical trials. *Future Oncology*, *16*(32), 2591-2594.

324. [1]VATHIOTIS, I. A., SYRIGOS, N. K., DIMAKAKOS, E. P. (2021). Tinzaparin safety in patients with cancer and renal impairment: A systematic review. *Clinical and Applied Thrombosis/Hemostasis*, *27*, 1076029620979592.

325. [1] GILYAREVSKY, S. R. (2020). Prescribing drugs for indications not specified in the instructions ("off-label"): a complex problem of modern clinical practice. Rational pharmacotherapy in cardiology, 16(2), 324-334.

326. [1]PALACKA, P., HIRMEROVÁ, J. (2017). Dva pohľady na venózny tromboembolizmus u onkologických pacientov. *Vnitřní lékařství*, *63*(6), 431-440.

327. [1] SHULMAN, S., MAKATSARIA, A. D., VOROBYOV, A. V., BITSADZE, V. O., KHIZROEVA, D. H., SOLOPOVA, A. G. (2019). Malignant neoplasms and thrombosis. Obstetrics and Gynecology, (7), 14-23.

328. [1]NACHAR, V. R., SCHEPERS, A. J. (2021). Clinical controversies in the treatment of cancer-associated venous thromboembolism. *Journal of Oncology Pharmacy Practice*, *27*(4), 939-953.

329. [1]HWANG, H. G., LEE, J. H., HONG, J., KIM, S. A., KIM, Y. K., KIM, M. S., BANG, S. M. (2021). Recurrence of cancer-associated venous thromboembolism between 2009 and 2013: a nationwide Korean study. *Clinical & Experimental Thrombosis and Hemostasis*, *7*(1), 14-19.

330. [1]ELEMARY, M., MOODLEY, O., PEARSON, D., GOUBRAN, H. (2020). Cancer-Associated Thrombosis (CAT). In *Precision Anticoagulation Medicine* (pp. 127-145). Springer, Cham.

331. [1]NOBLE, S. (2020). Venous thromboembolism in palliative care patients: what do we know?. *Thrombosis Research*, *191*, S128-S132.

332. [1]COSMI, B. (2021). An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. *Expert Opinion on Pharmacotherapy*, *22*(5), 583-594.

333. [1]SHARGALL, Y., SCHNEIDER, L., LINKINS, L. A., CROWTHER, M., FARROKHYAR, F., WADDELL, T. K., FINLEY, C. (2021, December). Double blind pilot randomized trial comparing extended anticoagulation to placebo following

major lung resection for cancer. In *Seminars in Thoracic and Cardiovascular Surgery* (Vol. 33, No. 4, pp. 1123-1134). WB Saunders.

334. [1]PATEL, T., IGLESIAS, D. A. (2020). Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?. *Current Treatment Options in Oncology*, *21*(5), 1-13.

335. [1]ROBERT-EBADI, H., RIGHINI, M. P. (2016). Modern Treatment Modalities and Duration of Treatment for Venous Thromboembolism. *Therapeutische Umschau*, *73*(10), 618-625.

336. [1]PINA, E., ANTONIO, M., PERIS, J., ROSSELLÓ, E., DOMÈNECH, P., PEÑAFIEL, J., TEBE, C. (2020). Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. *Clinical and Translational Oncology*, *22*(4), 616-620.

337. [1]WANG, W., SU, Y., WU, C., SUN, Y., DAI, N., CHEN, W., LI, J. (2020). Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. *BMC cardiovascular disorders*, *20*(1), 1-9.

338. [1]LI, X., PARTOVI, S., GADANI, S., MARTIN III, C., BECK, A., VEDANTHAM, S. (2020). Gastrointestinal malignancies and venous thromboembolic disease: clinical significance and endovascular interventions. *Digestive disease interventions*, *4*(03), 260-266.

339. [1]KORTE, W. (2018). Thrombosis and bleeding in cancer patients. In *The MASCC Textbook of Cancer Supportive Care and Survivorship* (pp. 303-318). Springer, Cham.

340. [1]MARAVEYAS, A., BEYER-WESTENDORF, J., LEE, A. Y., MANTOVANI, L. G., DE SANCTIS, Y., ABDELGAWWAD, K., COHEN, A. T. (2021). Cancer-Associated ThrOmboSIs–Patient-Reported OutcoMes With

RivarOxaban (COSIMO)–Baseline characteristics and clinical outcomes. *Research and practice in thrombosis and haemostasis*, *5*(8), e12604.

341. [1]HEROLD, J., BAUERSACHS, R. (2018). Die Unterschenkelvenenthrombose–eine Erkrankung für Spezialisten. *Phlebologie*, *47*(06), 319-328.

342. [1]LONG, B., KOYFMAN, A. (2019). Oncologic emergencies: too much clotting—venous thromboembolism in malignancy. *The Journal of Emergency Medicine*, *57*(6), 825-835.

343. [1]ANNINOS, H., MANOLIS, A. S. (2019). Management of Venous Thromboembolism and Atrial Fibrillation in Patients with Cancer. The Role of Direct Oral Anticoagulants. *Rhythmos*, *14*(1), 5-9.

344. [1]ELMI, G., PIZZINI, A. M., SILINGARDI, M. (2018). The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy. *Vascular*, *26*(6), 670-682.

345. [1]NELSON, A. J., MELLONI, C. (2020). Management of Cancer-Associated Thrombosis. *Current Treatment Options in Cardiovascular Medicine*, *22*(11), 1-13.

346. [1]MATZDORFF, A., LANGER, F. (2020). Factors influencing the choice between DOACs and LMWHs: A survey of German physicians on the treatment of cancer-associated venous thromboembolism. *Hämostaseologie*, *40*(05), 655-661.

347. [1]SCHAEFER, J. K., ELSHOURY, A., NACHAR, V. R., STREIFF, M. B., LIM, M. Y. (2021). How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis. *Journal of the National Comprehensive Cancer Network*, *19*(10), 1203-1210.

348. [1]WILSON, N. R., KHAN, M., COX, T. M., NASSIF, M., QIAO, W., GARG, N., ROJAS-HERNANDEZ, C. M. (2020). Bleeding outcomes in

thrombocytopenic acute leukemic patients with venous thromboembolism. *eJHaem*, *1*(2), 448-456.

349. [1]VOGEL, S. M., SMITH, L. V., & PETERSON, E. J. (2020). First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction. *Journal of pharmacy practice*, *33*(3), 356-363.

350. [1]PANAHI, L., UDEANI, G., HORSEMAN, M., WESTON, J., SAMUEL, N., JOSEPH, M., PATEL, P. (2021). Anticoagulants in the Management of Pulmonary Embolism. In *Pulmonary Embolism*. IntechOpen.

351. [1]VAN DER WALL, S. J., KLOK, F. A., DEN EXTER, P. L., BARRIOS, D., MORILLO, R., CANNEGIETER, S. C., HUISMAN, M. V. (2017). Continuation of LMWH treatment for cancer related venous thromboembolism–a prospective cohort study in daily clinical practice. *J Thromb Haemost*, *15*(1), 74-79.

352. [1]LAUNAY-VACHER, V., SCOTTÉ, F., RIESS, H., ASHMAN, N., MCFARLANE, P., RIBIC C, C. M., ELALAMY, I. (2018). Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: a position paper from the Cancer & the Kidney International Network. *Journal of Onco-Nephrology*, *2*(2-3), 37-49.

353. [1]PFREPPER, C. (2020). Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine. *Visceral Medicine*, *36*(4), 280-287.

354. [1]MÜLLER, O. J., BALDUS, C. D. (2020). Therapieempfehlungen in der Kardioonkologie–wo stehen wir?. *Der Internist*, *61*(11), 1125-1131.

355. [1]MAHÉ, I., BENHAMOU, Y., HELFER, H., CHIDIAC, J. (2018). Cancer et récidive thromboembolique veineuse: les clés d'une prise en charge optimale. *Bulletin du Cancer*, *105*(5), 508-516.

356. [1]MATZDORFF, A. (2015). Low molecular heparin for cancer-associated venous thromboembolism–still the “CATCH of the day “?. *Phlebologie*, *44*(05), 256-260.

357. [1]COUTURAUD, F., GIRARD, P., LAPORTE, S., SANCHEZ, O. (2021). Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale?. *Revue des Maladies Respiratoires*, *38*, e99-e112.

358. [1]MAHÉ, I., MEYER, G., GIRARD, P., BERTOLETTI, L., LAPORTE, S., COUTURAUD, F., SANCHEZ, O. (2021). Traitement de la maladie veineuse thromboembolique au cours du cancer. Mise à jour mars 2021. *Revue des Maladies Respiratoires*, *38*(4), 427-437.

359. [1]FRÈRE, C., FARGE, D. (2018). Traitement curatif de la maladie thromboembolique veineuse chez les patients atteints de cancer: quelle place pour les anticoagulants oraux directs en 2018?. *JMV-Journal de Médecine Vasculaire*, *43*(5), 293-301.

360. [1]LANGER, F. (2021). Malignomassoziierte venöse Thromboembolie. In *Klinische Angiologie* (pp. 1-11). Berlin, Heidelberg: Springer Berlin Heidelberg.

361. [1]BENGISUN, U. (2019). Derin ven trombozu ve pulmoner emboli tedavisinde temel prensipler. *TOTBİD Dergisi*, *18*(5), 505-513.

362. [1]DI NISIO, M., VANES, N., BÜLLER, H. (2016). Trombosis Venosa Profunda y Embolia Pulmonar. *Intramed [en línea]*.

363. [1]MEYER, G., GIRARD, P. (2016). Maladie veineuse thromboembolique et cancer. *Revue des Maladies Respiratoires Actualités*, *8*(5), 489-496.

364. [1]SJÄLANDER, S., SJÄLANDER, A. (2018). NOAK vid venös tromboembolism samt hantering av blödningar. *Lakartidningen. se*, 12-04.

365. [1] LU Y.. (2016). Novel oral anticoagulant drugs—a new option for anticoagulation therapy. Chinese Journal of Emergency Medicine, 25(008), 989-996.

366. [1]ABDEL-RAZEQ, H., MANSOUR, A. (2016). Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. *Drug Design, Development and Therapy*, *10*, 2677.

367. [1]VAN ES, N. Cancer and thrombosis., 1. doi: https://dare.uva.nl

368. [1] Z THEIN, K., W MYINT, Z., M TUN, A., H OO, T. (2016). Cancer associated thrombosis: Focus on prevention and treatment of venous thromboembolism. *Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents)*, *14*(2), 101-112.

369. [1]PETERSON, E., LEE, A. Treatment of VTE in Patients with Cancer.

370. [1]LIU, M. Y., BALLARD, D. W., HUANG, J. (2018). Acute Pulmonary Embolism in Emergency Department Patients Despite Therapeutic. *Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health*.

371. [1]IN, S. T. L., & EXTRA, H. H. E. Oral anticoagulants and cancer-associated thrombosis.

372. [1]ELALAMY, I., HANON, O., DERAY, G., LAUNAY-VACHER, V. (2017). Anticoagulants chez les patients fragiles. Sept situations à risque. *Journal de Pharmacie Clinique*, *36*(4), 205-213.

373. [1]AJMAL, F., HAROON, M., KALEEM, U., GUL, A., KHAN, J. (2021). Comparison of Chemical and Mechanical Prophylaxis of Venous Thromboembolism in Non-surgical Mechanically Ventilated Patients. *Cureus*, *13*(11).

374. [1]KHORANA, A. A., JANAS, M., JARNER, M. F., LEE, A. Y. (2017). Reply to R. Fonseca et al. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, *35*(19), 2218-2219.

375. [1]STANKOWICZ, M., BANASZYNSKI, P. M., CRAWFORD, R. Risk of Cancer-Associated Thrombosis and Bleeding in Veterans With Malignancy Who Are Receiving DOACs The low incidence of venous thromboembolism formation in this study and similar rates of bleeding in other clinical trials indicate that direct oral anticoagulant agents are safe alternatives in patients with cancer.

376. [1]IMAMURA, Y. British Journal of Cancer Research.

377. [1] YOU, D. Z. (2020). *Studying Hypercoagulability in Hip Fracture Patients as Determined by Thrombelastography* (Master's thesis, Cumming School of Medicine).

378. [1]COLWELL, J., FROST, M., WEEKLY, A. H., WEEKLY, A. I., MONTHLY, A. D., MONTHLY, A. G., INTERNIST, A. C. P. Venous thromboembolism in malignancy.

379. [1]ZHU, N. J., FAN, T. T., BAI, R., LI, M. L., WANG, X. F., LIU, H., WANG, Z. Anticoagulation for the Treatment of Acute Venous Thromboembolism a Systematic Review and Network Meta-Analysis. *Available at SSRN 3890716*.

380. [1]MOHAMED, M. F., ELSHAFEI, M. N., FATIMA, H., AL SHOKRI, S., MOHAMED, S., ABUBEKER, I. Y., BIDMOS, M. (2020). Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients: A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology. *Medicine*, *99*(14).

381. [1]VERSO, M., AGNELLI, G. (2020). Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. *Thrombosis Research*, *191*, S123-S127.

382. [1]FEITOSA, A. C. R., GUALANDRO, D. M., YU, P. C., CARAMELLI, B., MARQUES, A. C., CALDERARO, D., MATHIAS JÚNIOR, W. (2017). 3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology.

383. [1]HONG, J., AHN, S. Y., LEE, Y. J., LEE, J. H., HAN, J. W., KIM, K. H., OH, D. (2021). Updated recommendations for the treatment of venous thromboembolism. *Blood research*, *56*(1), 6-16.

384. [1]VAN DER WALL, S. J. (2019). *Venous and arterial thrombotic complications. Solutions in clinical practice* (Doctoral dissertation, Leiden University).

385. [1]NOBLE, S. (2018). Cancer associated thrombosis: Which lessons for the hematologist?. *HemaSphere*, *2*(Suppl).

386. [1]ROSOVSKY, R. P. (2013). Cancer and Coagulopathy. *Cancer Chemotherapy, Immunotherapy and Biotherapy*, 237.

387. [1]STREIFF, M. MASAB Memos - Blood Clots Skip to main content Menu Close About Clots Know Your Risk for
Blood Clots Signs and Symptoms of Blood Clots How is DVT diagnosed?

388. [1]TRAN, A. Pick your poison: Which anticoagulant for.

389. [1]WANG, T. F. (2021). Survival in patients with cancer-associated thrombosis in relation to anticoagulants: Re-vitalization of warfarin?. *Journal of thrombosis and haemostasis: JTH*, *19*(11), 2677-2679.

390. [1]KIM, S., PARK, J., KIM, H., YANG, K., CHOI, J. H., KIM, K., LEE, S. H. (2021). Intraoperative Hyperglycemia May Be Associated with an Increased Risk of Myocardial Injury after Non-Cardiac Surgery in Diabetic Patients. *Journal of clinical medicine*, *10*(22), 5219.

391. [1]FIORETTI, A. M., LEOPIZZI, T., ARGENTIERO, A., LATORRE, A. C., PARADISO, A. V., LORUSSO, V., OLIVA, S. (2021). New Horizons for the Use of Edoxaban to Treat Brachiocephalic Vein Thrombosis in Primitive Mediastinal Seminoma. Case Report and Literature Review.

392. [1]BIELSA, A. A. (2020). Prevention and Treatment of Venous Thromboembolism. In *Aesthetic Treatments for the Oncology Patient* (pp. 135-140). CRC Press.

393. [1]FERNÁNDEZ, M. C. (2017). Extended anticoagulation in venous thromboembolism disease. In favor. *Revista Clínica Española (English Edition)*, *217*(6), 359-364.

394. [1]POWER, K. Cancer-associated thrombosis.

395. [1]WEDDLE, K. J., KIEL, P. J., PATEL, P. J. (2019). Assessment of bleeding incidences associated with rivaroxaban therapy in adults with solid tumors. *Journal of Oncology Pharmacy Practice*, *25*(1), 192-197.

396. [1]BOZKURT, A. K., TOKUR, M., OKUMUŞ, M., KAHRAMAN, H., ÖZKAN, F., TABUR, A. THORACIC AND CARDIOVASCULAR SURGERY.

397. [1]BASU, A., & KHORANA, A. A. (2019). Gastrointestinal Cancers and Thrombosis. In *Textbook of Gastrointestinal Oncology* (pp. 367-378). Springer, Cham.

398. [1]HAJOULI, S. (2020). Massive Fatal Pulmonary Embolism While on Therapeutic Heparin Drip. *Journal of Investigative Medicine High Impact Case Reports*, *8*, 2324709620914787.

399. [1]SCHULMAN, S., FURIE, B. (2014). How I Treat. *blood*, *8*(597781), 25377783.

400. [1]CESARMAN-MAUS, G. N. (2015). The Cost of Treating Thrombosis. *ASH Clinical News*, *1*(10), 12-12.

401. [1]QARI, R., FRERE, C., FARGE, D., EL AYOUBI, H. (2017). Implementation of international good clinical practice guidelines to improve care of patients with cancer-related venous thromboembolism. *Journal of Applied Hematology*, *8*(3), 85.

402. [1]BUTTERFIELD, S., FROST, M., HUFF, C., WEEKLY, A. H., WEEKLY, A. I., MONTHLY, A. D., INTERNIST, A. C. P. Venous thromboembolism in malignancy.

403. [1]VAN DER WALL, S. J., KLOK, F. A., DEN EXTER, P. L., BARRIOS, D., MORILLO, R., CANNEGIETER, S. C., HUISMAN, M. V. (2019). Higher adherence to treatment with LMWH nadroparin than enoxaparin for cancer related venous thromboembolism. *and arterial thrombotic complications*, 49-52.

404. [1]IN, S. T. L., EXTRA, H. H. E. Perspectives for treating cancer-associated thrombosis.

405. [1]ROBADOR ARTETA, J. R. (2019). *Crosstalk between melanoma cells and the blood-brain barrier: Impact on coagulation and brain metastasis to identify new anti-metastatic targets* (Doctoral dissertation).

406. [1] TOMKOWSKI, W., KUCA, P., URBANEK, T., CHMIELEWSKI, D., KRASINSKI, Z., PRUSZCZYK, P., ZUBILEWICZ, T. (2017). Venous thromboembolism-guidelines for prophylaxis, diagnosis and therapy. Consensus of Poland 2017. *Acta Angiologica*, *23*(2), 73-113.

407. [1]FONTANELLA, A., CAMPANINI, M., DENTALI, F., GUSSONI, G., MANFELLOTTO, D. (2018). Antithrombotic Cancer Associated Thrombosis: It May Change. *J Blood Lymph S*, *1*, 2.

408. [1]CHIASAKUL, T., ZWICKER, J. I. (2021). The impact of warfarin on overall survival in cancer patients. *Thrombosis Research*.

409. [1]CHARALAMPOS, B. (2021). *FACULTY OF HEALTH SCIENCES* (Doctoral dissertation, ARISTOTLE UNIVERSITY OF THESSALONIKI).

410. [1]MENG, X., AHMED, M., COURTNEY, K. D., ARAFAT, W., IBRAHIM, I., MARGULIS, V., BAGRODIA, A. (2021). Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. *Frontiers in Oncology*, *11*.

411. [1]AKAY, H. T. (2021). National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society.

412. [1]PANAGIOTOPOULOS, K., KAPOURALOS, A. (2018). Venous Thromboembolic Disease and Cardio Oncology. *Oncology*, *2*(3), 000123.

413. [1]BUKA, R. J., CHANDRA, D., SUTTON, D. J. (2021). Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer-associated venous thromboembolism to patients with haematological malignancies?. *British Journal of Haematology*, *193*(1), 194-197.

414. [1]VOIGTLAENDER, M., YAMAMURA, J., LANGER, F. (2018). Neue Studiendaten zur Therapie der tumorassoziierten venösen Thromboembolie mit DOAKs. *Phlebologie*, *47*(06), 309-317.

415. [1]OLAKAREEM, H. (2017). *Prognostic factors associated with the development of post-thrombotic syndrome after a deep vein thrombosis of the lower limb* (Doctoral dissertation, University of Birmingham).

416. [1]DEBOURDEAU, P., WOODRUFF, S., DRANITSARIS G., SHANE L. G., GALANAUD J., STEMER G. (2017) Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria. ISSN 0941-4355. DOI 10.1007/s00520-017-3610-2. Springer

417. [1]ERIK ASTRUP DAHM, A. (2021). Cancer and Thrombosis: New Treatments, New Challenges.

418. [1]DOYLE, C. (2018). Strategies for Using Anticoagulation Therapy in Patients With Cancer.

419. [1]RYGIEL, K. (2020). To Use or not to Use Anticoagulation in Patients with Advanced Malignancies?–This is the Question. *Trends in Oncology*, *2*(2).

420. [1]BISCEGLIA, I., MAUREA, N. (2017). Thromboembolic Disorders as a Consequence of Cancer. In *Manual of Cardio-oncology* (pp. 57-74). Springer, Cham.

421. [1]ELALAMY, I., FALANGA, A. (2018). Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016. *Cancer Investigation*, *36*(1), 73-91.

422. [1]OMAR, M. B., & MAHARAJ, S. (2021). Left ventricular thrombi in malignancy: A therapeutic dilemma. *Heart & Lung: The Journal of Cardiopulmonary and Acute Care*, *50*(1), 231.

423. [1]AWADA, A., BAURAIN, J. F., CLEMENT, P., HAINAUT, P., HOLBRECHTS, S., JOCHMANS, K., VERHAMME, P. (2019). The rol of direct oral anticoagulants in the management of cancer-associated thrombosis. *Belgian Journal of Hematology*, *10*(4), 169-176.

424. [1]CAPUTO, R., PYLE, J., KURIAKOSE, P., LEKURA, J. (2021). A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism. *Journal of the American Pharmacists Association*, *61*(5), e26-e38.

425. [1]PRIBISH, A. M., SECEMSKY, E. A., SCHMAIER, A. A. (2021). Venous Thromboembolism for the Practicing Cardiologist. *Cardiology Clinics*, *39*(4), 551-566.

426. [1]WIETESKA-MIŁEK, M., WINIARCZYK, K., KUPIS, W. (2021). Treatment of pulmonary artery stump thrombosis after lobectomy: a case report and literature review. *Advances in Respiratory Medicine*, *89*(3), 311-315.

427. [1]REEVES, B. N., MOLL, S. (2017). Anticoagulation Failure in Venous Thromboembolism: Should We Test for JAK2 V617F or CALR Mutations?. *The Hematologist*, *14*(3).

428. [1]PANCHENKO, E. P. (2020). Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer. *Aterotromboz= Atherothrombosis*, (1), 47-54.

429. [1]OBRADOVIC, S., DZUDOVIC, B., SALINGER, S. M., MATIJASEVIC, J. (2021) Anticoagulant treatment of cancer associated venous thrombosis.

430. [1]HAN, D. K. Find Vein Doctors.

431. [1]FOGERTY, A. E., CONNORS, J. M. (2016). Bleeding and Thrombosis in a Cancer Patient. In *Nonmalignant Hematology* (pp. 395-402). Springer, Cham.

432. [1]STREIFF, M. B., MILENTIJEVIC, D., MCCRAE, K., YANNICELLI, D., LEJEUNE, D., NELSON, W. W., KHORANA, A. A. (2018). An answer to" anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". *American journal of hematology*, *93*(9), E225-E227.

433. [1]IONESCU, M., SÂRBU, G., MAZILU, L., PAREPA, I. R. (2019). Tromboza venoasă la pacientul oncologic. *Propunere indecentă*, 7.

434. [1]VAN MIERT, J. (2021). *Informed decisions about treatment with anticoagulants* (Doctoral dissertation, University of Groningen).

435. [1]LEE, A. I., LEE, E. J. (2018). Anticoagulation for Proximal Deep Vein Thrombosis. In *Current Management of Venous Diseases* (pp. 299-313). Springer, Cham.

436. [1]SIMONSEN, C. Z., ROTH, E., LESLIE-MAZWI, T. M. (2019). Ischemic lesions in all territories as a marker of malignant hypercoagulability. *Clinical Case Reports*, *7*(7), 1312.

437. [1]RYGIEL, K. (2021, November). Balancing Risk of Thromboembolism and Bleeding in Patients with Cancer: Selecting Anticoagulant Therapy Based on Recent Clinical Trials. In *ESMO Congress 2021* (p. 62).

438. [1]VATHIOTIS, I., SYRIGOS, N., DIMAKAKOS, E. (2020). Tinzaparin in Pregnancy, Cancer and Renal Impairment: A Systematic Review Focusing on Safety.

439. [1]GADE, I. L. (2018). Venous Thromboembolism in Solid and Hematological Cancers: cancer specific factors, time since cancer diagnosis and additional cancer.

440. [1]MAUREA, N., CARONNA, A., MOUHAYAR, E. N. (2019). Venous Thromboembolism. In *Cardiovascular Complications in Cancer Therapy* (pp. 141-150). Humana Press, Cham.

441. [1]STREIFF, M. (2018). MASAB Memo, MASAB Memo, April 2018.

442. [1]BARNES, G. D., RENNER, E. T. (2018). Anticoagulation in Venous Thromboembolism. In *Anticoagulation Therapy* (pp. 297-323). Springer, Cham.

443. [1]SARINAYOVA, S., HEIZMANN, M. (2018). Direkte orale Antikoagulanzien bei Krebspatienten: Sind wir so weit?. *Praxis (16618157)*, *107*(3).

444. [1]SCHULMAN, S., MAKATSARIA, N. A., VOROBYEV, A. V., BITSADZE, V. O., KHIZROEVA, D. K., SOLOPOVA, A. G. (2017) Malignant neoplasms and thromboses. (7) 14-23 doi: dx.doi.org/10.18565/aig.2019.7.14-23

445. [1]PARK, J., OH, A. R., LEE, S. H., LEE, J. H., MIN, J. J., KWON, J. H., LEE, S. M. (2020). Associations Between Preoperative Glucose and Hemoglobin A1c Level and Myocardial Injury After Noncardiac Surgery: a Retrospective Cohort Study.

446. [1]KEVANE, B. (2017). Novel Endothelial Protective and Anti-Thrombotic Effects of Therapeutic Agents in Malignant and Inflammatory Diseases: Molecular Mechanisms and Translational Relevance.

447. [1]MARUYAMA, A., TEJANI, A. M., PERRY, T. L. (2016). Tinzaparin vs Warfarin for Acute Venous Thromboembolism. *JAMA*, *315*(2), 200-200.

448. [1]WANG, K. L., CHU, P. H. (2021). Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates. *Acta Cardiologica Sinica*, *37*(2), 215.

449. [1]IGNATENKO, G. A., TARADIN, G. G., VATUTIN, N. T., KANISHEVA, I. V. (2019). Current view on anticoagulant and thrombolytic treatment of acute pulmonary embolism. *The Russian Archives of Internal Medicine*, *9*(5), 348-366.

450. [1]NOBLE, S. (2018). Thromboembolism and Bleeding. *Journal: Textbook of Palliative Care*, 1-20.

451. [1]STANKOWICZ, M., BANASZYNSKI, M., CRAWFORD, R. (2018). Risk of Cancer-Associated Thrombosis and Bleeding in Veterans With Malignancy Who Are Receiving Direct Oral Anticoagulants. *Federal Practitioner*, *35* (4), 28.

452. [1]BOZKURT, A. K., AKAY, H. T., ÇALKAVUR, İ. T., ŞIRLAK, M., BALKANAY, O. O., UĞUZ, E., YAVAŞ, S. (2021). National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and

Phlebology Society. *Turkish Journal of Thoracic and Cardiovascular Surgery*, *29*(4), 562.

453. [1]EADDY, N. (2016). Prevention and management of cancer-associated thrombosis. *Research review.* 1-8.

454. [1]KRASIŃSKI, Z., URBANEK, T., UNDAS, A., RUPA-MATYSEK, J., ARASZKIEWICZ, A., DERWICH, K., WINDYGA, J. (2021). Guidelines on the prevention and treatment of venous thromboembolism in cancer patients treated surgically, including patients under 18 years of age. *Acta Angiologica*, *27*(3), 81-112.

455. [1]CLIVE K., & MLS, E. L. (2021) Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report, ISSN: S0012-3692(21)01506-3, doi: doi.org/10.1016/j.chest.2021.07.055.

456. [1]COLOMBES, F. (2021). Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.

457. [1]STEEN, E. M. (2016). Topics in anticoagulation.

458. [1]IMAMURA, Y. (2020) Treatment of Asian Patients with Cancer-Associated Venous Thromboembolism in Direct Oral Anticoagulants Era–a Minireview of the Literature. doi: 10.31488/bjcr.155

459. [1]GOTO, H., UMETSU, M., AKAMATSU, D., SUGAWARA, H., TSUCHIDA, K., YOSHIDA, Y., KAMEI, T. (2021). Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism—A Retrospective Observational Study—. *Circulation Journal*, CJ-20.

460. [1]ALSUBAIE, N. S., AL RAMMAH, S. M., ALSHOUIMI, R. A., ALZAHRANI, M. Y., AL YAMI, M. S., ALMUTAIRI, A. R., ALMOHAMMED, O. A. (2021). The use of direct oral anticoagulants for thromboprophylaxis or treatment

of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines. *Thrombosis journal*, *19*(1), 1-11.

461. [1] SHIBA, P. T. G., SHARMA, V. (2019). The impact of venous thromboembolism on the outcomes of patients with cervical carcinoma, a retrospective analysis at a single institution. *Southern African Journal of Gynaecological Oncology*, *11*(2), 11-16.

462. [1]ILLIG, K. A., GOBER, L. (2021). Invited Review: Optimal Management of Upper Extremity DVT: Is Venous Thoracic Outlet Syndrome Underrecognized?. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*.

463. [1]STREIFF, M. (2018) MASAB Memo, April 2018 Categories: News.

464. [1]GALLANT, J., SHIPE, R. (2019). Venous Thromboembolic Disease. In *Lifestyle Medicine.* 621-629. CRC Press.

465. [1]MIESNER, A. (2019) History of the Adult Medicine Practice and Research Network (poster).*Adult Medicine PRN Spring Newsletter*, doi:10.13140/RG.2.2.17552.97280

466. [1]KEARON, C., AKL, E. A., ORNELAS, J., SOOD, M. D., STEVENS, S. M., VINTCH, J. R., MOORES, C. L. (2015). Word Count. (12) 840.

467. [1]BUI, T. (2018). Dose Appropriateness, Efficacy, and Safety of Rivaroxaban and Apixaban in the Treatment of Cancer-related Venous Thromboembolism: A Retrospective Study at a Single Center.

468. [1]VATHIOTIS, I., SYRIGOS, N., & DIMAKAKOS, E. (2020). Tinzaparin in Cancer and Renal Impairment: A Systematic Review Focusing on Safety. doi: doi.org/10.21203/rs.3.rs-41019/v2

469. [1]OLSON, S. R., SAMUELSON BANNOW, B. T. (2021). Anticoagulation and Antiplatelet Guidelines. In *Blood and Marrow Transplant Handbook* (pp. 201-223). Springer, Cham.

470. [1]BAUER, K. A., MANDEL, J. (2020). Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy. doi: medilib.ir/uptodate/show/1340

471. [1]QUINTANAR, T., FONT, C., GALLARDO, E., BARBA, R., OBISPO, B., DÍAZ-PEDROCHE, C. (2021). Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer. *Clinical and Translational Oncology*, *23*(4), 697-708.

472. [1]MAKÓ, K. (2021). Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism. *Journal Of Cardiovascular Emergencies*, *7*(2), 27-38.

473. [1]KOLBE, K., SCHREIBER, S., RIESS, H. (2020). Sebastian Schellong1, Albrecht Kretzschmar2, Andreas Heinken3, Melanie May4. *Interd sz pl när und prax s-or ent ert–de neue Kompaktre he Gesundhe ts w ssenschaften*, *49*(5), 403-409.

474. [1]GILYAREVSKIY, S. R. (2020). Off-Label Medicines Use: Complex Problem of Modern Clinical Practice. *Journal: Rational Pharmacotherapy in Cardiology*, (2), 324-334.

475. [1]PETROV, V. I., AKINCHITS, A. N., SHATALOVA, O. V., GORBATENKO, V. S., GERASIMENKO, A. S. (2020). Efficiency and safety of direct oral anticoagulants in onco-associated venous thromboembolic complications: meta-analysis. *Medical Journal of the Russian Federation*, *26*(6), 402-411.

476. [1]MAHÉ, I., MEYER, G., SANCHEZ, O. (2021). Quelles sont les particularités thérapeutiques de la MVTE au cours du cancer?. *Revue des Maladies Respiratoires*, *38*, e138-e144.

477. [1]RAFII, H., FRÈRE, C., BENZIDIA, I., CRICHI, B., ANDRE, T. (2020). m, n. *JMV—Journal de Médecine Vasculaire*, *45*, 28-40.

478. [1]BRUNI, S., GASSE, A. E., ROUGE-BURAT, M. E., BOULESTEIX, M. A., LÉGER, P., BURA-RIVIÈRE, A. (2017). Prise en charge thérapeutique de la maladie thromboembolique veineuse chez les patients atteints de cancer: évaluation des pratiques en Midi-Pyrénées. *JMV-Journal de Médecine Vasculaire*, *42*(2), 108-109.

479. [1]MATZDORFF, A. (2015). Niedermolekulares Heparin bei Tumor-assoziierter venöser Thromboembolie–immer noch „CATCH of the day "?. *Phlebologie*, *44*, 256-260.

480. [1]NOU, M., LAROCHE, J. P. (2016). Maladie thrombo-embolique veineuse au cours du cancer. Indication des héparines de bas poids moléculaires. *Journal des Maladies Vasculaires*, *41*(3), 197-204.

481. [1]SÁNCHEZ CÁNOVAS, M. (2021). Evaluación y validación del índice Epiphany en la estratificación pronóstica del paciente con cáncer y tromboembolismo pulmonar. *Proyecto de investigación:*. Doi: hdl.handle.net/10201/110142

482. [1]MONSUEZ, J. J., LE JEUNE, S. (2020). Anticoagulants oraux directs dans la maladie thromboembolique veineuse associée aux cancers. *Archives des Maladies du Coeur et des Vaisseaux-Pratique*, *2020*(288), 2-8.

483. [1] WAN J. ZHAI Z. (2019). Diagnosis and treatment of pulmonary thromboembolism in special circumstances: Interpretation of the 2018 Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism. Diagnostic Theory and Practice, 18(01), 34.

484. [1]MUÑOZ MARTÍN, A. J. (2016). Análisis del score de Khorana y predictores genómicos de riesgo de enfermedad tromboembólica venosa en pacientes

tratados con quimioterapia en un medio extrahospitalario. doi: eprints.ucm.es/id/eprint/44921/

485. [1] Khryshchanovich, V. Y. (2020). Treatment of cancer-associated venous thrombosis with direct oral anticoagulants. Cardiology in Belarus, 12(1), 100-114.

486. [1]TRAPPE, R. U., SINN, M., RIESS, H. (2016). Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten. *DMW-Deutsche Medizinische Wochenschrift*, *141*(20), 1446-1450.

487. [1]LABRADOR GÓMEZ, J. (2015). Complicaciones trombólicas y hemorrágicas relacionadas con el transplante alogénico de progenitores hematopoyéticos. Incidencia, factores de riesgo y significado pronóstico. doi: gredos.usal.es/handle/10366/128361

488. [1]RIESS, H. (2020). Tumorassoziierte venöse Thromboembolie–Pathogenese, Diagnose, Prävention und Therapie. *best practice onkologie*, *15*(10), 448-455.

489. [1]MATZDORFF, A. (2015). Diagnosis and therapy in cancer-associated thromboembolism–what about guideline recommendations?. *Phlebologie*, *44*(06), 299-303.

490. [1]LEE, A. Y., KAMPHUISEN, P. W., MEYER, G.(2015) Behandeling van veneuze trombo-embolie bij patiënten met kanker: tinzaparine of een vitamine K-antagonist?. *JAMA* 2015;314:677-86.

491. [1]SANTOS, A. T. (2020). Tratamiento de la trombosis venosa profunda de extremidades inferiores. *Revista Clínica Española*, *220*, 57-68.

492. [1] PARACUELLOS T.S. (2018). Role of the direct oral anticoagulants in cancer-associated thrombosis. doi: zaguan.unizar.es/record/111885/files/TAZ-TFG-2018-944.pdf

493. [1] PANCHENKO, E. P. (2020). The role of apixaban in the treatment of venous thromboembolic complications in patients with active cancer. Atherothrombosis, (1), 43-50.

494. [1]GEISLER, T., STIMPFLE, F. (2018). Thrombose, Lungenembolie und Antikoagulation. *Der Klinikarzt*, *47*(03), 86-94.

495. [1] KIRIENKO, A. (2020). Prevention of pulmonary arterial embolism and its recurrence in venous thrombosis. doi: dissercat.com/content/predotvrashchenie-embolii-legochnykh-arterii-i-ee-retsidiva-pri-venoznom-tromboze

496. [1]RENNI, M. J. P., MARINHO, T. A. S., DE SOUZA, M. C. (2019). Tratamento do Tromboembolismo Venoso em Pacientes com Câncer: Atualização quanto ao Papel dos Anticoagulantes Orais Diretos nesse Cenário. *Revista Brasileira de Cancerologia*, *65*(3).

497. [1]SWANSON, F. P., BAZIL, C. W., DALTON, V. K., MUKHERJEE, M. D., RODEN, D. M., SIMONS, F. E. R., YEE, A. (2018) *M. Médicaments pour le traitement et la prévention des thrombo embolies veineuses. 40(80)*, 57-62

498. [1]VIZCAÍNO, G., WEIR MEDINA, J., QUINTERO, J., VIZCAÍNO CARRUYO, J. (2020). Revisión sistemática y metanálisis del tratamiento anticoagulante en la trombosis asociada al cáncer. Implicaciones en estudios de no inferioridad. *Investigación Clínica*, *61*(2), 165-180.

499. [1]MONTEQUÍN, J. F., MILIÁN, M. B. (2020). Trombosis venosa y cáncer: un acercamiento a la epidemiologia, diagnóstico y tratamiento. *Revista Cubana de Cardiología y Cirugía Cardiovascular*, *26*(4), 9.

500. [1]BENHAMOU, Y., DELLUC, A., MAUGE, L., FISCHER, A. M., SANCHEZ, O. (2021). Quel bilan étiologique réaliser au décours d'une EP/TVP?. *Revue des Maladies Respiratoires*, *38*, e90-e98.

501. [1]STIMPFLE, F., GEISLER, T. (2019). Update Lungenarterienembolie. *Der Klinikarzt*, *48*(10), 384-395.

502. [1]CAPITAN, M. F. (2017). Anticoagulación extendida en la enfermedad tromboembólica venosa. A favor. *Revista Clínica Española*, *217*(6), 359-364.

503. [1]BAZÃ, M. (2020). Trombosis venosa y cancer: un acercamiento a la epidemiologia, diagnostico y tratamiento. *Revista Cubana de Cardiologia y Cirugia Cardiovascular*, *26*(4), 936.

504. [1]ZYDEK, B., LINDHOFF-LAST, E. (2019). Thrombose und Antikoagulation bei Tumorpatienten. *Der Klinikarzt*, *48*(03), 68-72.

505. [1] MIRANDA, S., LEVESQUE, H. (2020). Vers le recours en première intention aux anticoagulants oraux directs dans le traitement de la maladie thromboembolique associée aux cancers. *La Revue de Médecine Interne*, *41*(9), 575-577.

506. [1]RADKE, P. W., MÖCKEL, M. (2018). Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie. *Herz*, *43*(1), 34-42.

507. [1]BECKS, M., KNIPPENBERG, L., LEYSSEN, R., LIEVENS, J., EYNDE, R. V., VAN MUYSEN, L., DE LEPELEIRE, J. (2020). Evidence-based richtlijn voor palliatieve zorg. doi: icho-info.be/application/content/download-abstract/id/1656

508. [1]FIEFFE, M. (2017). *Thrombose et cancer: évaluation d'un outil d'accompagnement des patients à l'officine*. Doctoral dissertation.(Université Toulouse lll-Paul Sabatier).

509. [1]SIMÓN PARACUELLOS, T., ÁNGELES, S. G. M. (2018). Rol de los nuevos anticoagulantes orales en la trombosis asociada a cáncer. TAZ-TFG-2018-944 doi: zaguan.unizar.es/record/111885

510. [1]LIGNEREUX, B. (2017). *Application des recommandations dans la prise en charge de la maladie thromboembolique veineuse chez le patient cancéreux en Midi-Pyrénées,* Doctoral dissertation (Université Toulouse lll-Paul Sabatier).

511. [1] KYRIAZI, B. (2018). Trousseau syndrome Contemporary concerns and controversies. *Archives of Hellenic Medicine/Arheia Hellenikes Iatrikes*, 35(2).

512. [1]DEMELO RODRÍGUEZ, P. (2019). Anticoagulantes orales directos (ACOD) en enfermedad tromboembólica venosa: evaluación de la escala SAMe-TT2R2 para determinar su utilización frente a antivitamina K y utilidad clínica de los ACOD en diferentes escenarios. doi: eprints.ucm.es/id/eprint/57661/

513. [1]LISÓN PÁRRAGA, J. F., MONREAL BOSCH, M. (2017). Complicaciones durante el tratamiento anticoagulante y tras su interrupción, en pacientes con cáncer y tromboembolismo pulmonar incidental. Doctoral dissertation

514. [1] PETROV, V., AKINCHITS, A., SHATALOVA, O., (2020). Effectiveness and safety of direct oral anticoagulants in onco-associated venous thromboembolic complications: metaanalysis. Russian medical journal, 26(6), 402-411.

515. [1]BREYWISCH, F. (2016). Direkte orale Antikoagulanzien bei Tumorpatienten—eine Alternative?. *best practice onkologie, 11*(5), 8-14.

516. [1]STANCIU, S., VADIS, C. Q., GINGHINĂ, C., BARTOȘ, D., ILIESCU, C., MIOCARDIC, I. (2018) Tromboză Venoasă la Pacientul Oncologic–de la diagnostic la terapie.*Stetoscop cardio* doi: stetoscop.ro/ce-si-cum-tratam/cardiooncologie-2/tromboza-venoasa-la-pacientul-oncologic-de-la-diagnostic-la-terapie/

517. [1] Liu X., Xu X., Lu. W. (2016). A case of subarachnoid hemorrhage caused by oral warfarin. Journal of Mudanjiang Medical College, 37(5), 135-136.

518. [1]MONTEQUÍN, J. F., MILIÁN, M. B. (2020). Venous thrombosis and cancer: an approach to epidemiology, diagnosis and treatment. *Revista Cubana de Cardiología y Cirugía Cardiovascular*, *26*(4), 1-5.

519. [1]BLASCO PRADA, S. I. (2021). Trombosis asociada al cáncer. Doi: uvadoc.uva.es/handle/10324/47378

520. [1]IGNATENKO, G. A., TARADIN, G. G., VATUTIN, N. T., KANISHEVA, I. V. (2019). Modern views on anticoagulant and thrombolytic therapy for acute pulmonary embolism. Archives of Internal Medicine, 9 49(5), 348-366.

521. [1]BERTOLETTI, L., GIRARD, P., SANCHEZ, O. (2021). Quelles sont les indications du filtre cave?. *Revue des Maladies Respiratoires*, *38*, 69-73.

522. [1]DEMIR, A. M., ÖNGEN, H. G., TURAL, D. (2016). Profilaksi, Tanı ve Tedavi Kılavuzu. ISBN: 978-605-5720-15-5

523. [1]VOIGTLAENDER, M., LANGER, F. (2017) Tumorassoziierte venöse Thromboembolien. *Vasomed* 29(3), 127-135.

524. [1]DAHM, A., GHANIMA, W. (2017). Nye direktevirkende antikoagulasjonsmidler til kreftpasienter?. *Tidsskrift for Den norske legeforening*. 137: 171-2 doi: 10.4045/tidsskr.17.0008

525. [1]LA, I. D. L. R. A. (2017). Hipertensión como indicador. *Cardiooncología clínica*, 202. ISBN: 978-0-323-44227-5

526. [1]LEE, A. Y., KAMPHUISEN, P. W., & MEYER, G. (2015). Minerva-Bondige besprekingen-15/04/2016 Behandeling van veneuze trombo-embolie bij patiënten met kanker: tinzaparine of een vitamine K-antagonist?. *JAMA*, *314*, 677-86.

527. [1]VOIGTLÄNDER, M., LANGER, F. (2020). Therapie und Prophylaxe der tumor-assoziierten venösen Thromboembolie. *InFo Hämatologie+ Onkologie*, *23*(6), 25-30.

528. [1]HEIL, J., MIESBACH, W., VOGL, T., BECHSTEIN, W. O., REINISCH, A.(2017) Tiefe Venenthrombosen der oberen Extremität. *Dtsch Arztebl Int 2017; 114:* 244-249*;* doi: 10.3238/arztebl.2017.0244

529. [1] GUTIÉRREZ, L. C., MORENO, A. I. F., NAVARRO, M. J. G. (2019). Los anticoagulantes orales de acción directa en el tratamiento de la enfermedad tromboembólica venosa asociada a cáncer. *Medicina clínica*, *153*(3), 122-125.

530. [1]YATE CRUZ, J. A., PUENTES DÍAZ, A. L. (2019). *Coste-efectividad del Rivaroxabán frente a Dalteparina para prevención de trombosis recurrente en el paciente con cáncer* . Doctoral dissertation (Universidad del Rosario).

531. [1]SOFF, G. (2019). Marc Carrier, Gerald Soff and Grégoire Le Gal. *Thrombosis and Hemostasis in Cancer*, 103.

532. [1]DEBOURDEAU, P., COSSOU-GBETO, C., TAKAM-SOHWE, T., LAROCHE, J. P. (2020). Héparines de bas poids moléculaires dans la maladie thromboembolique veineuse liée au cancer: quelle place en 2019?. *Bulletin du Cancer*, *107*(2), 224-233.

533. [1] PILIPENKO, M. M., & BONDAR, M. V. (2020). Conducting pathophysiological disorders in the body in cases of acute intestinal obstruction (clinical lecture). *Emergency medicine emergency medicine*, 48.

534. [1] HOLT, A. M. I. (2017) Større fokus på venøs tromboemboli ved cancer. Dansk Selskab for Trombose og hæmostase & Dansk Selskab for klinisk onkologi*Retningslinjer* 2017, (11) 1-3.

535. [1]HEROLD, J. (2016). Kein Nutzen einer zusätzlichen CT-Diagnostik zur Tumorsuche bei Patienten mit unprovozierter Thrombose. *Der Pneumologe*, *13*(3), 198-199.

536. [1]LEE, A. Y., KAMPHUISEN, P. W., MEYER, G.(2015) Tinzaparine ou antivitamines K pour le traitement d'une thromboembolie veineuse dans le contexte d'un cancer?. *JAMA* 2015;314:677-686.

537. [1]GALEANO VALLE, F. (2021). Predicción de mortalidad y sangrado precoces en pacientes con enfermedad tromboembólica venosa aguda mediante medición de proteína C reactiva.*Repositorio internacional de la UCM* doi: eprints.ucm.es/id/eprint/67464/

538. [1]ROSSEL, A. (2021). *Choix du traitement anticoagulant pour les patients présentant un évènement thrombotique dans un contexte oncologique* Doctoral dissertation (University of Geneva).

539. [1]VOLK, T. (2016). Venenthrombose und Lungenembolie. *Der Anaesthesist*, *65*(3), 212-220.

540. [1]GRANDONI, F., KAISER, J., BLUM, S., ALBERIO, L. (2016). Thromboembolie und Antikoagulation bei Tumorpatienten. *Therapeutische Umschau*, *73*(10), 595-604.

541. [1]TRUJILLO SANTOS, A.J., Tratamiento de la trombosis venosa profunda de extremidades inferiores ISSN: S0014-2565(20)30148-X doi: doi.org/10.1016/j.rce.2020.05.009

542. [1]CASTELLÓN RUBIO, V. E. (2021). Biomarcadores séricos y genómicos predictores de riesgo de enfermedad tromboembólica venosa en pacientes con cáncer de pulmón localmente avanzado o metastásico en tratamiento quimioterápico ambulatorio. ISBN: 978-84-1306-756-8

543. [1]MAI, V. (2021). *Le traitement de la maladie thromboembolique veineuse: enjeux et nouveautés*. Doctoral dissertation(Université Laval).

544. [1]SIFRÉ, M. L. P. (2017). *Complicaciones durante el tratamiento anticoagulante y tras su interrupción, en pacientes con cáncer y tromboembolismo pulmonar incidental*. Doctoral dissertation (Universidad CEU-Cardenal Herrera).

545. [1] BI YIYAO, & LIU HUI. (2017). Research progress of malignant tumor-related venous thromboembolic events. *Journal of Clinical Pulmonology*, 3. doi: cnki.com.cn/Article/CJFDTotal-LCFK201703050.htm

546. [1]ZAWILSKA, K., ZAWILSKA, K. (2016). Venous thromboembolism—practical aspects of treatment. *Hematology in Clinical Practice*, *7*(3), 231-242.

547. [1]LEBELLEC, L., KOUAKAM, C., BERTRAND, N., PENEL, N. (2018). Quelle place pour les anticoagulants oraux directs en cancérologie?. *Bulletin du Cancer*, *105*(7-8), 631-633.

548. [1]MATZDORFF, A. (2016). Diagnostik und Therapie Tumorassoziierter venöser Thromboembolien–was sagen die Leitlinien?. *Onkologische Welt*, *7*(04), 167-170.

549. [1]LI Y., & SHI. J.. (2020). Research progress of venous thromboembolism, anticoagulation, bleeding and recurrence risk in cancer patients. Chinese Journal of Oncology, 47(24), 1287-1292.

Citácie v publikácii registrované v citačných indexoch v zmysle v Vyhlášky 397/2020 Z.z.

550. [1]TROUSSARD, X., MAÎTRE, E., CORNET, E. (**2022**). Hairy cell leukemia **2022**: Update on diagnosis, risk-stratification, and treatment. *American Journal of Hematology*, *97*(2), 226-236.

551. [1]PARK, J., OH, A. R., KWON, J. H., KIM, S., KIM, J., YANG, K., LEE, S. H. (**2022**). Association between cardiologist evaluation and mortality in myocardial injury after non-cardiac surgery. *Heart*, *108*(9), 695-702.

552. [1]MAHÉ, I., AGNELLI, G., AY, C., BAMIAS, A., BECATTINI, C., CARRIER, M., LAPORTE, S. (**2022**). Extended anticoagulant treatment with full-or reduced-dose apixaban in patients with cancer-associated venous thromboembolism:

rationale and design of the API-CAT study. *Thrombosis and haemostasis*, *122*(04), 646-656.

553. [1]YAMASHITA, Y., MORIMOTO, T., KIMURA, T. (**2022**). Venous thromboembolism: Recent advancement and future perspective. *Journal of Cardiology*, *79*(1), 79-89.

554. [1]MAHAJAN, A., BRUNSON, A., ADESINA, O., KEEGAN, T. H., WUN, T. (**2022**). The incidence of cancer-associated thrombosis is increasing over time. *Blood advances*, *6*(1), 307-320.

555. [1]BECATTINI, C., BAUERSACHS, R., MARAZITI, G., BERTOLETTI, L., COHEN, A., CONNORS, J. M., AGNELLI, G. (**2022**). Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. *Haematologica*, *107*(7), 1567.

556. [1] YAN, M. M., WU, S. S., QI, Y. P., LI, Z. R., ZHANG, Q., ZHAO, H., QIU, X. Y. (**2022**). Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of FAERS data. *Expert Opinion on Drug Safety*, *21*(2), 277-283.

557. [1]JONMARKER, S., LITORELL, J., DAHLBERG, M., STACKELBERG, O., EVERHOV, Å. H., SÖDERBERG, M., CRONHJORT, M. (**2022**). An observational study of intermediate-or high-dose thromboprophylaxis for critically ill COVID-19 patients. *Acta Anaesthesiologica Scandinavica*, *66*(3), 365-374.

558. [1]FARGE, D., FRERE, C., CONNORS, J. M., KHORANA, A. A., KAKKAR, A., AY, C., YASUDA, C. (**2022**). **2022** international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. *The Lancet Oncology*, *23*(7), e334-e347.

559. [1]GIUSTOZZI, M., FRANCO, L., AGNELLI, G.,VERSO, M. (**2022**). Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. *Trends in Cardiovascular Medicine*.

560. [1]RIAZ, I. B., FUENTES, H. E., NAQVI, S. A. A., HE, H., TAFUR, A. J., PADRANOS, L., MCBANE, R. D. (**2022**). Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living,

Interactive Systematic Review and Network Meta-analysis. In *Mayo Clinic Proceedings* (Vol. 97, No. 2, pp. 308-324). Elsevier.

561. [1]BOOTH, S., HAEMSTAR NETWORK, DESBOROUGH, M., CURRY, N., STANWORTH, S., JANUM, S., TEASDALE, L. (**2022**). Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. *Journal of Thrombosis and Haemostasis*, *20*(8), 1830-1838.

562. [1]ATHANAZIO, R. A., CERESETTO, J. M., MARFIL RIVERA, L. J., CESARMAN-MAUS, G., GALVEZ, K., MARQUES, M. A., COHEN, A. T. (**2022**). Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. *Clinical and Applied Thrombosis/Hemostasis*, *28*, 10760296221082988.

563. [1]MUSGRAVE, K., POWER, K., LAFFAN, M., O'DONNELL, J. S., THACHIL, J., MARAVEYAS, A. (**2022**). Practical treatment guidance for cancer-associated thrombosis–Managing the challenging patient: A consensus statement. *Critical Reviews in Oncology/Hematology*, 103599.

564. [1]FARMAKIS, D., PAPAKOTOULAS, P., ANGELOPOULOU, E., BISCHINIOTIS, T., GIANNAKOULAS, G., KLIRIDIS, P., PARASKEVAIDIS, I. (**2022**). Anticoagulation for atrial fibrillation in active cancer. *Oncology Letters*, *23*(4), 1-10.

565. [1]RIESS, H., KRETZSCHMAR, A., HEINKEN, A., MOHEBBI, D., MAY, M., SCHELLONG, S. (**2022**). Anticoagulation Therapy in Cancer Patients with Thrombosis in the Outpatient Sector of Germany (The CERTIFICAT Initiative)—German Practice of Anticoagulation Therapy of Cancer Patients with Thrombosis. *Hämostaseologie*, *42*(03), 166-173

566. [1]MUSGRAVE, K., POWER, K., LAFFAN, M., O'DONNELL, J. S., THACHIL, J., MARAVEYAS, A. (**2022**). Practical treatment guidance for cancer-associated thrombosis–Managing the challenging patient: A consensus statement. *Critical Reviews in Oncology/Hematology*, 103599.

567. [1]AMERALI, M., POLITOU, M. (**2022**). Tinzaparin—a review of its molecular profile, pharmacology, special properties, and clinical uses. *European Journal of Clinical Pharmacology*, 1-11.

568. [1] VERSO, M., AGNELLI, G., MUNOZ, A., CONNORS, J. M., SANCHEZ, O., HUISMAN, M., BECATTINI, C. (**2022**). Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. *European Journal of Cancer*, *165*, 136-145.

569. [1]KREUZIGER, L. B., FENG, M., BARTOSIC, A., SIMPSON, P., WANG, T. F. (**2022**). A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. *Blood Coagulation & Fibrinolysis*, *33*(3), 171-175.

570. [1]WUMAIER, K., LI, W., CUI, J. (**2022**). New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism. *Drug Design, Development and Therapy*, *16*, 2497.

571. [1]FIORETTI, A. M., LEOPIZZI, T., PUZZOVIVO, A., GIOTTA, F., LORUSSO, V., LUZZI, G., OLIVA, S. (**2022**). Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review. *International Journal of Clinical Practice*, ***2022***.

572. [1]IMAMURA, Y., OTSUI, K., MORI, K., KITAGAWA, K., OKADA, H., HATA, A., MINAMI, H. (**2022**). Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial. *International Journal of Hematology*, *115*(4), 499-507.

573. [1]CHOU, S. C., PAI, C. H., LIN, S. W., TIEN, H. F. (**2022**). Incidence and risk factors for venous thromboembolism in a cohort of Taiwanese patients with lung, gastric, pancreatic cancers or lymphoma. *Journal of the Formosan Medical Association*, *121*(1), 360-366.

574. [1]KIM, S. A., LEE, J. H., LEE, J. Y., HWANG, H. G., KIM, Y. K., YHIM, H. Y., BANG, S. M. (**2022**). Treatment and bleeding complications of cancer-associated venous thromboembolism: A Korean population-based study. *Thrombosis and Haemostasis*, (AAM).

575. [1]AKKURT, G., ALIMOĞULLARI, M., KARTAL, B., ALTAY, C. M., ALIMOĞULLARI, E., CAYLI, S. (**2022**). The Effectiveness of Long-term Use of Low-Molecular-Weight Heparin on Venous Thromboembolism After Sleeve Gastrectomy in Rats. *Bariatric Surgical Practice and Patient Care*, *17*(1), 47-55.

576. [1]SARANTIS, P., KARAMOUZIS, M. V. (**2022**). The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer. *Thrombosis Research*, *213*, S120-S126.

577. [1]MUÑOZ, A., GALLARDO, E., AGNELLI, G., CRESPO, C., FORGHANI, M., ARUMI, D., SOTO, J. (**2022**). Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. *Journal of Medical Economics*, *25*(1), 840-847.

578. [1]FALANGA, A., LEADER, A., AMBAGLIO, C., BAGOLY, Z., CASTAMAN, G., ELALAMY, I., ROCCA, B. (**2022**). EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. *HemaSphere*, *6*(8).

579. [1]LECUMBERRI, R., RUIZ-ARTACHO, P., TZORAN, I., BRENNER, B., BANCEL, D. F., AY, C., MONREAL, M. (**2022**). Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. *Thrombosis and Haemostasis*, (AAM).

580. [1]KIM, J. H., YOO, C., SEO, S., JEONG, J. H., RYOO, B. Y., KIM, K. P., PARK, S. R. (**2022**). A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. *Cancers*, *14*(3), 559.

581. [1]STRATMANN, J. A., MIESBACH, W. (**2022**). Therapie-Handbuch-Onkologie und Hämatologie, Journal, 77-83.

582. [1]DONAHUE, A., SOBOL, K. R., ABRAHAM, J. A. (**2022**). Venous thromboembolism in musculoskeletal oncology surgery.

583. [1]FRERE, C., CRICHI, B., RUEDA-CAMINO, J. A., CAJFINGER, F., SPIESS, N., JANUS, N., FARGE, D. (**2022**). Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. *JMV-Journal de Médecine Vasculaire*.

584. [1]YHIM, H. Y. (**2022**). Challenging issues in the management of cancer-associated venous thromboembolism. *Blood research*, *57*(Suppl 1), 44.

585. [1]KISHORE, S. A., BAJWA, R., VAN DOREN, L., WILKINS, C., O'SULLIVAN, G. J. (**2022**). Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population. *Current Oncology Reports*, 1-12.

586. [1]FIORETTI, A. M., LEOPIZZI, T., PUZZOVIVO, A., GIOTTA, F., LORUSSO, V., LUZZI, G., OLIVA, S. (**2022**). Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. *Medicine*, *101*(34).

587. [1]YAZBEK, G., PIGNATARO, B. S. (**2022**). Venous thromboembolism and Cancer. In *Vascular Surgery in Oncology* (pp. 439-466). Springer, Cham.

588. [1]MEANWATTHANA, J., MITSUNTISUK, P. (**2022**). Pharmaceutical Sciences Asia. 49(2), 147-152 doi: 10.29090/psa.**2022**.02.21.106

589. [1]SCHMIDT, R. A., LEE, A. Y. (**2022**). How I treat and prevent venous thrombotic complications in patients with lymphoma. *Blood, The Journal of the American Society of Hematology*, *139*(10), 1489-1500.

590. [1]ILLIG, K. A., GOBER, L. (**2022**). Optimal management of upper extremity deep vein thrombosis: Is venous thoracic outlet syndrome underrecognized?. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, *10*(2), 514-526.

591. [1]WANG, T. F. (**2022**). Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. *Thrombosis Research*, *213*, 66-S71.

592. [1]LYON, A. R., LÓPEZ-FERNÁNDEZ, T., COUCH, L. S., ASTEGGIANO, R., AZNAR, M. C., BERGLER-KLEIN, J., SROJIDINOVA, N. (**2022**). **2022** ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). *European Heart Journal-Cardiovascular Imaging*.

593. [1]SALGADO, M., BROZOS-VÁZQUEZ, E., CAMPOS, B., GONZÁLEZ-VILLARROEL, P., PÉREZ, M. E., VÁZQUEZ-TUÑAS, M. L., ARIAS, D. (**2022**). Venous Thromboembolism In Cancer Patients:“From Evidence to Care”. *Clinical and Applied Thrombosis/Hemostasis*, *28*, 10760296221098717.

594. [1]HINDRÉ, R., HAMDAN, A., PASTRÉ, J., PLANQUETTE, B., SANCHEZ, O. (**2022**). Traitement de la maladie veineuse thromboembolique au cours du cancer. *Bulletin du Cancer*.

595. [1]VACULA, I., RUSIŇÁKOVÁ, Z., ČELOVSKÁ, D., JACKULIAK, P., SLOPOVSKÝ, J., PALACKA, P., MAĎARIČ, J. (**2022**). Prevencia a liečba venózneho tromboembolizmu spojeného s malignitou-interdisciplinárny konsenzus. *Vnitřní lékařství*, *68*(4), 221-226.

596. [1] GOLOVINA, V., SELIVERSTOV, E., AN, E., ZOLOTUKHIN, I. (**2022**). Anticoagulant therapy of onco-associated deep vein thrombosis: lessons from randomized trials and real clinical practice. *Flebologia*, 16(2). 156-163

597. [1]BAKAMEL, L. (**2022**). Monitoring des anticoagulants oraux directs. doi:hdl.handle.net/123456789/19504

598. [1]HERMANS, C. Anticoagulation: quelle place pour les Héparines de Bas Poids Moléculaire en **2022**?. *Louvain Med 2021 11-12* (140) 444-450-

599. [1]HART, P. D. C., LANGER, F., REDAKTION, C. M. E. (**2022**) Tumorassoziierte venöse Thromboembolie Tumorassoziierte venöse Thromboembolie. doi: cme-kurs.de/kurse/tumorassoziierte-venoese-thromboembolie/

ADC 02

KHORANA, A. A., KAMPHUISEN, P. W., MEYER, G., BAUERSACHS, R., JANAS, M. S., JARNER M. F., LEE, A. Y.Y.TissueFactor As a PredictorofRecurrentVenousThromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. Journal of clinical oncology 2017; 35: 1078-1085. doi: 10.1200/JCO.2016.67.4564

On behalf of CATCH Investigators:

BELLA., S. R., CERANA, S., ZARBÁ J. J., ANDEL, J., BARRIOS, C. H., BORBA, R. A., CESARIO, F., DE AZEVEDO, S., FERREIRA F. A. F., FRANKE, F. A., PADILHA, S., PAIVA, Q. R., PIMENTA, A., RERIN, J., RIGO, R., ROCHA VAN EYLL, S. B., SANTOS, B. G., VACARO, G., ANASTASOV, V., DRAGNEVA, T., GEORGIEV, G.EORGI, CHAMPION, P., KURUVILLA, P., GONZALEZ, C., DITL, P., FÖRSTER, J, BUNCEK, L. VYDRA, J., ABO, E. H. R., SABRI, S., ALLAHLOUBI, N., ELZAWAWY, A., EZZAT, S. S., SABRY, E. K. M., BAUERSACHS, R., BACCHUS, L., BEYER-WESTENDORF, J., KAMPHAUSEN, U., NIEDERWIESER, D., OSTERMANN, H., SOSADA, M., ANAGNOSTOPOULOS, N., FOUNTZILAS, G., IOANNOU, C., LIAPIS, C., BARRIOS, S. F. J., ATILLI, S., BALSUBRAMANIAN, S., BONDARDE, S., DESAI, S., DESHMUKH, C., SINGH, D. P., GHARAMI, F., GOYAL, L., GUPTA S., GUPTE, S., MUKHERJEE, K. K., KRISHNAN, S., KUMAR, K., MEHTA, A., MISHRA, K., NAIK, R., PAWAR, S., RAJNISH, V. N., WARRIER, N., BRENNER, B. GAVISH, I., LUGASSY, G., KOLIN, M.,

BREDA, E., MAZZUCCONI, M. G., VISANI, G., AWIDI, A., NOVIKOVS, N., MISCUKS, J., ABIGERGES, D., KHOUEIRY, P., MAKAREM, J., ALVAREZ, O. O., ANAYA, S. E., CALDERILLO, R. G., DE LA CONCHA, U. H. J., PANTIGOSO W. S. R., PHILCO, M., ROMERO, P. A., VARGAS, Q. E. A., GAWRYCHOWSKI, K., WITKIEWICZ, W., MACIAS, E., TEIXEIRA, E., CIULEANU, T. E., LIGIA, C. C., LUNGULESCU, D., MANOLESCU I. G., RODICA, A., VOLOVAT, C., BUROV, Y., KATELNITSKY, I., SVISTOV, D., AHMAD, K., ALGAHTANI, F., AL-ZAHRANI, H., QARI, M., JOVANOVIC, D., PERIN, B., STOJANOVIC, V., TOMASIC, L., CHOVANEC, J., HERMAN O., KISSOVA, V., SASVARY, F., ŠPÁNIK, S., SZENTIVANYI, M., BARÓN, F., GALLARDO, E., JIMÉNEZ, D., REMEDIOS, O., SANCHEZ, A., ENGELBRECHT, J., JONAS, N., MCADAM, G., PATEL, M., RAPOPORT, B., ROBERTSON, B., DOYEUN, O., HAWK, K.; HOON-KYO, K., HYO J., K., HYO S., K., JIN S. A., JOOSEOP, C., JOUNG S. J., KEON, U. P., SANG-WON, S., SE H. K., SUNG-SOO, Y., YANG-KI, K., CHANG-FANG, C., CHENG-SHYONG, C., JIN-HWANG, L., SHANG-WEN, C., CHITTIMA, S., EKKAPONG, T., NONGLAK, K., PANTEP, A., PRAMOOK, M., THANAKRIT, S., PATRAPIM, S., SUMITRA, T., UDOMLUCK, C., KOBZA, I., NYKONENKO, O., PRASOL, V., VLADYCHUK, I.

Ohlasy (61)

1. [1]BOONE, B. A., MURTHY, P., MILLER-OCUIN, J., DOERFLER, W. R., ELLIS, J. T., LIANG, X., ZEH, H. J. (2018). Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. *BMC cancer*, *18*(1), 1-12.

2. [1]ZHONG, Y., ZHANG, Y., XU, J., ZHOU, J., LIU, J., YE, M., GUO, D. (2019). Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy. *ACS nano*, *13*(3), 3387-3403.

3. [1]WANG, T. F., LI, A., GARCIA, D. (2018). Managing thrombosis in cancer patients. *Research and Practice in Thrombosis and Haemostasis*, *2*(3), 429-438.

4. [1]EPPENSTEINER, J., DAVIS, R. P., BARBAS, A. S., KWUN, J., LEE, J. (2018). Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults. *Frontiers in immunology*, *9*, 190.

5. [1]KRAAIJPOEL, N., CARRIER, M. (2019). How I treat cancer-associated venous thromboembolism. *Blood, The Journal of the American Society of Hematology*, *133*(4), 291-298.

6. [1]VAN ES, N., LOUZADA, M., CARRIER, M., TAGALAKIS, V., GROSS, P. L., SHIVAKUMAR, S., WELLS, P. S. (2018). Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. *Thrombosis research*, *163*, 41-46.

7. [1]LEE, A. Y. (2017). When can we stop anticoagulation in patients with cancer-associated thrombosis?. *Hematology 2014, the American Society of Hematology Education Program Book*, *2017*(1), 128-135.

8. [1]SWAN, D., ROCCI, A., BRADBURY, C., THACHIL, J. (2018). Venous thromboembolism in multiple myeloma–choice of prophylaxis, role of direct oral anticoagulants and special considerations. *British Journal of Haematology*, *183*(4), 538-556.

9. [1]JARA-PALOMARES, L., SOLIER-LOPEZ, A., ELIAS-HERNANDEZ, T., ASENSIO-CRUZ, M. I., BLASCO-ESQUIVIAS, I., SANCHEZ-LOPEZ, V., OTERO-CANDELERA, R. (2018). D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. *British journal of cancer*, *119*(8), 915-921.

10. [1]KIM, A. S., KHORANA, A. A., MCCRAE, K. R. (2020). Mechanisms and biomarkers of cancer-associated thrombosis. *Translational Research*, *225*, 33-53.

11. [1]SONG, A. B., ROSOVSKY, R. P., CONNORS, J. M., AL-SAMKARI, H. (2019). Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. *Vascular health and risk management*, *15*, 175.

12. [1]REES, P. A., CLOUSTON, H. W., DUFF, S., KIRWAN, C. C. (2018). Colorectal cancer and thrombosis. *International journal of colorectal disease*, *33*(1), 105-108.

13. [1]ALATRI, A., MAZZOLAI, L., FONT, C., TAFUR, A., VALLE, R., MARCHENA, P. J., RIETE INVESTIGATORS. (2017). Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. *Thrombosis and haemostasis*, *117*(08), 1630-1636.

14. [1]ORVAIN, C., BALSAT, M., TAVERNIER, E., MAROLLEAU, J. P., PABST, T., CHEVALLIER, P., GROUP FOR RESEARCH ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (GRAALL). (2020). Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. *Blood*, *136*(3), 328-338.

15. [1]DELLUC, A., MIRANDA, S., DEN EXTER, P., LOUZADA, M., ALATRI, A., AHN, S., CARRIER, M. (2020). Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. *haematologica*, *105*(5), 1436.

16. [1]BRENNER, B., HULL, R., ARYA, R., BEYER-WESTENDORF, J., DOUKETIS, J., ELALAMY, I., ZHAI, Z. (2019). Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. *Thrombosis journal*, *17*(1), 1-12.

17. [1]SCHLIEMANN, C., GERWING, M., HEINZOW, H., HARRACH, S., SCHWÖPPE, C., WILDGRUBER, M., BERDEL, W. E. (2020). First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumors: Results of a phase I dose-escalation study. *Cancers*, *12*(6), 1488.

18. [1]MAHAJAN, A., WUN, T. (2019). Biomarkers of cancer-associated thromboembolism. In *Thrombosis and Hemostasis in Cancer* (pp. 69-85). Springer, Cham.

19. [1]TOBALDINI, L. Q., ARANTES, F. T., DA SILVA SARAIVA, S., DE MORAES MAZETTO, B., COLELLA, M. P., DE PAULA, E. V., ORSI, F. A. (2018). Circulating levels of tissue factor and the risk of thrombosis associated with antiphospholipid syndrome. *Thrombosis Research*, *171*, 114-120.

20. [1]MARAVEYAS, A., MUAZZAM, I., NOBLE, S., & BOZAS, G. (2017). Advances in managing and preventing thromboembolic disease in cancer patients. *Current opinion in supportive and palliative care*, *11*(4), 347-354.

21. [1]AY, C., MACKMAN, N. (2017). Tissue factor: catch me if you can!. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, *35*(10), 1128-1130.

22. [1]MUHSIN-SHARAFALDINE, M. R., MCLELLAN, A. D. (2018). Apoptotic vesicles: deathly players in cancer-associated coagulation. *Immunology and Cell Biology*, *96*(7), 723-732.

23. [1]LIEBMAN, H. A. (2018). Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk. *Thrombosis Research*, *164*, S19-S22.

24. [1]FOTIOU, D., GAVRIATOPOULOU, M., NTANASIS-STATHOPOULOS, I., MIGKOU, M., DIMOPOULOS, M. A.,TERPOS, E. (2019). Updates on thrombotic events associated with multiple myeloma. *Expert review of hematology*, *12*(5), 355-365.

25. [1]GALEANO-VALLE, F., ORDIERES-ORTEGA, L., OBLITAS, C. M., DEL-TORO-CERVERA, J., ALVAREZ-SALA-WALTHER, L., DEMELO-RODRÍGUEZ, P. (2021). Inflammatory biomarkers in the short-term prognosis of venous

thromboembolism: a narrative review. *International journal of molecular sciences*, *22*(5), 2627.

26. [1]FRERE, C., TRUJILLO-SANTOS, J., FONT, C., SAMPÉRIZ, Á., QUINTAVALLA, R., GONZÁLEZ-MARTÍNEZ, J., RIETE INVESTIGATORS. (2018). Clinical course of venous thromboembolism in patients with pancreatic cancer: insights from the RIETE registry. *Thrombosis and Haemostasis*, *118*(06), 1119-1122.

27. [1]FONSECA, R., CESARMAN-MAUS, G., BRAGGIO, E. D. (2017). Personalizing the use of circulating microparticle-associated tissue factor as a biomarker for recurrent thrombosis in patients with cancer. *Journal of Clinical Oncology*, *35*(19), 2217-2218.

28. [1]MEYER, G. (2019). Low-molecular weight heparin or direct oral anticoagulants for the treatment of cancer associated thrombosis. Are we at the crossroad?. *Thrombosis Research*, *173*, 156-157.

29. [1]SÁNCHEZ-LÓPEZ, V., GAO, L., FERRER-GALVÁN, M., ARELLANO-ORDEN, E., ELÍAS-HERNÁNDEZ, T., JARA-PALOMARES, L., OTERO-CANDELERA, R. (2020). Differential biomarker profiles between unprovoked venous thromboembolism and cancer. *Annals of medicine*, *52*(6), 310-320.

30. [1]ENGLISCH, C., MOIK, F., AY, C. (2021). Risk assessment for recurrent venous thromboembolism in patients with cancer. *Thrombosis Update*, *5*, 100080.

31. [1]BERDEL, A. F., SCHWÖPPE, C., BRAND, C., HARRACH, S., BRÖMMEL, K., HINTELMANN, H., KESSLER, T. (2021). Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction. *Cancers*, *13*(11), 2841.

32. [1]NISHIMOTO, Y., YAMASHITA, Y., MORIMOTO, T., SAGA, S., AMANO, H., TAKASE, T., COMMAND VTE REGISTRY INVESTIGATORS. (2020). Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated

venous thromboembolism: From the COMMAND VTE Registry. *Thrombosis Research*, *191*, 66-75.

33. [1]SHOJI, T., MIZUGAKI, H., IKEZAWA, Y., FURUTA, M., TAKASHIMA, Y., KIKUCHI, H., NISHIMURA, M. (2018). Successful application of edoxaban in the treatment of venous thromboembolism recurrence in a patient with non-small cell lung cancer after tumor shrinkage. *Internal Medicine*, 9741-17.

34. [1]REES, P. A. (2018). *The role of extrinsic clotting pathway activation in the colorectal cancer microenvironment*. The University of Manchester (United Kingdom).

35. [1]KHORANA, A. A., JANAS, M., JARNER, M. F., LEE, A. Y. (2017). Reply to R. Fonseca et al. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, *35*(19), 2218-2219.

36. [1]COLWELL, J., FROST, M., WEEKLY, A. H., WEEKLY, A. I., MONTHLY, A. D., MONTHLY, A. G., INTERNIST, A. C. P. Venous thromboembolism in malignancy.

37. [1]ROSOVSKY, R. P. (2013). Cancer and Coagulopathy. *Cancer Chemotherapy, Immunotherapy and Biotherapy*, 237.

38. [1]BUTTERFIELD, S., FROST, M., HUFF, C., WEEKLY, A. H., WEEKLY, A. I., MONTHLY, A. D., INTERNIST, A. C. P. Venous thromboembolism in malignancy.

39. [1]SATO, M. (2019). Chemotherapy induced changes to fibrin clots properties in lung cancer: is it favorable?. *Journal of Thoracic Disease*, *11*(Suppl 9), S1126.

40. [1]GARCÍA-ESCOBAR, I., BROZOS-VÁZQUEZ, E., GUTIERREZ ABAD, D., MARTÍNEZ-MARÍN, V., PACHÓN, V., MUÑOZ MARTÍN, A. J. (2021). Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence. *Clinical and Translational Oncology*, *23*(6), 1034-1046.

41. [1]MACKMAN, N., SACHETTO, A. T. A., HISADA, Y. (**2022**). Measurement of tissue factor-positive extracellular vesicles in plasma: strengths and weaknesses of current methods. *Current Opinion in Hematology*, *29*(5), 266-274.

42. [1]RYGIEL, K. K. Navigating in the labyrinth of thrombotic and bleeding risks in patients with malignancies–how to make the most reasonable choices for personalized anticoagulation?.

43. [1]VINCENT, F., MAZZOLAI, L., ALATRI, A., DUCHOSAL, M. Validation du score d'Ottawa dans une cohorte de patients suisses.

44. [1]GALVÁN, M. F. (2017). *Micropartículas circulantes y eventos trombóticos asociados al paciente con cáncer* (Doctoral dissertation, Universidad de Sevilla).

45. [1]BERNDT, C., LANGER, F. (2017). Biomarker für Thromboembolie-Rezidiv.

46. [1]AGNERYS, L. S., EDUARDO ELIGIO, B. F., JAVIER, C. R., WILFREDO, T. I., SADYS, R. P. (2021). Índice predictivo para la estratificación del riesgo de enfermedad tromboembólica venosa en hemopatias malignas. In *cibamanz2021*.

47. [1]LÓPEZ SACERIO, A., RENDÓN PERALTA, S., BARRETO FIU, E. E., ALVAREZ BASULTO, N., ACOSTA ALVAREZ, M. (2021). Índice predictivo para la estratificación del riesgo de enfermedad tromboembólica venosa en pacientes con hemopatías malignas. *Acta Médica del Centro*, *15*(4), 511-520.

48. [1] FERRER GALVÁN, M. (2017). Micropartículas circulantes y eventos trombóticos asociados al paciente con cáncer.

49. [1] KAKKAR, L. A. K., LYMAN, G. H., & KHORANA, A. A. A new concept about cancer-related thrombosis: what the latest NOAC data tell us.

50. [1]GALEANO VALLE, F. (2021). Predicción de mortalidad y sangrado precoces en pacientes con enfermedad tromboembólica venosa aguda mediante medición de proteína C reactiva.

51. [1] ROSSEL, A. (2021). *Choix du traitement anticoagulant pour les patients présentant un évènement thrombotique dans un contexte oncologique* (Doctoral dissertation, University of Geneva).

Citácie v publikácii registrovaná v citačných indexoch v zmysle v Vyhlášky 397/2020 Z.z.

52. [1]GIRARD, P., LAPORTE, S., CHAPELLE, C., FALVO, N., FALCHERO, L., CLOAREC, N., MEYER, G. (**2022**). Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study. *Thrombosis and haemostasis*, *122*(01), 151-157.
53. [1]MACKMAN, N., HISADA, Y., ARCHIBALD, S. J. (**2022**). Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer: Comment by Mackman et al. *Cancer Science*.
54. [1]FIORETTI, A. M., LEOPIZZI, T., PUZZOVIVO, A., GIOTTA, F., LORUSSO, V., LUZZI, G., OLIVA, S. (**2022**). Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review. *International Journal of Clinical Practice*, ***2022***.
55. [1]KOBO, O., MOLEDINA, S. M., RAISI-ESTABRAGH, Z., SHANMUGANATHAN, J. W. D., CHIEFFO, A., AL AYOUBI, F., MAMAS, M. A. (**2022**). Emergency department cardiovascular disease encounters and associated mortality in patients with cancer: A study of 20.6 million records from the USA. *International Journal of Cardiology*, *363*, 210-217.

56. [1] VERSO, M., AGNELLI, G., MUNOZ, A., CONNORS, J. M., SANCHEZ, O., HUISMAN, M., BECATTINI, C. (**2022**). Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. *European Journal of Cancer*, *165*, 136-145.

57. [1]ALI, N. T., YOUNG, A. (**2022**). Treatment and secondary prophylaxis of venous thromboembolism in cancer patients. *Supportive Care in Cancer*, 1-8.

58. [1] ETTELAIE, C., BENELHAJ, N., FEATHERBY, S., HAQUE, F., JOHNSON, M., COOKE, J., MARAVEYAS, A. (**2022**). Tumour-associated tissue factor (TF)-mRNA is a precursor for rapid TF-microvesicle release and a potential predictive marker for the risk of pulmonary embolism (PE) in gastrointestinal cancer patients. *Journal of Biotechnology and Biomedicine*, *5*(2).

59. [1]OTERO, R., SOLIER-LÓPEZ, A., SÁNCHEZ-LÓPEZ, V., OTO, J., ARELLANO, E., MARÍN, S., MEDINA, P. (**2022**). Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). *Cancers*, *14*(11), 2771.

60. [1]LI, H., YU, Y., GAO, L., ZHENG, P., LIU, X., CHEN, H. (**2022**). Tissue factor: a neglected role in cancer biology. *Journal of Thrombosis and Thrombolysis*, *54*(1), 97-108.

61. [1] SCHMIDT, R. A., LEE, A. Y. (**2022**). How I treat and prevent venous thrombotic complications in patients with lymphoma. *Blood, The Journal of the American Society of Hematology*, *139*(10), 1489-1500.

ADC 03

KAMPHUISEN, P. W. LEE, A. Y.Y., MEYER, G., BAUERSACHS, R., JANAS, M. S., JARNER M. F., KHORANA, A. A., Clinicallyrelevantbleeding in cancer patients treatedfor venous thromboembolismfromthe CATCH study. J Thromb Haemost. 2018;16:1069–77. doi: https://doi.org/10.1111/jth.14007

On behalf of CATCH Investigators:

BELLA., S. R., CERANA, S., ZARBÁ J. J., ANDEL, J., BARRIOS, C. H., BORBA, R. A., CESARIO, F., DE AZEVEDO, S., FERREIRA F. A. F., FRANKE, F. A., PADILHA, S., PAIVA, Q. R., PIMENTA, A., RERIN, J., RIGO, R., ROCHA VAN EYLL, S. B., SANTOS, B. G., VACARO, G., ANASTASOV, V., DRAGNEVA, T., GEORGIEV, G.EORGI,

CHAMPION, P., KURUVILLA, P., GONZALEZ, C., DITL, P., FÖRSTER, J, BUNCEK, L. VYDRA, J., ABO, E. H. R., SABRI, S., ALLAHLOUBI, N., ELZAWAWY, A., EZZAT, S. S., SABRY, E. K. M., BAUERSACHS, R., BACCHUS, L., BEYER-WESTENDORF, J., KAMPHAUSEN, U., NIEDERWIESER, D., OSTERMANN, H., SOSADA, M., ANAGNOSTOPOULOS, N., FOUNTZILAS, G., IOANNOU, C., LIAPIS, C., BARRIOS, S. F. J., ATILLI, S., BALSUBRAMANIAN, S., BONDARDE, S., DESAI, S., DESHMUKH, C., SINGH, D. P., GHARAMI, F., GOYAL, L., GUPTA S., GUPTE, S., MUKHERJEE, K. K., KRISHNAN, S., KUMAR, K., MEHTA, A., MISHRA, K., NAIK, R., PAWAR, S., RAJNISH, V. N., WARRIER, N., BRENNER, B. GAVISH, I., LUGASSY, G., KOLIN, M., BREDA, E., MAZZUCCONI, M. G., VISANI, G., AWIDI, A., NOVIKOVS, N., MISCUKS, J., ABIGERGES, D., KHOUEIRY, P., MAKAREM, J., ALVAREZ, O. O., ANAYA, S. E., CALDERILLO, R. G., DE LA CONCHA, U. H. J., PANTIGOSO W. S. R., PHILCO, M., ROMERO, P. A., VARGAS, Q. E. A., GAWRYCHOWSKI, K., WITKIEWICZ, W., MACIAS, E., TEIXEIRA, E., CIULEANU, T. E., LIGIA, C. C., LUNGULESCU, D., MANOLESCU I. G., RODICA, A., VOLOVAT, C., BUROV, Y., KATELNITSKY, I., SVISTOV, D., AHMAD, K., ALGAHTANI, F., AL-ZAHRANI, H., QARI, M., JOVANOVIC, D., PERIN, B., STOJANOVIC, V., TOMASIC, L., CHOVANEC, J., HERMAN O., KISSOVA, V., SASVARY, F., ŠPÁNIK, S., SZENTIVANYI, M., BARÓN, F., GALLARDO, E., JIMÉNEZ, D., REMEDIOS, O., SANCHEZ, A., ENGELBRECHT, J., JONAS, N., MCADAM, G., PATEL, M., RAPOPORT, B., ROBERTSON, B., DOYEUN, O., HAWK, K.; HOON-KYO, K., HYO J., K., HYO S., K., JIN S. A., JOOSEOP, C., JOUNG S. J., KEON, U. P., SANG-WON, S., SE H. K., SUNG-SOO, Y., YANG-KI, K., CHANG-FANG, C., CHENG-SHYONG, C., JIN-HWANG, L., SHANG-WEN, C., CHITTIMA, S., EKKAPONG, T., NONGLAK, K., PANTEP, A., PRAMOOK, M., THANAKRIT, S., PATRAPIM, S., SUMITRA, T., UDOMLUCK, C., KOBZA, I., NYKONENKO, O., PRASOL, V., VLADYCHUK, I.

Ohlasy(27)

1. [1] AKL, E. A., VASIREDDI, S. R., GUNUKULA, S., BARBA, M., SPERATI, F., TERRENATO, I., SCHUENEMANN, H. (2011). Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database of Systematic Reviews*, (6).

2. [1] KAHALE, L. A., HAKOUM, M. B., TSOLAKIAN, I. G., ALTURKI, F., MATAR, C. F., TERRENATO, I., AKL, E. A. (2018). Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. *Cochrane Database of Systematic Reviews*, (6).

3. [1] PATEL, H. K., KHORANA, A. A. (2019). Anticoagulation in cancer patients: a summary of pitfalls to avoid. *Current Oncology Reports*, *21*(2), 1-8.

4. [1] RECIO-BOILES, A., VEERAVELLI, S., VONDRAK, J., BABIKER, H. M., SCOTT, A. J., SHROFF, R. T., MCBRIDE, A. (2019). Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. *World Journal of Gastrointestinal Oncology*, *11*(10), 866.

5. [1]VOIGTLAENDER, M., LANGER, F. (2019). Low-molecular-weight heparin in cancer patients: overview and indications. *Hämostaseologie*, *39*(01), 067-075.

6. [1]SCOTTÉ, F., LEROY, P., CHASTENET, M., AUMONT, L., BENATAR, V., ELALAMY, I. (2019). Treatment and prevention of cancer-associated thrombosis in frail patients: Tailored management. *Cancers*, *11*(1), 48.

7. [1]LEADER, A., TEN CATE, V., TEN CATE-HOEK, A. J., BECKERS, E. A., SPECTRE, G., GIACCHERINI, C., TEN CATE, H. (2020). Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. *European journal of internal medicine*, *77*, 86-96.

8. [1]CARRIER, M., BLAIS, N., CROWTHER, M., KAVAN, P., LE GAL, G., MOODLEY, O. LEE, A. Y. (2021). Treatment algorithm in cancer-associated thrombosis: updated Canadian expert consensus. *Current Oncology*, *28*(6), 5434-5451.

9. [1]KIMPTON, M., CARRIER, M. (2019). Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. *Expert Opinion on Drug Safety*, *18*(4), 313-320.

10. [1]MEYER, G. (2019). Low-molecular weight heparin or direct oral anticoagulants for the treatment of cancer associated thrombosis. Are we at the crossroad?. *Thrombosis Research*, *173*, 156-157.

11. [1]CANDELORO, M., GUMAN, N. A., KRAAIJPOEL, N., DI NISIO, M. (2021). Risk assessment models for thrombosis and anticoagulant-related bleeding in ambulatory cancer patients. In *Seminars in Thrombosis and Hemostasis* (Vol. 47, No. 08, pp. 972-981). Thieme Medical Publishers, Inc..

12. [1]ENGLISCH, C., MOIK, F., AY, C. (2021). Risk assessment for recurrent venous thromboembolism in patients with cancer. *Thrombosis Update*, *5*, 100080.

13. [1]FRERE, C., FONT, C., ESPOSITO, F., CRICHI, B., GIRARD, P., JANUS, N. (2021). Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. *Supportive Care in Cancer*, 1-13.

14. [1]VOIGTLAENDER, M., BECKMANN, L., SCHULENKORF, A., SIEVERS, B., ROLLING, C., BOKEMEYER, C., LANGER, F. (2020). Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. *Journal of Thrombosis and Haemostasis*, *18*(12), 3267-3279.

15. [1] LI, X., PARTOVI, S., GADANI, S., MARTIN III, C., BECK, A., VEDANTHAM, S. (2020). Gastrointestinal malignancies and venous thromboembolic disease: clinical significance and endovascular interventions. *Digestive disease interventions*, *4*(03), 260-266.

16. [1] HEROLD, J., BAUERSACHS, R. (2018). Die Unterschenkelvenenthrombose–eine Erkrankung für Spezialisten. *Phlebologie*, *47*(06), 319-328.

17. [1]ZWICKER, J. Anticoagulation in individuals with thrombocytopenia. Ido:https://medilib.ir/uptodate/show/117208

18. [1]KATELNITSKAYA, O. V., KIT, O. I., KATELNITSKY, I. I., PROSTOV, I. I., CHERKES, M. A. (2020). Features of Anticoagulant Therapy of Venous Thromboembolism in Patients with Cancer. *Journal: Flebologiia*, (2), 135.

19. [1]GADE, I. L. (2018). Venous Thromboembolism in Solid and Hematological Cancers: cancer specific factors, time since cancer diagnosis and additional cancer.

20. [1]КАТЕЛЬНИЦКАЯ, О. В., КИТ, О. И., КАТЕЛЬНИЦКИЙ, И. И., ПРОСТОВ, И. И., ЧЕРКЕС, М. А. (2020). Особенности антикоагулянтной терапии венозных тромбоэмболических осложнений у пациентов со злокачественными новообразованиями. *Flebologia*, *14*(2).

21. [1]BOUZA, E. F. (2019). Ajuste de anticoagulación en poblaciones especiales: edad avanzada. *Guía gallega de manejo de la trombosis asociada a cáncer ii edición*, 7.

22. [1]VOIGTLÄNDER, M., & LANGER, F. (2020). Therapie und Prophylaxe der tumor-assoziierten venösen Thromboembolie. *InFo Hämatologie + Onkologie*, *23*(6), 25-30.

Citácie v publikácii registrovaná v citačných indexoch v zmysle v Vyhlášky 397/2020 Z.z.

23. [1]ESCOBAR, A., SALEM, A. M., DICKSON, K., JOHNSON, T. N., BURK, K. J., BASHOURA, L., FAIZ, S. A. (**2022**). Anticoagulation and bleeding in the cancer patient. *Supportive Care in Cancer*, 1-11.

24. [1] VERSO, M., AGNELLI, G., MUNOZ, A., CONNORS, J. M., SANCHEZ, O., HUISMAN, M., BECATTINI, C. (**2022**). Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. *European Journal of Cancer*, *165*, 136-145.

25. [1]FIORETTI, A. M., LEOPIZZI, T., PUZZOVIVO, A., GIOTTA, F., LORUSSO, V., LUZZI, G., OLIVA, S. (**2022**). Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review. *International Journal of Clinical Practice*, ***2022***.

26. [1]VACULA, I., RUSIŇÁKOVÁ, Z., ČELOVSKÁ, D., JACKULIAK, P., SLOPOVSKÝ, J., PALACKA, P., MAĎARIČ, J. (**2022**). Prevencia a liečba venózneho tromboembolizmu spojeného s malignitou-interdisciplinárny konsenzus. *Vnitřní lékařství*, *68*(4), 221-226.

27. [1]RAITHEL, M., HAIBACH, M., KREMENEVSKI, I., ARNOLD, E., & RINGWALD, J. (**2022**). Moderne Antikoagulation mit FXa-Inhibitoren in der Onkologie: Ist die gastrointestinale Blutungsrate (mit)-entscheidend?. *Zeitschrift für Gastroenterologie*.

ADC 04

BIELIK, P. - KANTARSKÁ, D. - BIELIKOVÁ, S. - MARŠÍK, L. - SASVÁRY, F. - ŠUPÍNOVÁ, M. Prevention of virilisation by prenatal treatment [Akcept. list redakcie]. In: *J. Mol. Genet. Med*. ISSN 1747-0862. 2014.

I1 Iný výstup publikačnej činnosti ako celok

GHG Práce zverejnené spôsobom umožňujúcim hromadný prístup (1)

GHG 01

SASVÁRY, F. Moderná antikoagulačná liečba [online].In: *Slovenský hematologický portál[dostupné na internete]* (2011),

Ohlasy (1)

[4] ADAMCOVÁ, A. - NETRIOVÁ, J. - MELUŠ, V. - KRAJČOVIČOVÁ, Z. Testovanie miery zhody stanovení koncentrácie D-diméru medzi ambulanciou lekára a laboratoriím. In: *Zdravotnické listy*. ISSN 1339-3022, 2013, roč.1, č. 3, s 54 – 59.

Práce zverejnené spôsobom umožňujúcim hromadný prístup (2)
DAI Dizertačné a habilitačné práce (2)

DAI 01

SASVÁRY, F. Zmeny frekvenčného spektra variácie srdcového rytmu [Dizertačná práca]. Bratislava: Lekárska fakulta UK, 1996. - 121 s.

DAI 02

SASVÁRY, F. Význam primárnej a sekundárnej prevencie venóznehotromboembolizmu z pohľadu verejného zdravotníctva na Slovensku: určenie rizika pacienta, stanovenie spôsobu intervencie a prínos pre komunitu. VŠZ a SPSv.A Bratislava, 2016

Štatistika publikačnej činnosti autora Ferdinand Sasváry

V1 Vedecký výstup publikačnej činnosti ako celok

AAA	Vedecké monografie vydané v zahraničí	4
AAB	Vedecké monografie vydané na Slovensku	1

V2 Vedecký výstup publikačnej činnosti ako časť editovanej knihy alebo zborníka

AED	Vedecké práce v domácich recenzovaných vedeckých zborníkoch, monografiách	3
AFD	Publik.príspev. na dom.ved.konf.	6
AFG	Abstr. príspevkov zo zahr.ved.konf.	4
AFH	Abstr. príspevkov z dom.ved. konf.	5
AFK	Postery zo zahr.konf.	3
AFL	Postery z dom.konferencií	1

V3 Vedecký výstup publikačnej činnosti z časopisu

ADF	Ved. práce v ostat.dom. časop.	3
ADM	Ved.práce v zahr.čas.reg. vo WoS a Scopus	7
ADN	Ved.práce v dom.čas.reg. vo WoS a Scopus	9

O2 Odborný výstup publikačnej činnosti ako časť knižnej publikácie alebo zborníka

BEF	Odb.práce v dom.zborníkoch	3
BFB	Abstr. odb. pr. dom.poduj.	3

O3 Odborný výstup publikačnej činnosti z časopisu

BDE	Odb. práce v ostat.zahr.časop.	1
BDF	Odb. práce v ostat.dom.časop.	2

P1 Pedagogický výstup publikačnej činnosti ako celok

ACB	VŠ učebnice vyd. v dom. vyd.	2
BCI	Skriptá a učebné texty	2

P2 Pedagogický výstup publikačnej činnosti ako časť učebnice alebo skripta

ADC	Vedecké práce v zahran. karent. časopisoch	4

I1 Iný výstup publikačnej činnosti ako celok		
GHG	Práce zverej.spôsob.umož.hromad.prístup	1
Práce zverejnené spôsobom umožňujúcim hromadný prístup		
DAI	Dizertačné a habilit. práce	2
Spolu		**66**

Štatistika ohlasov	
[1]	715
[2]	2
[3]	22
[4]	22
[5]	2
[6]	1
Spolu	**764**